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ABSTRACT
Despite the improvements made in the treatment of cancer in the last 50 years,
metastasis still results in up to 90% of cancer related deaths. Metastatic tumor cells
are not only more aggressive but they are often less immunogenic, able to escape
detection and elimination by the immune system. In addition, tumor-secreted fac-
tors induce the proliferation and activation of aberrant immune cells that further
suppress the anti-tumor immune response. New findings in the fields of cancer biol-
ogy and cancer immunology have enabled the development of targeted therapies and
immunotherapies that act to reverse this immunosuppression. The work presented
here aims take an engineering approach to build upon these findings. The develop-
ment and application of biomaterial platforms that can interact with and modulate
immune cells, may enable better understanding and treatment of underlying mech-
anisms driving cancer progression and metastasis.
This work describes the application of biomaterial nanoparticles as a novel treat-
ment for acute inflammation resulting from spinal cord injury. The nanoparticles
were internalized by proinflammatory immune cells, and diverted these cells away
from the injury site while reprogramming macrophages at the site to be more pro-
regenerative. Increased tissue regeneration, reduced scarring, and improved func-
tional recovery of the animal were observed with nanoparticle treatment. The im-
munomodulatory capabilities of nanoparticles were also tested in a model of metastatic
breast cancer. The nanoparticles were found to be internalized by disease-relevant
xi
immune cells and reduced the abundance of these cells in circulation as well as at
the metastatic site. The immunomodulation resulted in slower tumor growth, fewer
metastatic cells at the lung, and a survival benefit when combined with anti-PD-
1 therapy. This work also explores the use of implantable biomaterial scaffolds for
monitoring metastasis and disease progression, and introduces a scoring metric based
on gene expression of cells recruited to the scaffold to predict therapeutic outcome
and the likelihood of relapse. The scaffolds were also utilized to study the dynamics
of Gr1+ cell phenotype at sites of metastasis. RNA sequencing and functional stud-
ies revealed differences in the phenotype of these cells across tissues and over time.
These studies add to the existing body of knowledge of Gr1+ cells and introduces
potential considerations in the development of drugs targeting these cells.
xii
CHAPTER I
Introduction
1.1 Opening
Great strides have been made in the treatment of cancer in the last 50 years, but
metastasis still results in up to 90% of cancer related deaths. Metastatic tumor cells
are not only more aggressive but they are often less immunogenic, able to escape
detection and elimination by the immune system. In addition, tumor-secreted fac-
tors induce the proliferation and activation of aberrant immune cells that further
suppress the anti-tumor immune response. New findings in the fields of cancer biol-
ogy and cancer immunology have enabled the development of targeted therapies and
immunotherapies that act to reverse this immunosuppression. The work presented
here aims take an engineering approach to build upon these findings. The develop-
ment and application of biomaterial platforms that can interact with and modulate
immune cells, may enable better understanding and treatment of underlying mech-
anisms driving cancer progression and metastasis.
1.2 Contents
Chapter 1 presents the general scope of the work and introduces the specific
studies presented in this dissertation.
1
Chapter 2 provides the motivation and the context for the development of the
biomaterial strategies explored. The background information describes the innate
immune cell types that exhibit pro-tumor functions and support tumor growth and
metastasis, including a literature review of previous approaches used to study and
modulate these immune cells.
Chapter 3 presents the application of biomaterial nanoparticles as a novel treat-
ment for acute inflammation resulting from spinal cord injury. The nanoparticles
were delivered intravascularly and internalized by proinflammatory immune cells,
and diverted these cells away from the injury site while reprogramming macrophages
at the site to be more pro-regenerative. Increased tissue regeneration, reduced scar-
ring, and improved functional recovery of the animal were observed with nanoparticle
treatment. My contributions to the work included administration of the nanoparticle
therapy post surgery, aiding in designing and execution of animal studies, as well as
writing and editing the manuscript. This work has been published as follows:
Jonghyuck Park, Yining Zhang, Eiji Saito, Steve J. Gurczynski, Bethany B.
Moore, Brian J.Cummings, Aileen J. Anderson, and Lonnie D. Shea. Intravas-
cular innate immune cells reprogrammed via intravenous nanoparticles to pro-
mote functional recovery after spinal cord injury. Proceedings of the National
Academy of Sciences of the United States of America,116(30):1494714954, 2019.
Chapter 4 expands upon the the findings from Chapter 3. Nanoparticles were
synthesized and tested for internalization by innate immune cells in a model of
metastatic breast cancer. The nanoparticles were found to be internalized by disease-
relevant cells and reduced the abundance of these cells in circulation as well as at
the metastatic site, which resulted in slower tumor growth, fewer metastatic cells at
the lung, and a survival benefit when combined with anti-PD-1 therapy.
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Chapter 5 explores the use of implantable biomaterial scaffolds for monitoring
disease progression and predicting recurrence following therapy. This work is mo-
tivated by the lack of reliable diagnostics for metastasis, and aims to close the gap
for real-time monitoring of therapeutic efficacy of cancer treatments. The scaffold
microenvironment was found to reflect the disease state of the animal, and gene ex-
pression analysis was used to generate a quantitative score that predicted therapeutic
outcomes for surgical resection of the tumor. My contributions to the work included
the adoptive transfer studies to investigate Gr1+ cell trafficking to the scaffold as a
function of disease state, as well as aid in animal surgeries, sample processing, and
writing and revising. This work has been published as follows:
Oakes, R. S., Bushnell, G. G., Orbach, S. M., Kandagatla, P., Zhang, Y., Morris,
A. H., Hall, M. S., LaFaire, P., Decker, J. T., Hartfield, R. M., Brooks, M. D.,
Wicha, M. S., Jeruss, J. S., Shea, L. D. (2020). Metastatic Conditioning of
Myeloid Cells at a Subcutaneous Synthetic Niche Reflects Disease Progression
and Predicts Therapeutic Outcomes. Cancer Research, 80(3), 602612.
Chapter 6 utilizes the scaffold detailed in the previous chapter to study the dy-
namics of Gr1+ cell phenotype at site of metastasis. RNA sequencing was performed
over these time points to assess the changes in Gr1+ phenotype with disease progres-
sion. Functional studies revealed differences in the phenotype of these cells across
tissues and over time. These studies add to the existing body of knowledge of Gr1+
cells and introduces additional considerations in the development of drugs targeting
these cells.
Chapter 7 summarizes the findings and highlights the major findings, as well as
provide context for their potential impact and significance. Potential future direc-
tions for the work are also proposed.
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CHAPTER II
Immune Cells in Cancer and Metastasis
2.1 Challenges to treating metastatic cancer
Metastasis, the spread of cancer cells from a tumor to secondary sites in the body,
is the leading cause of cancer-related deaths. While significant progress has been
made in the treatment of primary disease with development and use of chemother-
apy, radiotherapy, surgery, and targeted antibody therapies, these treatments are
typically not effective against metastasis. The process by which cancer cells leave
the primary tumor, traffic to distal sites in circulation, and exit circulation to form a
secondary growth is known as the metastatic cascade. Once tumor cells go through
the metastatic cascade, they will have undergone phenotypic changes that make them
more invasive and aggressive compared to cells at the primary tumor, making them
more difficult to treat. Additionally, because metastatic cells are more invasive and
proliferative than the primary tumor, they often have already compromised organ
function by the time they are detectable by current methods.
Many of the challenges in treating metastasis and certain primary tumors lie in
the complex interactions between tumor cells and the immune system. The role of
the immune system in cancer has been widely studied, which has led to recent ad-
vancements in the treatment of metastatic cancer that have relied on modulating
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the immune response to tumor cells. The discovery of immune checkpoints and the
development of antibodies that target these checkpoints, for example, have drasti-
cally improved patient outcomes for several types of cancers. Despite these advances,
there still exists a large population of patients for whom existing immunotherapies
fail, which necessitates better understanding of specific immune cell interactions at
the primary tumor and metastatic sites in order to develop new methods to diagnose
and treat metastasis.
2.2 Understanding the immune system and the role of specific immune
cells
2.2.1 The pre-metastatic niche mediates metastasis
The idea that metastatic tumor cells are attracted to a specific environment or
niche traces back to Stephen Paget’s 1889 “seed and soil” hypothesis [1]. Paget
observed that breast cancers appeared to spread to specific organs, suggesting that
metastasis was not purely a random process. Comparing the cancer cell to the “seed”
and the organs to the “soil,” he hypothesized that certain qualities of the organs, at
the time unknown, provided a suitable environment for cancer cells that have left
the primary tumor to colonize and proliferate in the organ [1].
It was not until 2005 that Kaplan and Lyden provided experimental evidence to
support Paget’s hypothesis [2]. Kaplan and colleagues observed the increase of vas-
cular endothelial growth factor receptor-positive (VEGFR1+) bone marrow-derived
hematopoietic progenitor cells in common sites of metastasis prior to the arrival of
tumor cells in human patient samples. They then injected bone marrow-derived
cells (BMDCs) into mice and found that these immune cells localized to the lung
and actively recruited subsequently injected tumor cells. Their experiments show
5
that the VEGFR1+ bone marrow cells establish a “pre-metastatic niche,” analogous
to Paget’s “soil,” that attracts tumor cells from the primary tumor and promotes
their growth.
Figure 2.1: Interactions between immune cells and tumor cells at the primary tumor
and metastatic sites. (1) Immune cells such as CD8+ T cells and NK cells recognize
and kill tumor cells, while (2) tumor cells display inhibitory signals that diminish the
cytotoxic function of these immune cells. At the same time, (3) tumor-secreted factors
induce the accumulation of pro-tumor immune cells that aid tumor growth and metas-
tasis, and further suppress the function of T cells and NK cells. These events can be
observed at both the primary tumor as well as systemically.
6
2.2.2 Tumors induce expansion and recruitment of pro-tumor innate im-
mune cells
The findings from Kaplan and Lyden, which show that certain populations of
immune cells promote tumor growth and metastasis, stand in contrast to what was
previously understood about the role of the immune system in cancer and metastasis.
The idea that the immune system protects the body from tumors was posited as early
as 1909 by Paul Erlich. Furthering this concept, Burnet and Thomas introduced the
idea of cancer immunosurveillance, in which innate and adaptive immune cells act to
detect and eliminate tumor cells that arise in the body. More recently, however, it has
been hypothesized that immune cells aid tumor cell survival through immunoediting.
During immunoediting, immune cells eliminate immunogenic tumor cells and select
for the tumor cells that are less immunogenic and more aggressive [3], making it
more difficult for the immune system to recognize and kill these cells. In this way,
immune cells unwittingly play a role in promoting tumor growth and metastasis.
In addition to the immune system supporting tumor cells through immunoediting,
there now exists a substantial body of evidence indicating disease-induced immune
cells are critical in establishing the pre-metastatic niche and promoting metastasis [4]
(Fig. 2.1). The primary tumor secretes numerous factors to expand and recruit pro-
tumor immune cells, namely myeloid-derived suppressor cells (MDSCs) and Ly6Chi
monocytes that differentiate into tumor associated macrophages (TAMs). These
immune cells help to maintain an immunosuppressive microenvironment in the pre-
metastatic niche and support tumor cell growth.
Much of the effort to understand the mechanisms by which MDSCs, monocytes,
and TAMs contribute to tumor growth and metastasis has focused on the production
of and response to cytokines and chemokines to recruit these innate immune cells.
7
A number of tumor-secreted factors involved in niche formation have been identified
and studied. Interleukin-6 (IL-6), granulocyte/macrophage colony-stimulating factor
(GM-CSF), and vascular endothelial growth factor (VEGF) stimulate innate immune
cells to migrate out of the bone marrow and expand. Meanwhile, immune cell-
secreted interferon gamma (IFNγ), Toll-like receptor (TLR) ligands, IL-13, and IL-
4 in response to the tumor result in activation of these abhorrent cells [5, 6, 7].
Secreted factors can also directly interact with the pre-metastatic organ, for example,
by inducing fibronectin expression [8]. Hypoxic tumor cells have also been shown
to secrete lysyl oxidase (LOX), which crosslinks collagen IV at the pre-metastatic
organ [9]. These changes to the extracellular matrix of the pre-metastatic niche help
to recruit innate immune cells that then promote metastasis.
More recently, the role of tumor exosomes in niche formation and metastasis has
been studied. Exosomes are extracellular vesicles that contain cellular contents and
signaling molecules. Tumor cells have been shown to secrete exosomes that promote
metastasis. Xiang et al. demonstrated that prostaglandin E2 (PGE2) and trans-
forming growth factor-β (TGFβ) molecules within tumor exosomes cause MDSCs to
accumulate [10]. Furthermore, administration of anti-PGE2 and anti-TGFβ antibod-
ies in vivo decreased metastasis promotion by MDSCs [10]. Tumor exosomes have
also been shown to induce vascular leakiness in the lung, which is an early sign of
niche formation [11]. Exosomes containing integrins can determine the specific organ
to which the primary tumor spreads, and have thus been implicated in metastatic
organotropism [12].
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2.3 The role of disease-induced myeloid cells in cancer
2.3.1 Characteristics of myeloid-derived suppressor cells
Myeloid-derived suppressor cells have garnered much attention in the past decade
for their role in suppressing anti-tumor immunity. MDSCs are a heterogeneous
population of immature myeloid cells that are recruited from the bone marrow to
the tumor and metastatic sites. In mice, these cells are characterized by surface
expression of myeloid markers CD11b and Gr-1 (Ly6C/Ly6G), though these cells
are not distinguishable from neutrophils, monocytes, and macrophages by surface
markers alone [5]. Two subsets of MDSCs (characterized by Ly6Clo/Ly6G+ and
Ly6Chi/Ly6G− in mice) have been identified and there is increasing evidence to
suggest that these two populations have distinct pro-tumor functions. In humans,
MDSCs exhibit similar immunosuppressive functions, and are also identified by sur-
face expression of a number of myeloid lineage markers. Though there remains some
ambiguity in the identification of MDSCs, the suggested nomenclature for these cells
in mice and humans are detailed in the review from Bronte et al. [13].
2.3.2 MDSCs suppress T cell function
The success of most existing immunotherapies relies on the ability of CD8+ T
cells to recognize and kill tumor cells once they have been detected in the body. T
cells that are primed to recognize tumor antigen are highly specific for tumor cells,
and are efficient at recognizing and killing these cells. T cells also help to generate
memory against these antigens to provide long-term immunity. However, tumor cells
secrete or induce expression of factors that suppress T cell function. Immune check-
point blockade therapies, such as anti-PD-1 and anti-CTLA-4 antibodies, work by
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blocking the tumor and metastatic microenvironment from inducing T cell anergy
and activation by dendritic cells (DCs), respectively [14]. Clinical evidence suggests
that there is an additive effect in checkpoint blockade, in that combinations of multi-
ple checkpoint inhibitors have been shown to be more effective than single inhibitors.
Chimeric antigen receptor (CAR) T cell therapy aims to increase the ability of T
cells to recognize tumor antigens. Similarly, increased efficacy has been reported for
armored CAR T cells, which are engineered to secrete stimulatory cytokines that
help the CAR T cells to overcome tumor-induced immunosuppression. Dendritic
cell (DC)-based therapeutic vaccines such as Sipueleucel-T comprise of dendritic
cells are stimulated in vitro with tumor antigen and adoptively transferred into the
patient so the DCs can more readily activate adaptive response against the tumor
cells [15]. The efficacy of combination therapies illustrates the need to overcome
multiple mechanisms by which tumor cells and the tumor environment can suppress
adaptive immunity.
MDSCs primarily inhibit T cell function through the upregulation of immuno-
suppressive factors including arginase 1 (Arg1) and inducible nitric oxide synthase
(iNOS) and increased production of reactive oxygen species (ROS) and nitric oxide
(NO) [5]. Studies have shown that these MDSC-derived factors induce regulatory T
cells (Tregs) [4]. In addition to CD8+ T cells, NK cells have also been shown to play
a role in tumor cell killing by recognizing the absence or downregulation of MHC I
expression on the surface of tumor cells. The presence of MDSCs in tissues resulted
in decreased NK cell cytotoxicity [7].
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2.3.3 Contributions of monocytes and tumor associated macrophages
Aberrant monocytic cells, characterized as being CD11b+ Ly6Chi/Ly6G− in mice,
are also referred to as monocytic MDSCs (M-MDSCs). These have been shown to dif-
ferentiate into tumor associated macrophages (TAMs), which interact with primary
tumor cells to promote both tumor growth and metastasis [16]. The importance of
monocytes and TAMs in tumor growth and metastasis has been highlighted by a
number of studies in which these cells are depleted or their recruitment to the tu-
mor or metastatic sites is blocked. Blockade of monocyte recruitment with a small
molecule inhibitor of C-C motif chemokine ligand 2 (CCL2/MCP-1), for example,
resulted in reduced tumor growth and metastasis [17]. Other studies that induced
ablation of these cell types also resulted in reduced disease progression [18].
2.3.4 Expansion and recruitment of myeloid cells
Expansion and migration of MDSCs is attributed to a large number of tumor-
induced factors including prostaglandins, GM-CSF, macrophage colony-stimulating
factor (M-CSF), several interleukins (IL-1β, IL-6, IL-10, IL-12), and transforming
growth factor beta (TGF-β) have all been shown to contribute to expansion and ac-
tivation of MDSCs [4, 13, 5]. CCL2/MCP-1 has been identified as a potent driver of
MDSC trafficking to the tumor; several studies that block CCL2 have demonstrated
reduced metastasis and tumor growth. C-X-C motif chemokine receptor 2 (CXCR2)
and its ligands (CXCL1, CXCL2, CXCL5), as well as S100A8/9, have also been im-
plicated in the recruitment of MDSCs to tumors and metastatic sites.
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2.3.5 Myeloid cells alter the tumor and metastatic microenvironments
In addition to direct immune suppression through CD8+ T cell inhibition, MDSCs
also support tumor growth and metastasis through the production of factors that re-
model the tumor and metastatic microenvironment. At the primary tumor as well as
at metastatic sites, MDSCs exhibit increased matrix metallopeptidases (MMPs), in
particular MMP-9, which remodel the tumor extracellular matrix in order for tumor
cells to spread and metastasize. MMP-9 also increases levels of VEGF in the tumor
microenvironment, and the presence of MDSCs has been shown to reduce the efficacy
of anti-VEGF therapy [19]. Taken together, these studies elucidate the multi-faceted
roles of innate immune cells in promoting metastasis and tumor growth. In addition,
the large number of interactions and signaling molecules that have been studied also
serve to highlight the complexity of the interactions between tumor and immune cells
as well as the need for better understanding and more effective treatments.
2.4 Scaffold-based strategies for studying and modulating immune cell
function in vivo
2.4.1 Implantable scaffolds recruit tumor cells in vivo
Given the complexities of the interactions between innate immune cells and tu-
mor cells, there remain many aspects of myeloid cells at the pre-metastatic niche
that have yet to be investigated. The ability to study these interactions in vivo is
limited by the difficulty in detecting micro-metastases. In addition, analyses of these
sites often require explanting the diseased tissue, which prevents longitudinal moni-
toring of gene expression throughout disease progression. Implantable scaffolds have
emerged as a method to recapitulate the metastatic niche environment for further
study.
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2.4.2 Cargo-free polymer scaffolds
The Shea lab has developed porous polycaprolactone (PCL) scaffolds that can be
used to study the metastatic environment in vivo. The scaffold structure is comprised
of a network of interconnected pores that support cell infiltration and colonization,
resulting in the recruitment of metastatic and highly aggressive tumor cells [20]. It
has been shown that key immune cells such as MDSCs, monocytes, and macrophages
traffic to the scaffold from the peripheral blood to form an attractive environment
for circulating tumor cells to home. Subsequently, the scaffolds are able to lower
the tumor burden in other metastatic organs to provide a therapeutic benefit to the
animal [21, 22].
Polymer scaffolds not only have therapeutic and diagnostic potential but are also
important tools that can be leveraged to further study metastasis. Little is known
about the dynamics of early niche formation or cancer cell colonization in vivo be-
cause the pre-metastatic niche is difficult to identify until the arrival of tumor cells.
Porous PCL scaffolds provide a unique opportunity to study the dynamics of niche
formation in immune competent BALB/c mice as well as in other cancer modles. Rao
et al. have that demonstrated immune changes occur in scaffolds in the presence of
a primary tumor to form the pre-metastatic niche [22]. However, these data provide
a static image of the immune cells at the scaffold, and do not indicate whether or
not the cells proliferate once at the scaffold, or if they leave the scaffold and are
constantly replenished by interaction with the primary tumor. Further elucidating
the process of niche formation and the role of immune cells within the niche will
inform potential diagnostic and therapeutic interventions.
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2.4.3 Loaded polymer scaffolds
Other groups have also created polymer scaffolds or microparticles that recruit
tumor cells in vivo. These approaches included the released chemokines, or the scaf-
folds were embedded with extracellular matrix proteins or were seeded with stem
cells in order to recruit metastatic tumor cells to the scaffolds [23, 24]. Scaffolds
have also been seeded with cells or loaded with protein or lentivirus expressing cy-
tokines or growth factors to study the effects of these factors on the recruitment of
tumor cells [25].
2.5 Methods for targeting innate immune cells
In addition to studying innate immune cells to monitor disease progression, there
has been considerable effort towards developing therapies that target the immuno-
suppressive function of disease-induced myeloid cells. Many of the previous studies
targeting pro-tumor innate immune cells in the tumor microenvironment, namely
MDSCs, monocytes, and TAMs, act by either 1) blocking cell trafficking to the tu-
mor and metastatic sites, or 2) depleting the immune cells.
Macrophages have been depleted with small molecule colony stimulating factor 1
receptor (CSF1R) inhibitors, though the mechanism of inhibition appears to greatly
influence therapeutic outcomes. In one study, depletion of TAMs using BLZ945
was effective against primary disease, but appeared to be tissue-specific and was
not able to reduce the number of TAMs or reduce tumor burden in the lung in
PyMT model [18]. Other studies employing CSF1R blockade observed increased
sensitivity of tumors to paclitaxel [26] [deNardo 2011] and anti-PD-1 [27]. Simi-
larly, blocking neutrophil recruitment to the pre-metastatic site and inhibition of
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leukotriene-generating enzyme arachidonate 5-lipoxygenase (Alox5) has been shown
to reduce metastasis in vivo [28]. However, there is evidence that there exist redun-
dant pathways to activating and recruiting TAMs to sites of metastasis, suggesting
that blocking CCL2/CCR2 signaling alone is not enough to reduce metastasis [29].
Macrophage populations are also readily reduced or depleted with clodronate lipo-
somes, which induces apoptosis upon uptake. One such study demonstrated that
macrophage depletion with clodronate liposomes and zoledronic acid used in combi-
nation with sorafenib inhibited tumor progression, angiogenesis, and lung metastasis
compared with sorafenib alone in models of hepatocellular carcinoma [30]. Depletion
of TAMs through systemic injection of clodronate liposomes has also shown efficacy
in reducing tumor growth in instances where CCL2 blockade has not [31]. Additional
studies involving ablation of TAMs demonstrate the challenges in targeting cells that
have migrated into tissues [32]. These studies highlight the therapeutic potential in
depletion of tumor associated macrophages, and the need for a more effective method
for doing so.
2.5.1 Inhibition of immune cell trafficking
As previously mentioned, inhibition of immune cell recruitment to tumors or
metastatic sites has been shown to be effective in reducing tumor growth and metas-
tasis. A commonly used method for preventing cell trafficking employs small molecule
inhibitors of surface receptors for chemokines. In one such study, antibody blockade
of CCL2-CCR2 binding using anti-CCL2 antibody was shown to reduce the number
of metastatic nodules in several mouse models of metastatic breast cancer [17]. By
leveraging a different mechanism, several groups observed that antibody targeting of
CCR2 results in deletion of CCR2-expressing monocytes and macrophages and ob-
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served improved disease outcomes. In combination with anti-PD-1, anti-CCR2 also
extended survival in glioma models, which were previously shown to be resistant to
anti-PD-1 [33].
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CHAPTER III
Intravascular Innate Immune Cells Reprogrammed via
Intravenous Nanoparticles to Promote Functional Recovery
After Spinal Cord Injury
3.1 Authors
Jonghyuck Park, Yining Zhang, Eiji Saito, Steve J. Gurczynski, Bethany B.
Moore, Brian J. Cummings, Aileen J. Anderson, and Lonnie D. Shea
3.2 Abstract
Traumatic primary spinal cord injury (SCI) results in paralysis below the level
of injury and is associated with infiltration of hematogenous innate immune cells
into the injured cord. Methylprednisolone has been applied to reduce inflammation
following SCI, yet was discontinued due to an unfavorable risk-benefit ratio associ-
ated with off-target effects. In this study, i.v. administered poly(lactide-coglycolide)
nanoparticles were internalized by circulating monocytes and neutrophils, reprogram-
ming these cells based on their physicochemical properties and not by an active
pharmaceutical ingredient, to exhibit altered biodistribution, gene expression, and
function. Approximately 80% of nanoparticle-positive immune cells were observed
within the injury, and, additionally, the overall accumulation of innate immune cells
17
at the injury was reduced 4-fold, coinciding with downregulated expression of proin-
flammatory factors and increased expression of antiinflammatory and proregenerative
genes. Furthermore, nanoparticle administration induced macrophage polarization
toward proregenerative phenotypes at the injury and markedly reduced both fibrotic
and gliotic scarring 3-fold. Moreover, nanoparticle administration with the implanted
multichannel bridge led to increased numbers of regenerating axons, increased myeli-
nation with about 40% of axons myelinated, and an enhanced locomotor function
(score of 6 versus 3 for control group). These data demonstrate that nanoparti-
cles provide a platform that limits acute inflammation and tissue destruction, at a
favorable risk-benefit ratio, leading to a proregenerative microenvironment that sup-
ports regeneration and functional recovery. These particles may have applications to
trauma and potentially other inflammatory diseases.
3.3 Introduction
Traumatic spinal cord injury (SCI) results in an initial injury, followed by sec-
ondary events that can last from hours to weeks leading to permanent loss of func-
tion [34, 35, 36]. Inflammatory responses are initiated in part by the rapid influx
of immune cells, including inflammatory monocytes and neutrophils, via a broken
blood-spinal cord barrier. These cells infiltrate the injury site within hours and
secrete proinflammatory cytokines, reactive oxygen species, and nitric oxide, all of
which can contribute to additional neuronal cell death, axonal demyelination, and
functional deficits following SCI [37, 38, 39, 40]. Critically, while glucocorticoids
such as methylprednisolone were once the standard of care for acute SCI due to
their antiinflammatory properties, these agents are also associated with unfavorable
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Figure 3.1: PLG multichannel bridge and hemi-sectional SCI model. (A) Photomicro-
graph of a bridge with 200 µm multichannel. (B) Schematic representation of
hemi-section SCI at T9-T10 and multichannel bridge implantation illustrating approx-
imate bridge dimensions. (C)Schematic multichannel bridge regions where the bridge
was divided for analysis. From the rostral edge of the bridge/tissue interface, rostral
region analysis was done at 0-400 µm, central at 400-800 µm, and caudal at 800-1200
µm.
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side effects, such as sepsis, gastrointestinal bleeding, and thromboembolism [41, 42],
indicating that improved methods are needed. Systemic depletion of neutrophils
or monocytes has either not altered or has had a small effect on SCI outcome [43].
Because monocytes and neutrophils are necessary for wound healing and tissue regen-
eration after injury, reprogramming the immune response could be a more effective
strategy to minimize loss of function and enable repair.
We have previously demonstrated that 500-nm-diameter poly(lactide-coglycolide)
(PLG)-based nanoparticles (NPs) carrying a negative zeta potential distract circu-
lating immune cells such as inflammatory monocytes and neutrophils away from
the injury site [44, 45]. i.v.-administered NPs reduced pathological symptoms and
produced a therapeutic benefit in inflammation-mediated diseases on the central
nervous system (CNS) including West Nile virus, encephalitis, and experimental au-
toimmune encephalomyelitis [44, 45, 46]. Highly negatively charged NPs are thought
to bind to the scavenger receptor on circulating immune cells, effectively reprogram-
ming them to influence their trafficking to the spleen and, thus, indirectly attenuate
the immune pathology at the inflamed area [45, 46]. In SCI, recent studies demon-
strate that hematogenous-infiltrating immune cells are predominantly responsible for
secondary axonal dieback, suggesting that reducing hematogenous immune cell infil-
tration at early time points may indirectly reduce tissue degeneration by attenuating
the inflammation-mediated secondary events [47, 48]. Reprogramming immune cells
to accumulate at the injury and assume proregenerative phenotypes may provide a
means to directly modulate the injury environment to promote regeneration.
Herein, we investigate NPs that reprogram inflammatory cells intravascularly to
obtain a fraction that home to the injury and modulate the microenvironment, re-
sulting in enhanced regeneration and functional recovery after SCI. NPs (500 nm
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Figure 3.2: In vivo biodistribution analysis and internalization of NPs. (A) Experimen-
tal timeline in this study. (B) In vivo imaging system images from the spinal cord
and spleen were acquired at day 1 after injection. (C) The fluorescence intensity
was quantified in organs from all conditions. (D) NPs-Cy5.5 were observed within
the injury from SCI group at day 7 after SCI. The white line indicates implanted
bridge area within the spinal cord. (E) Spinal cord sections were labeled with anti-
7/4 and Hoechst at day 7 after SCI. NPs-Cy5.5 colocalized with inflammatory mono-
cytes/neutrophils (yellow) within SCI in the NP group. (Inset) High-magnification
image of Hoechst+/7/4+/NP+ within bridge area (white arrowheads). (F) and (G)
The number of Hoechst+/7/4+/NP+ and Hoechst+/7/4+ cells within bridge area from
the NPs group (F) and percentage of NPs-Cy5.5 expressing immune cells (G) at day
7 and 10 after SCI. More than 80% of immune cells were colocalized with NPs-Cy5.5
within SCI. (H) 7/4+ immune cells distribution from both groups at day 10 after SCI.
(I) Number of accumulated immune cells was quantified at day 7 (E) and 10 (H) after
SCI from both conditions from ipsilateral and contralateral sides. A 2-way ANOVA
with Tukeys post hoc test for the multiple comparisons or unpaired t test ( 2-tailed)
was performed (G), where ***P<0.001 and ****P< 0.0001 compared with PBS group,
mean ± SD, n = 5 per group and time point. n.s., not significant. (Scale bars: D, 200
µm; E, 50 µm; H, 100 µm.)
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diameter, zeta potential < -30 mV) were administered i.v. daily for 7 d immediately
after SCI. A lateral hemisection SCI model was employed, with bridge implantation
employed in all studies as a means to define a region in which spared axons can be
distinguished from regenerating axons (Fig. 3.1). We investigate the biodistribution
of NPs among tissues by fluorescence imaging and, subsequently, within the spinal
cord. Inflammatory responses were characterized histologically and through gene
expression analysis. Regeneration following NP treatment was assessed through the
number of axons, the presence of serotonergic axons, and myelination of axons with
locomotor functional testing performed. The administration of NPs targets innate
immune cells to reprogram their function, which represents a strategy for neuropro-
tection and neuroregeneration after SCI.
3.4 Results
3.4.1 NP Internalization and Immune Cell Sequestration
In vivo images were acquired to investigate the biodistribution of NPs. Initially,
NPs (1 mg, Cy5.5-conjugated [NPs-Cy5.5]) were administered i.v. on a daily basis
for 7 d starting the day of injury (Fig. 3.2A). The spinal cord, spleen, and liver were
collected for analysis at day 1, 4, and 8 after injection from all conditions (day 7,
10, and 14 after SCI) (Fig. 3.2B and Figs. 3.3 and 3.4). In both SCI and sham
groups, the greatest fluorescence intensity from NPs was observed in liver. However,
fluorescence associated with NPs was also observed in the spinal cord and spleen
(Fig. 3.2C). Radiant efficiency levels associated with NPs-Cy5.5 in the spinal cord
were approximately 3-fold greater in the SCI group compared with the sham group;
in contrast, in the spleen and liver, no differences were observed between sham and
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SCI groups. Subsequently, fluorescence levels gradually decreased in all sites over
time (Figs. 3.3 and 3.4). At day 4 after injection (day 10 after SCI), the fluorescence
associated with NPs-Cy5.5 was substantially decreased in the spleen and liver, yet no
significant differences were observed in the spinal cord compared with those at day 1
post injection. However, the fluorescence associated with NPs-Cy5.5 was decreased
in all organs as in the na¨ıve group at day 8 after injection.
Figure 3.3: In vivo biodistribution of NPs over time. (A)The spinal cord and spleen were
collected from SCI with NPs treatment group at day 4 and 8 post-injection and IVIS
images were acquired. (B) and (C) The fluorescence intensity was quantified in spinal
cord (B) and spleen (C)as a function of time. A two-wayANOVA with Tukeys post hoc
test for the multiple comparisons, where ****P<0.0001, mean ± SD, n=5/group and
time point.
Next, the distribution of particles within the spinal cord and cell types with in-
ternalized particles were investigated. Cy5.5 fluorescence was observed within the
bridge area after SCI (Fig. 3.2D). In addition, immunofluorescence data indicated
that about 80% of NPs-Cy5.5 were colocalized with 7/4 (Ly-6B.2)+ inflammatory
monocytes/neutrophils within the bridge (Fig. 3.2 EG). Anti-7/4 was selected as
a marker for inflammatory monocytes/neutrophils, since the 7/4 antigen is present
on the cell surface of both inflammatory monocytes and neutrophils [49]. We sub-
sequently investigated inflammation within the spinal cord, specifically focusing on
the accumulation of inflammatory monocytes/neutrophils and gene expression asso-
23
Figure 3.4: NPs biodistribution in liver after SCI (A) IVIS images from the liver were acquired
at day 1 post-NPs injection. Radiant efficiency levels associated with NPs-Cy5.5in sham
and SCI groups were substantially increased compared to nave group. (B) The liver
wascollected from SCI with NPs treatment group and the fluorescence intensity was
quantified at various time points in liver. A two-way ANOVA with Tukeys post hoc
test for the multiple comparisons, where****p<0.0001, mean ± SD, n=5/group and
time point.
ciated with immune cells. At days 7 and 10 after SCI, 7/4+ cell numbers in the injury
with NP administration were significantly reduced relative to control conditions and
no differences were observed in contralateral spinal cord (Fig. 3.2 H and I and 3.5).
Gene expression levels for neutrophils (CD11b and Ly6G) and inflammatory mono-
cytes (CCR2 and Ly6C) were investigated in the spinal cord and spleen at day 7 after
SCI. The data indicated that NP administration significantly decreased the expres-
sion of genes associated with neutrophils and inflammatory monocytes within the
spinal cord compared with the phosphate-buffered saline (PBS) group (Fig. 3.6A).
Although Ly6C gene expression level within the spleen for NP treatment trended
toward greater expression compared with the PBS group, these trends were not sig-
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Figure 3.5: Inflammatory monocytes/neutrophils distribution within contralateral side
of spinal cord. (A and B) Contralateral side of spinal cord sections were stained with
anti-7/4 and Hoechst at day 7 post-SCI (A) and at day 10 post-SCI (B) from both
PBS and NPs groups. Dashed line indicates the implanted bridge area and white line
indicated host spinal cord, scale bar = 200 µm.
nificant. However, CD11b, Ly6G, and CCR2 expression levels in the spleen from
the NP group were significantly increased relative to the PBS group (Fig. 3.6B).
In the spleen, NPs colocalized with 7/4 cells (Fig. 3.7) and MARCO+ cells (Fig.
3.8 AC). Additionally, in vitro NP internalization assays demonstrated that addition
of soluble MARCO significantly decreased NPs internalization (Fig. 3.8D). Collec-
tively, in agreement with previous studies [45, 46, 50], these results suggest that NP
administration associates with innate immune cells such as inflammatory monocytes
and neutrophils, which influence their numbers in the spleen and spinal cord. In
addition, NP administration contributes to decreasing immune cells accumulation at
inflamed sites.
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Figure 3.6: Gene expression of neutrophils markers Cd11b and Ly6G and inflammatory
monocytes markers Ly6c and Ccr2 were investigated from (A) spinal cord and
(B) spleen through qRT-PCR at day 7 post-SCI in all conditions. The data suggest
that NP-Cy5.5 downregulate the levels of neutrophils and inflammatory monocytes
at the injured area. A one-way ANOVA with Tukeys post hoc test for the multiple
comparisons, where **P<0.01, and ****P<0.0001 n=5/group.
3.4.2 NPs Induce Macrophage Polarization at the Injury Site
We next investigated macrophage polarization following NP treatment of SCI, as
macrophages play pivotal roles in inflammatory responses after injury [47, 51] (Fig.
3.9). Macrophages have the potential for plasticity in their phenotype depending
on their microenvironment, and although macrophage phenotypes are not binary,
they have been classified as inflammatory M1 and proregenerative M2 phenotypes
for ease of description [51]. We have reported that M2 macrophages contribute to
creating proregenerative microenvironments leading to axonal regrowth and remyeli-
nation, and locomotor recovery after SCI [52, 53]. Analysis of markers for M1 and
M2 macrophages in the spinal cord indicated that expression levels of the proin-
flammatory markers inducible nitric oxide synthase (iNOS), CD86, and monocyte
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Figure 3.7: 7/4+ immune cells and NPs colocalization in the spleen. Spleen sections were
collected from (A)na¨ıve, (B) PBS injection, and (C)NPs injection groups and were
labelled with Hoechst and anti-7/4 at day 7 post-SCI. NPs-Cy5.5 were colocalized with
inflammatory monocytes/neutrophils within the spleen in NPs group. Inset: high-
magnification image of Hoechst+/7/4+/NP+ within the spleen (yellow, scale bar: 200
µm
chemoattractant protein-1 (MCP-1) were significantly down-regulated in the NPs
compared with the PBS group from day 7. As key markers for M1 phenotypes,
these factors are associated with inflammatory responses and release of proinflam-
matory factors, contributing to an inhibitory microenvironment at the injury [51]. In
contrast, levels of the M2 markers CD206 and interleukin (IL)-10 were significantly
increased in the NPs relative to the PBS group. These results were maintained until
day 84 after SCI (Fig. 3.9 A and B). In agreement with previous studies [52, 54], no
difference was observed in Arginase1 (Arg1) expression between groups at day 7, yet
Arg1 was significantly up-regulated following NP treatment at day 14 and 84 after
SCI compared with PBS. Interestingly, expression levels of proinflammatory factors
(CD86 and MCP-1) were reduced in the PBS group compared with SCI only, while
antiinflammatory markers (Arg1 and CD206) were substantially increased in the PBS
group compared with SCI only at day 84 after SCI, indicating a role of the bridge
for limiting inflammation. Subsequently, immunofluorescence data were investigated
to quantify the total number of CD206+ cells (Hoechst+/CD206+), macrophages
(Hoechst+/F4/80+), and M2 macrophages (Hoechst+/F4/80+/CD206+) at day 7
and 84 after SCI (Fig. 3.9 C and D). The number of CD206+ cells was significantly
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Figure 3.8: NPs colocalization and internalization with MARCO+ cells in the spleen.
(A)-(C) Spleen tissue sections were labelled for Hoechst (blue), anti-MARCO (red),
and NPs (green) from (A) na¨ıve, (B) PBS injection, and (C) NPs injection conditions
at day 7 post-SCI.NP-Cy5.5 were colocalized with MARCO+ cells (yellow) within the
spleen in NPs group (scale bar: 100 µm). (D)Bone marrow derived macrophages were
incubated with Cy5.5-NPs and 100 µg/ml of soluble MARCO (sMARCO)in cell culture
media. The mean NPs fluorescent intensity was investigated using flow cytometry. The
data indicated that sMARCO significantly reduced NPs internalization. Unpaired T-
test was performed, where *P<0.05, n=4/group.
increased in the NPs compared with PBS group (Fig. 3.9F). The density of prore-
generative M2 macrophages was about 2-fold up-regulated for the NPs group at day
7 and 84 after SCI (Fig. 3.9G). Furthermore, no statistical difference was noted in
the total number of infiltrated macrophages for all conditions (Fig. 3.9E) over time,
thus the ratio of M2 phenotypes to the total number of macrophages was substan-
tially up-regulated in NP group (Fig. 3.9H). Therefore, NP administration influences
macrophage polarization at the SCI.
3.4.3 NP Treatment Decreases Scarring Formation after SCI
SCI results in formation of both fibrotic and gliotic scar tissues at the lesion epi-
center; we therefore investigated the impact of the NPs on these parameters. The scar
tissue acts as a mechanical barrier to axon elongation and inhibiting axonal regener-
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Figure 3.9: Immunomodulation and macrophages polarization by NPs. (A) and (B) qRT-
PCR data indicate modulation of selected proinflammatory (A) and antiinflammatory
(B) markers at day 7, 14, and 84 after SCI by NP treatment. A 2-way ANOVA with
Tukeys post hoc test for the multiple comparisons, where aP<0.05, bP<0.01, cP<0.001,
and dP<0.0001, compared with PBS group and P¡0.05 and P<0.01 relative to SCI only
group, mean ± SD, n=5 per group and time point. (C) and (D) Immunodetection of M2
(CD206+/F4/80+/Hoechst+; red, green, and blue, respectively) macrophages (yellow),
(white arrowheads) within bridge from all conditions at day 7 (C) and day 84 after
SCI (D). (Inset) High-magnification image of M2 within bridge area. (E) The density
of total F4/80+ macrophages within the bridge. No changes were observed between
groups. (F) The quantitative analysis of CD206+ cells. NPs up-regulate the expression
of CD206+ cells. (G) The density of M2 by NPs. (H) The ratio of M2 to the total
number of macrophages. A 2-way ANOVA with Tukeys post hoc test for the multiple
comparisons, where *P<0.05 compared with PBS group, mean ± SD, n=5 per group
and time point. (Scale bars: C and D, 100 µm; C and D Inset, 50 µm.)
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Figure 3.10: NP treatment reduces the fibrotic and gliotic scarring after SCI. (A) and (C)
Spinal cord tissues were stained with anti-fibronectin (A) and anti-GFAP (C) using
longitudinal sections from 4 wk after SCI (Br, bridge); dashed line indicates the area
of fibrotic scar tissue around bridge and white line indicates host spinal cord. (Scale
bar: 400 µm.) (B) and (D) Quantification of fibrotic (B) and glial (D) scarring around
implanted bridge area. No differences were observed between the nave and NP group.
The area of both fibrotic and glial scar was substantially decreased by NP treatment.
A one-way ANOVA with Tukeys post hoc test for the multiple comparisons, where
***P<0.001 and ****P<0.0001 compared with PBS group, meanSD, n=5 per group
and time point.
ation through accumulation of inhibitory molecules as a chemical barrier [34, 35]. A
fibrotic scar is characterized by accumulation of fibronectin, fibroblasts, and various
extracellular matrix molecules. Reactive astrocytes play prominent roles in forma-
tion of gliotic scar and act as a major impediment to axonal regeneration [35]. At 4
wk after SCI, the area of fibrotic scar tissue in the NP treatment group was decreased
more than 2-fold compared with PBS (Fig. 3.10 A and B). Similar to the level of
fibronectin, the area of glial fibrillary acidic protein (GFAP) staining in the NP group
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was also substantially decreased 2- to 3-fold relative to the PBS group (Fig. 3.10 C
and D). No differences were observed compared with na¨ıve group (Fig. 3.11). These
data indicate that NP administration significantly decreased both fibrotic and gliotic
scarring after SCI.
Figure 3.11: Uninjured spinal cord tissues were labelled with anti-fibronectin (A) and
anti-GFAP (B) using longitudinal sections from 4 weeks after SCI (the white line
indicates host spinal cord, scale bar=400 µm).
3.4.4 NPs Enhance Axonal Regrowth and Remyelination within an Im-
planted PLG Bridge
We investigated the impact of NP treatment on axonal regrowth and myelination
in the chronic (day 84 after SCI) phase of SCI (Fig. 3.12). Spinal cord sections
were stained using neurofilament 200 (NF200), myelin basic protein (MBP), and
myelin protein zero (P0). Immunofluorescence data indicated that axons were ob-
served throughout the bridges in all conditions (Fig. 3.12 A and B and Fig. 3.13).
High magnification images showed that regenerating axons were found in bundles
within the bridge (Fig. 3.12 A and B). NP administration substantially increased
the number of NF200+ axons relative to the PBS group (Fig. 3.12C). Similar to
NF200+ axons number, all myelinated axons (NF200+/MBP+) were increased 3-fold
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Figure 3.12: NPs improve the axonal regrowth and remyelination in the chronic SCI
phase. (A and B) Spinal cord sections were labeled using NF200 (axons), MBP
(all myelination), and P0 (Schwann cells derived myelination) from PBS (A) and
NP (B) conditions at the rostral location. The line indicated the bridge area for
quantification and dashed line is for higher magnification area in A’ and B’. White
arrowheads show all myelinated axons (NF200+/MBP+), and white arrows indicate
Schwann cell-derived myelinated axons (NF200+/MBP+/P0+). (C) Quantification of
tothnnal number of NF200+, NF200+/MBP+, NF200+/MBP+/P0 (oligodendrocyte-
mediated myelinated axons), and NF200+/MBP+/P0+. (D) Proportion of axons that
was myelinated within the bridge area. (E) Percentage of axons that was myelinated
by oligodendrocytes. A 2-way ANOVA with Tukey’s post hoc test for the multiple
comparisons were performed where **P<0.01, ***P<0.001, and ****P<0.0001 rela-
tive to PBS group, meanSD, n=5 per group. (Scale bars: A and B, 300 µm; A’ and
B’, 100 µm.)
in response to NPs relative to PBS injection. In addition, the significantly greater
number of oligodendrocyte- (NF200+/MBP+/P0) and Schwann cell-derived myeli-
nated (NF200+/MBP+/P0+) axons were observed for NP treatment relative to the
PBS group. Furthermore, about 43% of the NF200+ axons were myelinated in the
NP condition, with 40% of those axons myelinated by oligodendrocytes, which were
similar to those in uninjured contralateral side (Fig. 3.12 D and E). Collectively,
these data suggest that NPs produce an environment more permissive to axonal
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Figure 3.13: Higher magnification area in figure 3.12A’ and 3.12B’. Spinal cord sections
were stained with P0 (Schwann cells derived myelination) from both PBS and NPs
groups. Scale bar; 50 µm.
growth and remyelination after SCI.
Figure 3.14: Density of serotonergic fibers by NPs. (A) and (B) Spinal cord sections were
labeled for serotonin from PBS (A) and NP (B) conditions at the rostral location in the
chronic SCI phase. The line indicated the bridge area for quantification and dashed
line is for higher magnification area in A and B. (C) Quantification of serotonergic
axonal density in the bridge at rostral (0-400 µm), central (400-800 µm), and caudal
(800-1,200 µm) locations from the rostral edge of the bridge/tissue interface. A 2-way
ANOVA with Tukey’s post hoc test for the multiple comparisons, where ****P<0.0001
compared with PBS group, mean ± SD, n=5 per group. (Scale bars: A and B, 300
µm; A and B, 100 µm.)
3.4.5 NPs Increase the Density of 5-Hydroxytryptamine Fibers after SCI
The presence of axons that are positive for the neurotransmitter serotonin (or
5-hydroxytryptamine [5-HT]) was assessed because these axons have been associated
with recovery of function and attenuation of allodynia/hyperalgesia after SCI [55, 56].
This role of 5-HT axons in function makes it a good marker for regeneration of
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descending tracts. Spinal cord tissues were immunostained for 5-HT at day 84 after
SCI, and the densities of 5-HT fibers quantified at 3 distinct locations of the bridge:
rostral, central, and caudal (Fig. 3.14 and Fig. 3.1C). 5-HT fibers were identified
throughout the bridge; however, about 5 to 9 times greater density of 5-HT fibers
was observed with NP treatment in all 3 locations compared with PBS (Fig. 3.14 A,
B, and C). Although data showed a trend toward greater intensity of 5-HT at rostral
and central locations in contralateral side relative to NPs, no significant changes were
observed between groups. These data suggest that in addition to the observation
of neurofilament axons and active remyelination within the bridge, NP treatment
specifically resulted in the growth of descending motor axons as assessed by density
of 5-HT fibers within the bridge.
3.4.6 NPs Improve Locomotor Function after SCI
We next investigated the expression of regeneration-associated genes (RAGs) fol-
lowing NP administration in the acute and chronic SCI phase from the injured
spinal cord tissue (Fig. 3.15 A and B). Genes were selected from neural system
development (Gene Ontology [GO] accession no. GO:0007399), locomotor recovery-
(GO:0007626), and chemical synaptic transmission- (GO:0007268) associated gene
ontologies based on a previous study [53]. Gene expression data indicated that se-
lected genes had up-regulated expression in the the NP group for both the acute
and chronic phase of SCI relative to PBS injection. Interestingly, in the chronic SCI
phase, expression levels of RAGs (ChAT, Hoxd10, and Lhx5) in the PBS injection
group were also statistically up-regulated relative to SCI only group, suggesting a role
for the bridge alone in supporting regeneration. Subsequently, ipsilateral hindlimb
locomotor recovery was assessed through the Basso Mouse Scale (BMS) before injury,
at day 3, and weekly for 84 d after SCI (Fig. 3.15C). All animals exhibited normal
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open field locomotion before SCI (BMS;9). No ipsilateral hindlimb movement was
observed at day 3 after SCI in any treatment group (BMS;0). However, BMS scor-
ing in the NP group revealed a substantially improved locomotor function compared
with the PBS group from day 7 through day 84 after SCI. In agreement with gene
expression data, the BMS score in PBS group was significantly increased relative to
the SCI-only group from day 70 after SCI, indicating that the bridge itself also has
a positive effect on locomotor recovery. These data demonstrate that NPs have an
early effect on reprogramming of circulating immune cells, which synergize with the
microenvironment created by the bridge to induce long-term expression of RAGs at
the injury, resulting in a proregenerative microenvironment that is associated with
an improved locomotor function after SCI.
Figure 3.15: Locomotor functional recovery by NPs. (A and B) Regeneration associated genes
were investigated via qRT-PCR in the acute (A) and chronic (B) SCI phase. A one-
way ANOVA with Tukeys post hoc test for the multiple comparisons, where *P<0.05,
***P<0.001, and ****P<0.0001 compared with PBS group, P<0.01 and P<0.0001
relative to SCI only, meanSD, n=5 per group. (C) The ipsilateral hindlimb locomotor
function was assessed using the BMS weekly for 84 d after SCI. NPs enhance the
locomotor function following SCI. BL, baseline. A 2-way ANOVA with Tukeys post
hoc test for the multiple comparisons, where, *P<0.05, **P<0.01, and ***P<0.001,
compared with PBS group and ˆP<0.05 relative to SCI only, mean ± SD, n=18 per
group and time point.
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3.5 Discussion
In the present study, we investigated the potential for reprogramming of circulat-
ing innate immune cells through NP administration to enhance functional regenera-
tion following SCI. When innate immune cells are activated in the blood and spleen,
they have high phagocytic capacity for scavenging apoptotic cells, cellular debris,
and foreign invasive materials [57, 58]. Generally, NPs may be perceived by inflam-
matory monocytes and neutrophils as foreign material and are then rapidly internal-
ized [46, 59, 60]. The rapid infiltration of various immune cells including inflamma-
tory monocytes and neutrophils into the SCI leads to inflammatory response-derived
secondary damage, contributing to further neuronal cell death, axonal dieback, de-
myelination, and scar tissue formation [37, 61]. For in vivo SCI treatment, systemic
depletion of immune cells has led to mixed results with some studies showing im-
proved regeneration with partial depletion of select immune populations, while other
studies show worsened histological and functional outcomes with complete depletion
of certain immune populations [61]. Herein, we focused on a nondepleting strategy
targeting inflammatory cells in the vasculature, before their extravasation to the in-
jury. We tested the hypothesis that particles could reprogram innate immune cell
trafficking and phenotype to limit deleterious inflammatory responses, and promoting
an environment that is a more permissive for regeneration.
i.v.-delivered NPs influence trafficking patterns of inflammatory monocytes and
neutrophils, with a modest proportion of NP-positive cells trafficking to the spinal
cord and the majority accumulating in the spleen. The spleen plays substantial roles
in coordinating inflammatory responses and restoring immune homeostasis that lead
to functional recovery after SCI [62]. i.v.-administered NPs are thought to bind to cir-
36
culating immune cells via scavenger receptors such as MARCO. NPs with a diameter
of 500 nm were selected based on our previous work with autoimmune disease [63] and
a greater internalization due in part to binding affinity for immune cells and flow pat-
terns within the blood [45]. Previous studies reported that neither resident microglia
nor T lymphocytes express scavenger receptors such as MARCO [64], thus indicating
that NPs target selectively circulating immune cells that would normally infiltrate a
SCI. In agreement with previous studies, in vitro studies have demonstrated that NPs
were internalized by bone marrow-derived macrophages (Fig. 3.8) [45, 50]. The se-
questration of inflammatory monocytes/neutrophils in the spleen has been observed
in other inflammation-mediated diseases models by NP treatment [45, 46, 48]. In
agreement with these previous studies, NPs reduced the number of inflammatory
monocytes/neutrophils in the injured spinal cord, with this decrease likely indirectly
decreasing tissue degeneration due to the reduced immune cell infiltration. However,
we observed that NP-positive cells were present within the spinal cord, and our data
suggest that these cells directly influenced the microenvironment by inducing a prore-
generative phenotype that was more permissive for tissue regeneration. These results
are also supported by gene expression analysis (Fig. 3.6). In particular, both human
and mice inflammatory monocytes express CCR2, which is principally responsible for
recruitment and accumulation of these cells at inflammatory sites [45, 65]. Previous
study showed that delivery of CCR2 small interfering RNAs via liposome-reduced
inflammatory monocyte trafficking in inflammatory disease models [65]. However,
because of widespread expression of CCR2 in other immune cells such as B cells and
T cells, targeting CCR2 may have undesired side effects [66].
The cumulative effect of NP treatment is modulation of the microenvironment,
which induces macrophage polarization from a proinflammatory phenotype toward
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a proregenerative phenotype. In the intact CNS, microglia/macrophages have both
M1 and M2 properties; however, following SCI, proregenerative M2 macrophages
are typically decreased, while pathological M1 phenotypes are increased and pro-
duce proinflammatory factors [54]. Therefore, a transient and low number of M2
phenotype cells at the injury may fail to control secondary inflammatory events fol-
lowing primary SCI. NP treatment modulated the microenvironment and led to an
M2-enhanced environment at the SCI site, with down-regulation of proinflamma-
tory factors and up-regulated expression of antiinflammatory factors such as Arg1,
CD206, and IL-10 throughout day 84 after SCI. Interestingly, NP treatment also de-
creased the expression level of MCP-1, which is responsible for attracting circulating
inflammatory monocytes to injuries by binding to its receptor CCR2 [45] and may
also influence trafficking patterns of inflammatory monocytes after SCI. In addition,
down-regulation of proinflammatory factors following NP treatment indicates that
repeated-administration of NPs was well tolerated and reduced scar formation. Arg1
has been shown to promote wound healing and decrease the intensity and duration
of inflammation [53]. Similarly, CD206 and IL-10 both have demonstrated roles in
modulating immune responses and secondary damage after injury. CD206 binds and
removes apoptotic and necrotic cells without generation of cytotoxic byproducts after
injury [54]. The antiinflammatory cytokine IL-10 suppresses nuclear factor-κB (NF-
κB) activation, leading to down-regulation of proinflammatory factors secretion [53].
Consistent with these roles, NP treatment up-regulated the number of CD206+ cells
and M2 macrophages (CD206+/F4/80+) compared with the PBS group.
NP treatment significantly reduced both fibrotic and gliotic scarring after SCI.
Lesion scarring represents both a mechanical and chemical impediment to axonal out-
growth and regeneration, and previous studies have demonstrated that macrophages
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lead to a profibrotic microenvironment by releasing proinflammatory factors. In both
mice and human, these proinflammatory factors contribute to fibroblast activation
and the induced secretion of connective tissue growth factor (CTGF) and collagen
IV through SMAD2/3-mediated pathways, initiating formation of a dense, insoluble
fibrotic matrix [67]. Additionally, prior reports demonstrate that both circulating
immune cells and hematogenous-derived macrophages recruit perivascular fibroblasts
at the SCI, while depleting of hematogenous macrophages decreases the fibroblast
accumulation and fibrotic scar area, enhancing axonal regrowth [68]. In addition to fi-
brotic scarring, astrocytes also become reactive after SCI and are a major component
of gliotic scarring. Reactive astrocytic responses are also initiated by proinflamma-
tory factors that act through up-regulation of extracellular signal regulated kinase
(ERK) signaling [41]. In this study, NP inhibition of immune cell accumulation, in-
duction of proregenerative phenotypes, and generation of antiin flammatory factors
at the injury site may have altered fibroblast migration and astrocyte-activation,
reducing fibrotic and gliotic scarring and promoting axonal regeneration following
SCI.
NP treatment has positive effects on axonal regeneration and remyelination after
SCI. In the inflammatory microenvironment, proinflammatory factors are cytotoxic
to neuronal cells and stimulate a short and arborizing growth pattern of axons af-
ter SCI [41, 54, 69]. NP administration promotes axonal regrowth throughout the
implanted-multichannel bridges compared with PBS injection. In the data reported
herein, NP treatment influences the gene expression dynamics and macrophages po-
larization at the injury. Increased Arg1 by NPs at the injury enhances overexpression
of polyamines, promoting cAMP downstream signaling pathway to activate axonal
regrowth even in a myelin inhibitory microenvironment [54, 70]. IL-10 has been re-
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ported to up-regulate expression of antiapoptotic factors and provide a direct trophic
effect on axonal regeneration under the neurotoxic microenvironment [53, 71]. CD206
promotes tissue remodeling after injury involving wound retraction and inflamma-
tory resolution for tissue homeostasis [47]. All of these factors may contribute to
creating a proregenerative environment after SCI leading to axonal regeneration. Ax-
onal remyelination after SCI is considered as a major component of the regenerative
process and is mediated by multipotent oligodendrocytes progenitor cells (OPCs).
Previous studies have indicated that macrophages polarization into proregenerative
M2 phenotypes is an essential step for differentiation of OPCs for remyelination af-
ter SCI [53, 72]. Moreover, an M2 mediated-regenerative factor activin-A directly
binds to OPCs and facilitate OPC differentiation at the SCI [72, 73]. Therefore,
NP treatment-mediated reprogramming of innate immune cells toward proregener-
ative phenotypes may be a key component of the regenerative process for axonal
regeneration and remyelination after SCI.
The early effects of NP treatment synergize with multichannel bridge to up-
regulate long-term expression of RAGs and enhance functional recovery after SCI.
PLG has been widely used for nerve tissues repair [41, 52, 74], with PLG biode-
grading slowly into lactic and glycolic acid that are readily cleared from the tissue,
metabolized, and eliminated from the body as carbon dioxide and water via citric
acid cycle [75]. Previously, we reported that bridge implantation alone increased
the expression levels of axonal guidance-associated and synaptogenesis- associated
gene ontologies at the SCI lesion [53], and altered the chemical balance and physical
cues for a more permissive environment via infiltration of endogenous supportive
cells, leading to release of factors for injury stabilization and attenuation of inflam-
matory responses [41, 52]. Furthermore, mechanical guidance by the 3D structure
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of the bridge contributed to regeneration of descending axons and an increase in
growth associated protein 43 (GAP-43) expression below the injury, leading to fore-
limb functional recovery [74]. In addition, the bridge contributes to reducing the
extent of scar formation and astrogliosis [53, 53]. These characteristics of bridge
implantation are consistent with the observed up-regulation of RAG expression and
reduction of proinflammatory factors in our control group, which consisted of PBS
injections in conjunction with bridge implantation. These results indicate that the
bridge itself has the potential to support axonal regeneration via modest alteration of
inflammatory responses and up-regulation of RAGs, leading to the locomotor func-
tional recovery over the SCI-only group over time. BMS scores in the NP group were
significantly increased starting from 1-wk after SCI compared with PBS, indicating
that rapid NP-mediated inhibition of inflammatory immune cells accumulation led
to less degeneration for rapid recovery of motor function. Furthermore, an improve-
ment of locomotor skills was also observed from the PBS group at the chronic SCI
phase compared with SCI only, which likely results from a more permissive environ-
ment enabling regeneration. These results were also supported by gene expression
data. NP-derived immune cells modulation led to the long-term expression of multi-
ple antiinflammatory factors and RAGs and induced a proregenerative environment
at the injury. A number of genes associated with motor neurons were observed to
be up-regulated at later time points. Choline acetyltranferase (ChAT), which marks
mature motor neurons [76], had increased expression. Similarly, an increased expres-
sion of Homeobox D10 (Hoxd10) was observed, which organizes the patterning of
motor neurons in the spinal cord [53]. LIM homeobox 5 (Lhx5), implicated in the
proliferation and differentiation of motor neurons [61], and transient receptor poten-
tial channel subfamily C (Trpc5), which leads to differentiation of neural progenitor
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cells [41, 42], were also up-regulated. Following SCI, descending serotonergic pro-
jections to spinal motor neurons were disrupted, leading to a decrease in serotonin
levels and enhancing the locomotor dysfunction [55, 56]. Our data demonstrate that
NP treatment up-regulates the number of 5-HT fibers within bridges, which also
may contribute to locomotor recovery. Taken together, these data demonstrate that
NP treatment has early and rapid therapeutic impacts, which have long-term con-
sequences with multichannel bridges synergistically, contributing to immune cells
reprogramming toward pro-regenerative phenotypes. In addition, these effects lead
to the long-term up-regulation of antiinflammatory factors, RAGs, and serotonergic
fibers, promoting locomotor recovery after SCI.
In conclusion, this report demonstrates that NP treatment can modulate the
inflammatory microenvironment after SCI. NP-mediated rapid reprogramming of
innate immune cells has a sustained impact on microenvironment modulation at
the SCI injury when combined with bridge implantation. In addition, this regen-
erative microenvironment initiates a cascade of events, including induction of gene
expression profiles associated with neural development and regeneration, which likely
contributes to the enhanced numbers of regenerating and myelinated axons and im-
proved functional recovery. Collectively, this strategy of targeting the innate immune
cells in the vasculature before their extravasation to a SCI may have applications to
other injury models associated with inflammation-mediated tissue damage. Further-
more, NPs are made of a Food and Drug Administration-approved material, stable
at room temperature, do not contain an active pharmaceutical ingredient (API),
and can be readily stored for immediate i.v. administration within the standard of
therapy guidelines to limit secondary damage.
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3.6 Materials and Methods
3.6.1 Multichannel bridges fabrication
Initially, Poly(D,L-lactide-co-glycolide)(PLG, 75:25 lactide:glycolide; i.v. 0.76
dL/g; Lakeshore Biomaterials, Birmingham, AL, USA) was dissolved in dichloromethane
(6 % w/w) and emulsified in 1% poly(ethylene-alt-maleic anhydride) using a homog-
enizer (PolyTron 3100;Kinematica AG, Littau, Switzerland) to make microspheres
(z-average diameter 1µ m). D-sucrose (Sigma Aldrich), D-glucose (Sigma Aldrich),
and dextran MW 100,000 (Sigma Aldrich) were mixed at a ratio of 5.3:2.5:1 re-
spectively by mass then were caramelized, cooled, and drawn from solution using
a Pasteur pipette to create sugar fibers. These fibers were coated mixture of PLG
microspheres and salt (with a 1:1 ratio), then pressed into a salt-lined aluminum
mold. Subsequently, it was equilibrated, and gas formed with high pressure of CO2
gas (800 psi) for 16 h in a custom-made pressure vessel. The pressure was released
over a period of 40 min, which fused adjacent microspheres to produce a continuous
polymer structure. The bridges were cut into 1.2mm sections, and the porogen was
leached in water for 2 hours, then the bridges were dried over-night and stored in a
desiccator (Fig. 3.1A).
3.6.2 Nanoparticle fabrication and injection
First, 50:50 PLG (inherent viscosity = 0.55dL/g) was purchased from Absorbable
Polymers (Birmingham, AL), and conjugated with Cyanine 5.5 amine dye (Lu-
miprobe corporation, Cockeysville, MD) using a N-(3-Dimethylaminopropyl)-N-ethylcarbodiimide
hydrochloride (EDC) (Sigma-Aldrich, St. Louis, MO)/ N-hydroxysuccinimide (NHS)(Thermo
Fisher Scientific, Waltham, MA) chemistry. Then, 50:50 PLG particles were fabri-
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cated using an oil-in-water single emulsion solvent evaporation method. Briefly,
50:50 PLG polymer and the polymer conjugated with cyanine 5.5 dye were dis-
solved in dichloromethane. Then, the mixture was added to Poly (ethylene-alt-
maleic anhydride) (Polyscience, Inc., Warrington, PA) solution, sonicated using a
Cole-Parmer CPX130 Ultrasonic Processor (Vernon Hills, IL), and stirred overnight
to remove organic phase. The resulting polymeric particles were washed three times
and lyophilized with combination sucrose and D-mannitol (Sigma-Aldrich, St. Louis,
MO). For the injections, PLG particles were resuspended in PBS at a concentration
of 5 mg/ml and aggregates were removed with a 35 µm mesh filter. Each animal
received 1 mg of particles (200 µl of suspension) via tail veil injection within two
hours after SCI per day for 7 days. The same volume of PBS was injected as a control.
3.6.3 Spinal cord hemisection injury model and animal care
All animal surgery procedures and animal care were conducted according to the
Animal Care and use Committee guideline at University of Michigan. The impact
of NPs on biodistribution, inflammatory responses, and locomotorregeneration was
assessed after SCI within five treatment groups: i) Nave (normal health animal),
ii) Sham (laminectomy only), iii) SCI only (without bridge implantation), iv) PBS
(SCI + bridge + PBS injection), and v) NPs (SCI + bridge + NPs injection)(Table
3.1) and immunofluorescence was investigated with; i) Na¨ıve, ii) PBS (SCI + bridge
+ PBS), and NPs (SCI + bridge + NPs) (Table 3.2). A mouse hemisection SCI
model was performed as described previously [53](1). Briefly, C57/BL6 female mice
(6-8 weeks old; Jackson Laboratory, Bar Harbor, ME, USA) were anesthetized using
isoflurane (2%). A dorsal laminectomy was performed at T9-T10 level then a 1.2 mm
long lateral of the midline spinal cord segment was cut and removed to generate a
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hemisection SCI model. Bridges were implanted in the injury site and covered using
Gelform (Pfizer, New York, NY, USA) (Fig. 3.1B). Muscle was sutured together,
then the skin was stapled. The animals were placed on a heating pad for recovery. For
post-operative animal care, Baytril (enrofloxacin 2.5 mg/kg, once a day for 2 weeks),
buprenorphine (0.1 mg/kg, twice a day for 3 days), and lactate ringer solution (5
mL/100 g, once a day for 5 days) were administrated subcutaneously. Bladders were
manually expressed until bladder reflexive function was observed twice a day.
Table 3.1: All experimental groups and total number of animals
Table 3.2: All experimental groups and total number of animals for IHC
3.6.4 In vivo bio-distribution of Nanoparticle
For the in vivo biodistribution of NPs study, animals were administered via tail
vein with 200 µl of 5mg/ml Cy5.5 conjugated NPs every day for 7 times. 1, 3,
and 7 days after injection, animals were euthanized, and tissues were dissected from
spinal cord and spleen. Each tissue was imaged using an IVIS Lumina LTE camera
system (Caliper Life Sciences, Hopkinton, MA). The region-of-interest values from
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each organ were recorded as photon flux in total photon count per cm2 per steradian.
3.6.5 RNA isolation and Quantitative Reverse-Transcriptase PCR
Initially, the spinal cord tissues were removed from all conditions. The spinal
cord tissues were removed and cut into about 2 mm segments centered on 1.2 mm
of bridge region; samples were not pooled. Next, samples were homogenized us-
ing 1 mL of Trizol reagent (Invitrogen, Carlsbad, CA) with a glass tissue grinder.
Samples were not pooled. RNA isolation was followed by chloroform extraction and
isopropanol precipitation [42]. The concentration of RNA was measured using Nan-
oDrop 2000C (Thermo Scientific, Newark, DE). Next, we conducted the quantitative
Reverse-Transcriptase PCR (qRT-PCR) using spinal cord for the gene expression
analysis over time. cDNA was synthesized using iScriptTM cDNA Synthesis kit (Bio-
Rad, Hercules, CA). Primers were designed for qRT-PCR (Table 3.3) [53, 38, 39].
The qRT-PCR products were assessed using the accumulation level of iQTM SYBR
Green Supermix (Bio-Rad) fluorescence following a manufacturers protocol on CFX
ConnectTM Real-Time PCR Detection System (Bio-Rad). The gene expression level
was normalized by the expression of 18s-rRNA and differences in gene expression
were presented as fold ratios from control group. Relative quantification was calcu-
lated as X = 2 ∆∆Ct, where ∆∆Ct = ∆E∆Ct and ∆E = Ct,expCt,18s−rRNA, ∆Ct
= Ct,controlCt,18s−rRNA [77]. All qRT-PCR values were expressed as the log2 trans-
formed after normalization to the housekeeping gene 18s-rRNA and +1 was marked
as cut-off value for upregulation.
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Table 3.3: Primer sequences for qRT-PCR
3.6.6 Nanoparticles internalization
Bone marrow derived macrophages (BMDMs) were generated as previously re-
ported [78]. BMDMs (0.5 million/well) were plated in 12-well plates. Cy5.5-NPs
were incubated in cell culture media for 30 min and incubated in 100 µ g/mL of sol-
uble MARCO (sMARCO, Recombinant mouse MARCO, R&D system, Minneapolis,
MN) for 45 min. Then, 100 µg/mL of sMARCO treated particles were added to each
well and cultured for 2 hours. Cells were harvested, blocked with TruStain FcXTM
(anti-mouse CD16/32, BioLegend, San Diego, CA) and stained with fluorochrome-
conjugated antibodies (BV650 Rat Anti-Mouse CD11b and BV510 Rat Anti-Mouse
CD45, BD Biosciences, San Jose, CA). Data was acquired with a flow cytometry
(LSRFortessa, BD Biosciences) and analyzed with FlowJo software (BD Biosciences).
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3.6.7 Behavioral test for locomotor function
Locomotor functional recovery in the ipsilateral hindlimb after SCI was accessed
using open field Basso Mouse Scale (BMS) locomotor rating scale with a score from 0
(no movement) to 9 (normal gait) [79]. The score is based on the ipsilateral hindlimb
locomotor ability of SCI mice. SCI mice (n=18/group) were observed in an open
field for 4 minutes after they had gently adapted to the field. Only the ipsilateral
hindlimb side was assessed at days 3 and then weekly after SCI for 12 weeks. The
score was obtained by taking an average value of results from each experimental
group. A baseline (BL) was determined at day 7 and 1 prior to the SCI. Animals
were randomly assigned to treatment group and assessment was performed by re-
searchers blinded to the group.
3.6.8 Tissue processing and immunofluorescence
Spinal cord tissues were collected at 1, 4, and 12 weeks after SCI. Those tissues
were then snap frozen in isopentane and embedded in Tissue Tek O.C.T compound
(Sakura Finetek, Torrance, CA, USA) with 30% sucrose. Samples were cryosectioned
in 18 µm transversely or in 12 µm longitudinally. All primary and secondary antibod-
ies were provided in Table 3.4. The number of immune-positive cells were manually
counted and done under blinded conditions. Multiple markers by co-staining was
examined by evaluating pixel overlap of different channels in NIH ImageJ (Bethesda,
MD, USA). Nonadjacent nine spinal cord tissues were selected randomly from three
distinct locations at caudal (0-400 µm), central (400-800 µm), and rostral (800-1200
µm) from the caudal edge of the bridge/tissue interface (total 27 tissues were assessed
per animal) (Fig. 3.1C). The accumulated inflammatory monocytes/neutrophils were
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identified by co-labelling Hoechst+ to 7/4 immunoreactive cells from day 7 and 10
following SCI within a bridge and from day 7 within the spleen. The percentage
of 7/4+ inflammatory monocytes/neutrophils that was co-labeled with NPs-Cy5.5
was determined from the ratio of the number of Hoechst+/7/4+/NP+ cells divided
by the number of Hoechst+/7/4+ cells within the bridge area. The total number of
macrophages and pro-regenerative M2 macrophages within a bridge area were eval-
uated by determining Hoechst+/F4/80+ cells and Hoechst+/F4/80+/CD206+ cells.
Macrophages were identified by localizing Hoechst+ staining to F4/80+ immunoreac-
tive and labeling them in ImageJ. Then, cell numbers were normalized to the counted
area in each tissue section. To investigate the numbers of regenerated and myelinated
neurofilaments, we used NF200+, NF200+/MBP+, and NF200+/MBP+/P0+ axonal
fibers to identify the numbers of axons, all myelinated axons, and myelinated ax-
ons by infiltrating Schwann cells, respectively. The percentage of myelinated axons
was determined from the ratio of the number of myelinated axons (NF200+/MBP+)
divided by the number of axons (NF200+) within the bridge area. To determine
the source of the myelination, we performed triple staining of NF200, MBP and
P0. NF200+/MBP+/P0− neurofilaments were considered as oligodendrocyte-derived
myelination. The fraction of oligodendrocyte-derived myelination was calculated as
NF200+/MBP+/P0− divided by NF200+/MBP+. To evaluate fibrotic and glial scar-
ring area around implanted multichannel bridges, nine nonadjacent sagittal sections
were selected randomly from each animal and condition, and the area of fibrotic and
gliotic scarring around the implanted bridge was investigated. The immunofluores-
cence images were converted to black and white then a standardized optical density
threshold to each image was applied. ImageJ was used to measure the amount of
stained area around the implanted bridges. To investigate the intensity of serotoner-
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gic fibers, total labelled pixels of serotonin labeled axons within the bridge area were
quantified and divided by the bridge area to obtained mean serotonergic axon den-
sity. Uninjured contralateral spinal cord tissues were obtained from PBS and NPs
injection groups and the density was obtained by taking an average value of results.
All tissues were imaged on an Axio Observer Z1 (Zeiss, Oberkochen, Germany) using
a 10x or 20x/0.45 M27 apochromatic objective and an ORCA-Flash 4.0 V2 Digital
CMOS camera (C11440-22CU, Hamamatsu Photonics, Hamamatsu City, Shizuoka,
Japan).
Table 3.4: Primary and secondary antibodies for immunofluorescence
3.6.9 Statistical analysis
A one or two-way ANOVA and Tukey’s post hoc test for the multiple compar-
isons, and Students t test were used for the statistical analysis. We performed the
Kolmogorov-Smirnov normality test [80]. P-value (alpha) 0.05 was used as a cut-off
such that P-values larger than 0.05 are considered as passing the normality test. To
achieve reasonable statistical power analyses, type II errors were controlled at 0.2
level for all the statistical tests and α=0.05. Equal variance (ANOVA Model) was
validated and assumed for each study. Given the above parameters, a conservative
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effect size was 0.25 for appropriate sample size for each study and all statistical analy-
sis were performed using G* Power Software [53], OriginPro (OriginLab Corporation,
Northampton, MA, USA), and Prism 6 (GraphPad Software, La Jolla, CA, USA).
P<0.05 was considered as statistically significant and the all values were expressed
in mean ± standard deviation (SD).
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CHAPTER IV
Therapeutic Benefit of Cargo-Free Immunomodulatory
Nanoparticles Combined with Anti-PD-1 Antibody
4.1 Authors
Yining Zhang, Kevin R. Hughes, Jacqueline S. Jeruss, and Lonnie D. Shea
4.2 Abstract
The presence of immunosuppressive innate immune cells such as myeloid derived
suppressor cells (MDSCs), Ly6C-high monocytes, and tumor-associated macrophages
(TAMs) at a tumor can inhibit effector T cell and NK cell function. Immune check-
point blockade using anti-programmed death 1 (PD-1) antibody aims to overcome the
immune suppressive environment, yet only a fraction of patients respond. Herein,
we test the hypothesis that cargo-free poly(lactide-co-glycolide) (PLG) nanoparti-
cles administered intravenously can divert circulating immune cells from the tumor
microenvironment to enhance the efficacy of anti-PD-1 immunotherapy in the 4T1
mouse model of metastatic triple-negative breast cancer. In vitro studies demon-
strate these nanoparticles decrease the expression of monocyte chemoattractant pro-
tein 1 (MCP-1) by 5-fold and increase the expression of tumor necrosis factor alpha
(TNF-α) by more than 2-fold upon uptake by innate immune cells. Intravenous
52
administration of particles results in internalization by neutrophils and monocytes,
with particles arriving in the liver, lung, spleen, and primary tumor. Nanoparticles
and anti-PD-1 antibody combination therapy significantly slowed tumor growth and
prolonged survival, while neither monotherapy did. Nanoparticle delivery decreased
the abundance of MDSCs in circulation and in the lung, the latter being the primary
metastatic site in the 4T1 model. Gene expression analysis by Gene Set Enrichment
Analysis (GSEA) indicated that inflammatory myeloid cell pathways were down-
regulated in the lung and upregulated in the spleen and tumor. Upregulation of
extrinsic apoptotic pathways was also observed in the primary tumor. Collectively,
these results demonstrate that cargo-free PLG nanoparticles can reprogram immune
cell responses and alter the tumor microenvironment in vivo to overcome the local
immune suppression attributed to myeloid cells to enhance the efficacy of anti-PD-1
therapy.
4.3 Introduction
Tumor growth and metastatic progression are aided in part by the function of
innate immune cells, which can be induced toward an immune suppressive function
by tumor-secreted factors [4]. Disease-induced cell types found at the primary tu-
mor or metastatic niche include inflammatory monocytes (CD11b+ Ly6Chi cells in
mice), tumor-associated macrophages (TAMs), and myeloid-derived suppressor cells
(MDSCs). Circulating inflammatory monocytes differentiate into tumor-associated
macrophages (TAMS) in tissues, which have immunosuppressive phenotypes and
induce angiogenesis to aid metastasis [81, 82]. Additionally, myeloid cell recruit-
ment has been shown to be critical for pre-metastatic niche development prior to
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metastatic cell colonization [6]. MDSCs are a class of neutrophil that has been im-
plicated in aiding tumor growth and metastasis, especially to the lung [5, 28]. These
cells normally serve to regulate the immune response to pathogens, but in the context
of cancer, MDSCs secrete immunosuppressive cytokines and reactive oxygen species
(ROS) to inhibit anti-tumor T cell and NK cell function [7]. These cells contribute
to the failure of immune checkpoint blockade or T-cell immunotherapies [83].
The immunosuppression and pro-tumor functions of myeloid cells have been the
targets of numerous therapies to alter either their numbers or phenotypes. Small
molecule inhibitors have been applied to inhibit cytokine secretion that recruits
myeloid cells [84, 85] or T cell function [86, 83], or repolarizing cells such as tumor-
associated macrophages [87]. Small molecule inhibitors of specific protein activators
of MDSCs and TAMs have been shown to reduce their number and abrogate dis-
ease [58, 18]. Depletion of one or more cell types has also been studied in this
context [58, 88, 89]. However, the large number of cells, cytokines, and other factors
that contribute to the immune suppression limit the efficacy of therapies that target
a single cell type or protein [90]. In addition, myeloid cell phenotypes within various
tissues are distinct [91], which motivates the development of therapies that can elicit
a tissue-dependent response.
An emerging approach for modulating innate immune cell response in tissues
are nanoparticles administered intravenously that target circulating immune cells.
Cargo-free polymer nanoparticles (NPs) have been shown to redirect the trafficking
of phagocytic innate immune cells upon, and moderate the disease-induced aberrant
behavior of these cells. The therapeutic benefit of these NPs has been demonstrated
in a West Nile virus infection model, ischemic reperfusion injury [45], traumatic brain
injury [92], as well as in spinal cord injury [93]. NPs have highly negative surface
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charge that result in uptake through scavenger receptors including MARCO [45], and
the specificity and biodistribution of polymeric NPs can be tuned with changes to the
polymer backbone. As such, NPs are not limited to uptake targeting ligands [94],
and they do not induce systemic responses in multiple tissue as with steroids or
NSAIDs.
In this report, we test the hypothesis that cargo-free PLG nanoparticles adminis-
tered intravenously divert circulating immune cells from the tumor microenvironment
or metastatic sites, altering the immune responses at the niche and enhancing the ef-
ficacy of anti-PD1 immunotherapy. In the orthotopic 4T1 mouse model of metastatic
triple negative breast cancer, disease-induced myeloid cells rapidly increase in number
systemically with disease progression [22] and metastatic 4T1 cells readily colonize
the lung due to the host of factors secreted by aberrant monocytes, macrophages,
and MDSCs. These myeloid cells have also been shown to directly contribute to
resistance to anti-PD-1 and anti-CTLA-4 in the 4T1 model [58]. The cell types and
biodistribution of nanoparticles are analyzed, and the impacts of the particles on the
cell phenotypes are analyzed both in vitro and in vivo. Particle administration is
analyzed with respect the the growth of the primary tumor, as well as the impact on
survival. Finally, impact of nanoparticles on gene expression within the primary tu-
mor or metastatic site is analyzed. The ability of nanoparticles to reprogram innate
immune cells within the primary tumor and metastatic tissues represents an oppor-
tunity to improving the therapeutic benefit of anti-PD-1 and other immunotherapies.
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4.4 Results
4.4.1 Nanoparticle Internalization by Innate Immune Cells
PLG nanoparticle internalization by tumor-induced immune cells was initially in-
vestigated in vitro. Three fluorescently labeled NP formulations were synthesized by
varying the surfactant type and PLG molecular weight (Fig. 4.1A) and incubated
with blood leukocytes from tumor-bearing mice at 5 ug/mL and 50 ug/mL NP
concentration (Fig. 4.1B). PEMA-High NPs exhibited high internalization at both
concentrations, so the subsequent studies were performed with PEMA-High NPs.
Myeloid-derived suppressor cells (MDSCs, CD11b+/Ly6Clo/−/Ly6G+) and other
myeloid cells (CD11b+/Ly6C−/Ly6G-) showed increased Cy5.5-NP internalization
at 50 µg/mL relative to 5 µg/mL (Fig. 4.1C), whereas the increased concentration
had no effect on the number of Cy5.5-NP+ monocytes as a percentage of total cells.
As MDSCs comprise a large majority of immune cells in circulation, internalization
was also quantified as the percentage of Cy5.5-NP+ cells relative to the number of
single cells for each cell subtype (Fig. 4.1D). At 5 µg/mL, nearly all monocytes are
NP+ (89.4 ± 5.4%) while a lower percentage of MDSCs and other myeloid cells have
lower relative internalization (23.7 ± 10.4% and 72.3 ± 14.5%, respectively). When
the NP+ cell numbers are increased at 50 µg/mL, nearly all cells are Cy5.5-NP+ in
all three cell populations (99.3 ± 0.5% of MDSCs, 99.9 ± 0.1% of monocytes, and
99.6 ± 0.2% of other myeloid cells). Taken together, these data demonstrate that
monocytes more readily internalize NPs than other myeloid subtypes at low concen-
trations, yet nearly all MDSCs and other myeloid cells have internalized NPs.
The biodistribution and in vivo internalization by myeloid cell subsets was next
studied following intravenous injection of Cy5.5-NPs. Assessment of whole-organ flu-
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Figure 4.1: Cy5.5-NPs are internalized by innate immune cells and are distributed in
disease-relevant tissues. (A) Three NP formulations with different combinations of
surfactant and PLG molecular weight were tested for uptake in vitro. (B) Blood leuko-
cytes from 4T1 tumor-bearing mice at 21 days post inoculation were incubated in vitro
with each formulation at 5 µg/mL and 50 µg/mL, and internalization was quantified.
PEMA-High NPs exhibited high uptake at both concentrations, and subsequent stud-
ies were performed with the PEMA-High NPs. Uptake was quantified (C and D) for
myeloid cell subtypes (C) as a percentage of all cells and (D) as a percentage of each cell
subtype. CD11b+/Ly6Clo/−/Ly6G+ cells (MDSCs) and CD11b+/Ly6C−/Ly6G− cells
(other myeloid cells) showed increased uptake with increase in NP concentration, while
monocytes did not. These data indicate that monocytes more readily internalize NPs
compared to MDSCs and other myeloid cells. A 2-way ANOVA with Tukeys multiple
comparisons test was performed (A and B), bars show mean ± SEM for n = 3 biological
replicates per condition, where ** p < 0.01, *** p < 0.001, ns, not significant.
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Figure 4.2: Uptake specificity can be tuned by changing surfactant and polymer molec-
ular weight.
orescence (Fig. 4.3A and Fig. 4.4) indicated that Cy5.5-NPs accumulated primarily
in the liver and spleen, and Cy5.5-NPs were detected in these organs through 48
hours post injection. NPs accumulated in the lung at 12 hours, yet the majority was
cleared from the lung by 48 hours. Relatively low levels of Cy5.5-NPs were detected
in the tumor. The cell types within these organs that were associated with NPs was
quantified by flow cytometry and each NP+ cell type was shown as a percentage of
all NP+ cells within each organ (Figs 2B, S2B). Monocytes comprised the largest
population of NP+ myeloid cells in all organs (37.6 ± 7.9%, 46.3 ± 7.9%, 26.6 ±
4.3%, 7.6 ± 2.4% in tumor, lung, spleen, and liver, respectively) compared to MDSCs
(15.6 ± 5.3%, 34.8 ± 10.0%, 7.8 ± 2.0%, 3.6 ± 0.7% in tumor, lung, spleen, and
liver, respectively) and macrophages (19.5 ± 7.7%, 3.3 ± 0.5%, 3.5 ± 0.8%, 4.0 ±
0.9% in tumor, lung, spleen, and liver, respectively).
4.4.2 Nanoparticle Administration Alters Immune Cell Distribution in
Blood and Organs
We next investigated whether the intravenously delivered NPs would influence
the distribution of innate immune cells in circulation, and at the primary tumor or
metastatic sites (i.e., lung). The analysis of blood revealed that the proportion of
MDSCs decreased from 82.5 ± 2.8% to 63.5 ± 13.9% (Fig. 4A). No significant change
58
Figure 4.3: In vivo distribution of Cy5.5-NPs. (A) Ex vivo imaging following i.v. injection
of 1 mg of Cy5.5-NPs shows they primarily accumulate in spleen and liver, and are
detectable for more than 48 hours post injection. (B) Quantification of particle uptake
by myeloid cell subsets within tissues as a percentage of total NP+ cells for a given
tissue.
was observed in the percentage of macrophages (CD11b+/F4/80+), monocytes, or
dendritic cells (DCs, CD11c+) in the blood with NP administration (Fig. 4.5). The
accumulation of cells within the primary tumor and metastatic sites was analyzed
following 6 consecutive days of NP administration. The quantity of MDSCs as a per-
centage of all single cells in the lung (Fig. 4.5C) decreased with NP administration
(30.0 ± 3.7% for PBS vs. 21.1 ± 6.2% for NP), consistent with a decrease observed
in the blood (Fig. 4.5A). No significant differences in myeloid cell proportions were
observed in the spleen or primary tumor.
4.4.3 Synergistic Therapeutic Effect Observed in Nanoparticles Com-
bined with Anti-PD-1
The therapeutic efficacy of NPs against 4T1 tumor growth and metastasis was
next investigated. Mice were inoculated with orthotopic 4T1 tumors and placed in
one of four treatment groups: 1) PBS control, 2) anti-PD-1 antibody only, 3) NPs
only, and 4) NPs + anti-PD-1 (Fig. 4.6A). Average tumor size was decreased for
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Figure 4.4: Quantification of Cy5.5-NP signal by IVIS (A, n = 3 NP+, n = 2 PBS) and
(B) flow cytometry.
combination NPs + anti-PD-1 (V = 1240 ± 298 mm3) compared to PBS control
(V = 1940 ± 431 mm3; p = 0.038), but was not decreased for either monotherapy
(V = 1630 ± 578 mm3 for anti-PD-1; V = 1690 ± 575 mm3 for NPs) (Fig. 4.6B).
Survival, based on body condition and tumor appearance, was monitored after day
22 post inoculation (Fig. 4.6C). Median survival was 24 days for the PBS and anti-
PD-1 groups, 25 days for NPs alone, and 28 days for NPs + anti-PD-1 combination
treatment. A survival benefit was observed for the combination treatment cohort
compared to cohorts treated with PBS (p = 0.001), or cohorts treated with either
anti-PD-1 or NP monotherapy (p = 0.015 and p = 0.030, respectively). The efficacy
of the combination therapy on metastatic burden was evaluated through analysis of
tumor cell numbers in the lung. Combination therapy reduced the lung metastatic
burden by 2-fold compared to PBS control (p = 0.018). Taken together, these data
indicate an additive or synergistic therapeutic effect by combining NPs and anti-PD-
1 antibody.
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Figure 4.5: In vivo administration of cargo-free NPs reduces the proportion of MDSCs
in circulation and at metastatic organs. (A) Tumor-bearing mice at were admin-
istered i.v. 1 mg of NPs in 200 µL of PBS or the equivalent volume of PBS only (n
= 4 per group), and innate immune cells were quantified in the blood 12 hours post
injection by flow cytometry. (B-D) NPs were administered at a dose of 1 mg/200 µL
for 6 days to allow for accumulation and uptake of NPs (n = 4 PBS control, n = 5 NP).
Flow cytometry quantification of immune cells in the spleen (B), lung (C), and primary
tumor (D) was performed on day 10 post inoculation. Decrease in MDSCs observed in
the blood (A) and lung (C) with NP administration. A 2-way ANOVA with Tukeys
multiple comparisons test was performed (A-D), bars show mean ± SEM, where *** p
< 0.001, and **** p < 0.0001.
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Figure 4.6: NPs + anti-PD-1 combination therapy delays 4T1 tumor growth and reduces
metastasis. 4T1-bearing mice were treated with PBS (control), anti-PD-1 (aPD-1),
NPs (particles), or combination therapy (particles + aPD-1). (A) Schematic of disease
model and treatment. (B) A two-fold reduction in lung metastatic burden (n = 4 per
group) at day 14 post inoculation as measured by flow cytometry for particles + aPD-1
compared to control. (C) Tumor volumes, and (D) survival curves are shown for the
four treatment conditions (control, n = 7; aPD-1, n = 9; particles, n = 8, particles
+ aPD-1, n = 9), indicating a therapeutic benefit for particles + aPD-1 but not for
either monotherapy compared to control. Two-tailed unpaired t test (B) and 2-way
ANOVA with Tukey’s multiple comparisons tests were performed. Bars show mean ±
SEM where * p < 0.05 compared to control (C), and where * p < 0.05 compared to
particles + aPD-1 (D).
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4.4.4 Nanoparticle Internalization Results in Upregulation of Inflamma-
tory Pathways
The mechanism by which NP administration may reduce tumor growth and metas-
tasis was investigated in vitro by analyzing cell secretion of multiple cytokines as-
sociated with tumor progression following nanoparticle treatment. Mice were first
treated with anti-PD-1 antibody post inoculation (Fig. 4.7A), and splenocytes were
then isolated from healthy and tumor-bearing mice (with and without anti-PD-1
treatment) at day 14 post inoculation. Splenocytes from tumor-bearing (Tumor+)
mice secreted elevated amounts of the cytokines interleukin 6 (IL-6), granulocyte-
macrophage colony-stimulating factor (GM-CSF), monocyte chemoattractant pro-
tein 1 (MCP-1), and tumor necrosis factor alpha (TNF-α), but not transforming
growth factor beta (TGF-β) relative to those of Tumor− mice (Fig. 4.7 B-F). Treat-
ment of these cells with NPs significantly decreased secretion of MCP-1 (Fig. 4.7D)
and increased TNF-α ecretion (Fig. 4.7E). This effect is amplified with the addition
of anti-PD-1 (Tumor+ αPD-1+). No alteration in cytokine expression was observed
for NP treatment for production of IL-6 (Fig. 4.7B) or TGF-β (Fig. 4.7F) in
tumor-bearing mice with or without anti-PD-1. Increased granulocyte-macrophage
colony-stimulating factor (GM-CSF) production was observed with NP treatment
only in the Tumor+ αPD-1+ group (Fig. 4.7C). Notably, NP+ treatment increased
TNF-α production by more than 2-fold in tumor-bearing mice both with and with-
out anti-PD-1 (Fig. 4.7E). The production of MCP-1 is also greatly increased in
tumor-bearing mice, yet there is a nearly 5-fold decrease in secreted MCP-1 with NP
treatment in both the Tumor+ and Tumor+ αPD-1+ groups. These data indicate
that NPs can alter the production of inflammatory cytokines and that anti-PD-1
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contributes to additional changes in cytokine levels.
Figure 4.7: Reprogramming of inflammatory response by NP treatment in vitro. A)
Schematic and timeline of the study. Splenocytes from tumor-bearing mice that were
treated with or without aPD-1 and incubated with NPs. (B-F) Cytokine secretion
as measured by ELISA for splenocytes isolated from healthy (tumor-), tumor-bearing
(tumor+), and in vivo aPD-1-treated (tumor+ aPD-1+) mice. Solenocytes were treated
in vitro with (particle+) or without (particle-) NPs. Notably, there was a large decrease
in the production of the MDSC-recruiting chemokine MCP-1 (D) and an increase in
the production of proinflammatory TNF-a (C). 2-way ANOVA with Tukeys multiple
comparisons tests were performed. Bars show mean ± SEM where * p < 0.05, ** p
< 0.01, *** p < 0.001, **** p < 0.0001 compared to particle− control (n = 4 per
condition).
4.4.5 Tissue-Specific Deactivation of Disease-Relevant Pathways In Vivo
Gene expression within the primary tumor and metastatic site was analyzed at
day 14 post inoculation to assess the impact of NP and anti-PD-1 treatment on
these tissues. Gene expression at the spleen was analyzed as a control for systemic
immune changes. Principal component analysis based on DESeq2 normalized total
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Table 4.1: Summary of in vivo gene expression changes with treatment compared to
PBS.
expression [95] showed that different tissues clustered together by gene expression,
yet the treatment groups were not readily distinguished (Fig. 4.8). Differential gene
expression was evaluated for each tissue compared to the PBS control group (Table
4.1). In addition, pathway changes were investigated using Gene Set Enrichment
Analysis (GSEA) for a total of 5,944 gene sets were examined (Fig. 4.9). Gene sets
that showed the greatest enrichment (positive or negative) for immune cells were
obtained for each tissue and condensed into a list of 14 disease-relevant pathways
(Fig. 4.10). Pathways with normalized enrichment score (NES) > 1.3 or NES < -1.3
was considered differentially expressed compared to untreated control. NP treatment
resulted in downregulation of pathways associated with pro-tumor innate cells and
upregulation of IL-2 biosynthesis in the lung. The addition of anti-PD-1 appeared to
downregulate negative regulation of T cell proliferation. Cells in NP-treated spleens
exhibited downregulation of intrinsic apoptosis and upregulation of T cell chemo-
taxis. Anti-PD-1 additionally increased signaling by VEGF and along with several
immune activation pathways in the spleen. The intrinsic apoptotic pathway was
downregulated in the tumor, while extrinsic apoptotic signaling was upregulated
in both treatments. Taken together, these data suggest deactivation of pro-tumor
immune cells and upregulation of anti-tumor pathways with NP treatment.
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Figure 4.8: Principal component analysis of RNAseq for each sample and condition show
organs cluster together.
4.5 Discussion
In this study, cargo-free PLG NPs were investigated for systemic delivery and
therapeutic efficacy in the 4T1 mouse model of metastatic breast cancer. Innate
immune cells, such as MDSCs, inflammatory monocytes, and TAMs have been re-
vealed to support pro-tumor functions at the primary tumor and metastatic niche.
These cells have been widely studied for their potential as biomarkers for early diag-
nostics of cancer and metastasis [96, 97, 98, 99, 100]. Furthermore, the therapeutic
benefit of immunotherapies, such as immune checkpoint blockade (ICB) and CAR
T-cells, which primarily aim to improve the adaptive anti-tumor immune response,
are limited by the presence of these immunosuppressive innate cells [58, 88, 89]. As
such, targeting of these innate immune cells has emerged as a potential cancer im-
munotherapy. The data presented here demonstrate that NPs delivered systemically
alter the phenotype of the pro-tumor innate immune cells at the primary tumor and
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Figure 4.9: Gene set enrichment analysis (GSEA) heatmap for a set of 5,944 pathway
changes for lung, spleen, and tumor compared with tissues from PBS-treated
mice. Pathway changes in the spleen were more similar to those in the tumor. The
lung showed broad downregulation of immune-related pathways.
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Figure 4.10: Tissue-specific in vivo reprogramming by NP and aPD-1 treatment. Gene
expression by RNA-seq was performed on lung, spleen, and tumor tissue from mice
treated with PBS, NPs, or NPs + anti-PD-1 (n = 3 per condition), and phenotypic
differences were analyzed by Gene Set Enrichment Analysis. (A and B) Pathway
enrichment for NP (A) and NP and aPD-1 (B) treated mice as shown by normalized
enrichment score (NES) compared with PBS for the given gene sets. Pathways with
NES > 1.3 or NES < -1.3 were considered differentially expressed. Changes in the
tumor largely reflected systemic changes as seen in the spleen, with positive enrichment
of immune cell function, whereas the lung showed negative enrichment in many of these
pathways.
metastatic sites, resulting in a therapeutic benefit when combined with anti-PD-1.
Previous studies have targeted innate immune cells with antibodies or small
molecules against cell surface receptors or their ligands. MDSC depletion with anti-
bodies either against Gr-1 or Ly6G has been reported to have a therapeutic benefit in
multiple cancer models [101, 102]. In the 4T1 model, diversion or depletion of MDSCs
has resulted in a survival benefit following resection of the primary tumor [103, 22].
Inhibiting MDSC activation resulted in total elimination of tumors in mice treated
with combination anti-PD-1 and anti-CTLA-4 [58]. Alternatively, small molecule
inhibitors of myeloid cell recruitment and activation have also proven to be effective
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for targeting specific myeloid cells and improving the efficacy of immuno-, chemo-,
and radio-therapies. However, there have been several reports of adverse effects of
existing therapies. Stopping CCL2 inhibition has been shown to accelerate breast
cancer metastasis [104]. CSF1R inhibition delays tumor growth [18], yet also pro-
moted metastasis by diminishing the amount of IL-15 and reducing the number of
NK cells [105]. The NPs reported here do not deplete the cell types, and do not con-
tain an active pharmaceutical ingredient. No adverse effects were observed for NP
treated animals in these studies, suggesting that NPs may provide an opportunity
to enhance outcomes and improve safety by avoiding off target effects. In addition,
human MDSCs cannot be readily targeted with these antibodies due to differences
between mouse and human surface proteins [5, 90, 106]. NPs may instead provide
an opportunity to modify human MDSCs based on a similar functionality between
human and mice.
Administration of cargo-free PLG NPs intravenously in the cancer model leads to
their subsequent association with monocytes, MDSCs, and other myeloid cells (Fig.
4.3B), which results in a reduction in the percentage of myeloid cells present in the
blood and lung (Fig. 4.5). The NPs accumulated primarily in the spleen and liver,
and to a lesser extent in the lung for the first 48 hours post injection. Previous
reports have suggested that intravenous NP administration diverted inflammatory
cells to the spleen [45, 93], while others have observed granulocyte trafficking to the
liver in several inflammatory disease models [107]. A greater percentage of Ly6Chi
monocytes was observed to internalize NPs relative to MDSCs and other myeloid
cells, though no significant decrease in monocytes was observed in tissues. These
monocytes are thought to be precursors of TAMs [81], and previous studies found
decreased metastatic seeding in the lung when monocyte recruitment was inhib-
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ited [17]. The lower level of association with MDSCs is consistent with a decreased
capacity for phagocytosis [13], yet confirms previous findings that MDSCs can still be
targeted through particle internalization [108]. The difference in NP uptake may also
be explained in part by physicochemical properties of the NPs. Preferential internal-
ization by specific cell types was reported to be a function of the surfactant used for
NP manufacturing [109] or polymer properties [110]. In addition, nanoparticle size
and surface charge influence internalization by myeloid cells [111], and selectivity can
be achieved without targeting moieties [112, 113].
Reduced primary tumor growth in addition to reduced lung tumor burden was
observed in the 4T1 model with combination NP and anti-PD-1 treatment (Fig.
4.6). NP internalization induces phenotypic changes in the myeloid cells, with the
response dependent upon the status of the immune system. PLG nanoparticles have
been applied to reduce inflammation in spinal cord injury, yet the NPs appear to
induce inflammatory pathways both in vitro and in vivo in the 4T1 model. In
vitro studies of NP internalization indicated upregulation of two immunostimulatory
cytokines TNF-α and GM-CSF. These cytokines have relatively nuanced roles in
cancer progression. Neutralization of systemic GM-CSF with cytokine sponges can
enhance the efficacy of anti-PD-1 treatment [114]. Conversely, combinations of GM-
CSF, IL-6, and TNF-a have also been shown to inhibit human T cell activation
in vitro, though solid tumors that contained MDSCs were found to consistently
downregulate GM-CSF [90]. NP treatment in vitro also resulted in a decrease in
the production of MCP-1 (CCL2), which is a critical cytokine for the recruitment of
MDSCs [17]. Signaling within the tumor microenvironment or the metastatic niche
is complex, and the survival advantage provided by these particles warrant further
investigation into the mechanisms of action.
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NP treatment led to substantial changes in the gene expression systemically and
within the primary tumor and metastatic sites, which may contribute to the de-
layed progression of disease and the survival benefit. Differential gene expression
and pathway analysis revealed downregulation of neutrophil-related signaling and
function, notably a decreased expression of matrix metallopeptidase 9 (MMP9) in
the lung. MMP9 has been shown to be a major contributor to the establishment of
the pre-metastatic niche [115, 116], and its downregulation along with other proteins
in ECM pathways indicate the NPs may have altered the lung microenvironment to
be less favorable for tumor cell colonization. Additional downregulation of pro-tumor
neutrophil/MDSC-related pathways and upregulation of IL-2 biosynthesis and sig-
naling pathways were observed in the lungs of treated with NPs. IL-2 is primarily
produced by CD4+ T cells and can stimulate growth and proliferation of CD8+ T
cells, and IL-2 therapy has been successfully been used to treat metastatic cancer,
but exhibits high toxicity when delivered systemically [117]. The upregulation of IL-
2 in the lung and not the liver or spleen indicates tissue-specific activation of IL-2,
which may confer anti-tumor benefit at the metastatic site while reducing toxicity.
The enrichment of extrinsic apoptosis response at the primary tumor may be reflec-
tive of increased tumor cell killing as evidenced by slower tumor growth. This effect
was not detected in the lung or spleen, which may be due to the relatively small
numbers of tumor cells in the organs compared. The addition of anti-PD-1 led to
downregulated negative regulation of T cell proliferation, which is consistent with
findings that PD-1 downregulates T cell proliferation [118].
In conclusion, we report that PLG NPs delivered systemically to target circulat-
ing immune cells improve the efficacy of ICB. The NPs are well-tolerated due to the
absence of an active pharmaceutical ingredient may reduce off target effects. The
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NPs reprogram immune cell phenotypes by altering their trafficking and expression
of key cytokines, which can alter the microenvironment of the primary tumor or
metastatic sites. Modulation for the innate cell responses by the NPs combined with
ICB therapy that targets the adaptive responses contributes to an improved thera-
peutic outcome. PLG NPs that target circulating innate immune cells may provide
novel therapeutic strategies in cancer, used either alone or to complement current or
emerging T-cell-targeted immunotherapies.
4.6 Materials and Methods
4.6.1 Nanoparticle fabrication
To fabricate fluorescent nanoparticles, acid-terminated 50:50 Poly(DL-Lactide-co-
Glycolide)(PLG) polymer (inherent viscosity 0.55-75 dL/g, Lactel) was first conju-
gated with cyanine 5.5 amine dye (Lumiprobe) using N-(3-Dimethylaminopropyl)-
N-ethylcarbodiimide hydrochloride (EDC) (Sigma-Aldrich)/N-hydroxysuccinimide
(NHS) (Thermo Fisher Scientific) chemistry. Unconjugated polymer and cyanine 5.5-
conjugated polymer were then dissolved in ethyl acetate at 99:1 weight ratio. The dis-
solved polymer was added to a Poly (ethylene-alt-maleic anhydride) (PEMA)(Polyscience)
solution and the mixture was sonicated using a Cole-Parmer CPX130 Ultrasonic
Processor to form the nanoparticles. Organic solvent was removed by evaporation
overnight, and nanoparticles were lyophilized for storage following three washes in
DI water.
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4.6.2 Tumor cell culture and inoculation
4T1-luc2-tdTomato cells (Perkin Elmer) were expanded in RPMI 1640 + Gluta-
MAX (Thermo Fisher Scientific) with 10% FBS for 5 days at 37◦C and 5% CO2 prior
to inoculation. Cells were removed from culture flasks by incubation with trypsin
for 10 minutes at 37◦C and resuspended in RPMI 1640. Cells were then pelleted
by centrifugation at 300 x g and washed with DPBS, and resuspended at 1 x 107
cells/mL of DPBS. Orthotopic tumor inoculations were performed by injection of 5 x
105 tumor cells resuspended in 50 µL DPBS (Life Technologies) into the fourth right
mammary fat pad of 8- to 10-week-old female BALB/c mice (Jackson Laboratory).
The cell line was confirmed to be pathogen free and authenticated by short tandem
repeat DNA analysis and compared to the ATCC STR profile database (DDC Med-
ical).
4.6.3 Nanoparticle and anti-PD-1 treatment
Nanoparticles were resuspended in DPBS (Life Technologies) at 1mg in 200 µL
and passed through a 35 µm filter mesh prior to intravenous administration via tail
vein injection. Control animals received 200 µL of DPBS intravenously. InVivoMab
anti-mouse anti-PD-1 (CD279) antibody (clone RMP1-14, Bio X Cell) was diluted
in DPBS to a final concentration of 1 mg/mL immediately prior to i.p. injection.
For therapeutic efficacy studies, NPs and anti-PD-1 were administered once every 3
days, for a total of 4 doses. For studies with NP biodistribution in tissues, Cy5.5-NPs
were administered at a dose of 1 mg/200 µL for 6 days to allow for accumulation
of NPs and to observe potential NP-induced cell trafficking (n = 4 PBS control, n
= 5 NP). Organs were explanted at day 10 post inoculation and innate immune cell
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distribution was quantified by flow cytometry. For studies of NPs and blood-based
immune cell distribution, a single dose of NPs was injected and flow analysis of blood
was performed 12 hours post injection.
4.6.4 Tumor size measurement and survival monitoring
Tumors were measured using standard electronic calipers (VWR) while mice were
anesthetized with 2% v/v% isoflurane. Tumor volume was calculated as V = 0.5 x
L x W2, where L is the length of the longest dimension of the tumor and W is the
length of the tumor perpendicular to the longest dimension. Mice were monitored
for tumor size and body conditioning to determine survival. Mice were euthanized
if any of the following criteria were met: tumor size of > 2cm in any dimension,
ulceration of more than 50% of the visible tumor area, partial paralysis due to tumor
invasion of hind limb muscle, labored breathing, ascites, lethargy, or visible weight
loss.
4.6.5 Ex vivo fluorescence and bioluminescence imaging
Nanoparticle distribution was measured in explanted whole organs following parti-
cle injection at 675/700 Ex/Em using an IVIS Lumina LTE imaging system (Caliper
Life Science). Fluorescence signal intensity is reported as photon flux in total photon
count per cm2 per steradian. Metastatic tumor burden of luciferase-expressing tumor
cells in explanted lungs was measured by bioluminescence imaging with the IVIS.
Lungs were incubated in 50 µM d-luciferin (Caliper) at room temperature for 10 min-
utes prior to imaging. Bioluminescence signal intensity is reported as integrated light
flux (photons/sec) as calculated by the Living Image Software (Caliper Life Sciences).
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4.6.6 Flow cytometry
Flow cytometry was performed on primary cells obtained from explanted organs.
Spleens, lungs, primary tumors, and livers were minced and enzyme digested with
Liberase TL or TM (Roche), then filtered through a 70 µm cell strainer (Corning) to
obtain a cell suspension. Whole blood was collected by cardiac puncture and mixed
with 10 v/v% 25mM EDTA (Life Technologies). Red blood cell lysis of whole blood,
spleens, and lungs was performed with ACK Lysing Buffer (Life Technologies). Cells
were pelleted by centrifugation at 400xg for 5 minutes and resuspended in MACS
buffer. Nonspecific staining was blocked with anti-CD16/32 (Biolegend) and samples
were stained for innate immune markers with anti-mouse CD45 AF700, F4/80 PE-
Cy7, Ly6G PacBlue, Ly6C FITC (Biologend), and CD11b BV510 (BD Biosciences).
For adaptive markers, samples were stained with anti-mouse CD45 AF700, CD4
V500, CD8 FITC, CD19 PacBlue, and CD49b PE-Cy7 (Biolegend). Stained sam-
ples were analyzed using the MoFlo Astrios Flow Cytometer or CytoFLEX (Beckman
Coulter), and data were processed using FlowJo (BD) and MATLAB release 2019a
(MathWorks).
4.6.7 In vitro nanoparticle uptake and ELISA
Single cell suspensions were isolated from spleens and whole blood of tumor-
bearing mice at 14 or 21 days post tumor inoculation as described above. For
nanoparticle uptake assays, cells were resuspended in RPMI 1640 media with 10%
FBS and seeded in 24-well plates at 1 x 106 cells per well. Nanoparticles were re-
suspended in DPBS at 1mg/mL and added to the wells. Uptake was characterized
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following a 30 minute incubation at 37◦C by flow cytometry as described above.
For cytokine secretion assays, cells were resuspended in media and seeded in 96-well
plates at 2.5 x 105 cells per well. Nanoparticles were resuspended as described above
and added to each well. Following incubation for 6, 18, or 24 hours, cells were pel-
leted at 1000 x g for 5 minutes and the supernatant was removed and diluted 4x for
quantification of cytokine secretion by ELISA, which was performed by the Caner
Center Immunology Core at the University of Michigan.
4.6.8 Gene expression analysis by RNA-seq
Tissues were flash-frozen as described above and homogenized in TRIzol reagent
(Thermo Fisher Scientific). RNA was extracted from each tissue sample with the
Direct-zol RNA spin column kit (Zymo Research). Purified RNA concentration was
measured by UV spectroscopy using a Nanodrop 2000c (Thermo Scientific) to con-
firm all samples had concentrations 10 ng/µL. RNA quality control, QuantSeq 3
mRNA-seq library prep and quality control, and sequencing were performed by the
Advanced Genomics Core at the University of Michigan. Samples were sequenced
using the Illumina NextSeq 550 sequencer, and sequences were aligned to Gene Sym-
bols. Raw sequencing counts were normalized and differential gene expression was
calculated in R and using DESeq2 [95]. Normalization of raw counts was performed
for principal component analysis [119] and genes with differential expression were
identified. For pathway analysis, mouse gene symbols for counts obtained through
RNA-seq were first converted to human gene symbols using the biomaRt package
in R. Gene Set Enrichment Analysis (GSEA) was performed on DESeq2-normalized
counts and the corresponding human gene symbols for a total of 5,944 MsigDB gene
sets (Hallmark, Reactome, PID, and Gene Ontology (GO)). A positive normalized
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enrichment score (NES) indicates enrichment in the treated cohort compared with
PBS control.
4.6.9 Statistical analysis
One-way or two-way ANOVA and Tukey’s multiple comparisons tests were per-
formed on groups with more than 2 conditions. Two-tailed unpaired t test was
used for single comparisons between two conditions. Median survival and survival
curves were analyzed with the log-rank (Mantel-Cox) test for statistical significance.
Following normalization of RNA-seq gene expression data with DESeq2, genes with
adjusted p-value < 0.05 were considered differentially expressed. Statistical analyses
were performed using Prism 8 (GraphPad Software). A p-value < 0.05 was consid-
ered to be statistically significant and all values are expressed in mean ± standard
deviation (SD). Error bars one plotted data represent standard error of the mean
(SEM).
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CHAPTER V
Metastatic Conditioning of Myeloid Cells at a Subcutaneous
Synthetic Niche Reflects Disease Progression and Predicts
Therapeutic Outcomes
5.1 Authors
Robert S. Oakes, Grace G. Bushnell, Sophia M. Orbach, Pridvi Kandagatla, Yin-
ing Zhang, Aaron H. Morris, Matthew S. Hall, Petrina LaFaire, Joseph T. Decker,
Rachel M. Hartfield, Michael D. Brooks, Max S. Wicha, Jacqueline S. Jeruss, and
Lonnie D. Shea
5.2 Abstract
Monitoring metastatic events in distal tissues is challenged by their sporadic oc-
currence in obscure and inaccessible locations within these vital organs. A synthetic
biomaterial scaffold can function as a synthetic metastatic niche to reveal the nature
of these distal sites. These implanted scaffolds promote tissue ingrowth, which upon
cancer initiation is transformed into a metastatic niche that captures aggressive cir-
culating tumor cells. We hypothesized that immune cell phenotypes at synthetic
niches reflect the immunosuppressive conditioning within a host that contributes
to metastatic cell recruitment and can identify disease progression and response to
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therapy. We analyzed the expression of 632 immune-centric genes in tissue biopsied
from implants at weekly intervals following inoculation. Specific immune populations
within implants were then analyzed by single-cell RNA-seq. Dynamic gene expres-
sion profiles in innate cells, such as myeloid-derived suppressor cells, macrophages,
and dendritic cells, suggest the development of an immunosuppressive microenviron-
ment. These dynamics in immune phenotypes at implants was analogous to that in
the diseased lung and had distinct dynamics compared with blood leukocytes. Fol-
lowing a therapeutic excision of the primary tumor, longitudinal tracking of immune
phenotypes at the implant in individual mice showed an initial response to therapy,
which over time differentiated recurrence versus survival. Collectively, the microen-
vironment at the synthetic niche acts as a sentinel by reflecting both progression and
regression of disease.
5.3 Introduction
All too often, the detection of cancer occurs after some tissue such as the lung
or bone begin to fail, which typically represents an advanced stage of disease that
is challenging to treat. Systems for the early detection of cancer would provide the
opportunity to intervene at earlier stages and prior to tissue dysfunction. The risk
for distant recurrence is being determined by gene and protein expression in primary
tumor samples that define molecular signatures of patient tumors. Clinically, these
molecular signatures are reduced to predictive scores, which help guide decisions
about systemic therapy for patients with cancer [120]. Clinical examples include On-
cotype DX [121], Mammaprint [122], PAM50 ROR Score [123, 124], Breast Cancer
Index [125], and EndoPredict [126]. Yet, the information obtained from the primary
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Figure 5.1: Development of the pre-metastatic niche (preMN), metastatic niche (MN),
and synthetic diagnostic site. Circulating tumor cells exhibit a tropism for specific
distal microenvironments, thus indicating that metastasis is pre-determined. Devel-
opment of these predetermined sites is driven by (1) systemic conditioning from the
primary tumor through secretion of factors and exosomes, which is amplified by simul-
taneous conditioning o the bone-marrow and alterations in bone-marrow derived cells.
(2) This process conditions distal tissues and contributes to the (3) aggregation of pre-
metastatic immune cells and extracellular matrix proteins. (4) These primed distal
microenvironments are denoted as the preMN and facilitate homing then colonization
of (5) circulating tumor cells which (6) extravasate and (7) migrate into distal organs
where they may become a (8) disseminated tumor cells if the conditions are hospitable.
This disseminated tumor cell may then undergo a phenotypic shift to initiate a (9)
metastatic secondary growth, thus leading to development of a metastatic niche. Given
that the preMN contains a unique mixture of soluble factors, extracellular matrix, stro-
mal and immune cells (e.g., cancer-associated fibroblasts and myeloid-derived suppressor
cells, MDSCs), it is reasonable that preMN function could be synthesized through the
recapitulation these unique factors at a synthetic site in vivo. This rationale underpins
the development of material based synthetic diagnostic site that (2.1) is conditioned,
(3.1) populated by disease associated immune cells, (4.1) develops characteristics of a
preMN, and (7.1) captures metastatic tumor cells.
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tumor is focused on measurements taken prior to the initiation of firstline treatment
of the primary tumor, which limits this approach to pretreatment predictions of dis-
ease progression. Liquid biopsies show promise, yet face challenges associated with
low cell numbers, as well as phenotypic relevance, as approximately 0.01% of circulat-
ing tumor cells will become metastatic foci and circulating immune cells are distinct
from those in distal tissue [127, 128, 129]. We and others have previously reported
that biomaterial implants function as a synthetic metastatic niche, with recruitment
of early metastatic cells that represent aggressive populations observed within the
lung [20, 21, 22, 25, 130, 131, 132, 133, 134]. The development of the metastatic niche
is driven by circulating acellular material from the primary tumor that alters the im-
mune system of the host, including discrete sites in distal organs [2, 135, 136, 137].
These sites precede and support colonization by metastatic tumor cells (Fig. 5.1).
The identification of the metastatic niche was enabled through mouse models of
metastasis, which recapitulated the conditioning of distal sites and validated the
long standing seed and soil hypothesis [8]. The metastatic niche develops, in part,
from an influx of bone marrowderived cells, such as hematopoietic progenitor cells
and myeloid-derived suppressor cells (MDSC), that differentiate within the distal
sites and create a permissive metastatic site in target organs [2, 135]. Monitoring
the natural metastatic niche could alter the course of therapeutic interventions, yet
the potential is hindered because of metastatic niche formation in obscure and in-
accessible locations within vital organs, such as the lung and the liver. A synthetic
metastatic niche provides a technical solution by predefining sites in readily acces-
sible locations.We tested the hypothesis that analysis of immune dynamics at bio-
material implants, functioning as a synthetic metastatic niche, would provide unique
information that correlates with disease progression. The tissue within the implant
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integrates with the host and is subsequently modified by disease onset and progres-
sion [138, 139]. Following implantation, a porous biomaterial scaffold supports cell
infiltration, vascularization, and the persistent recruitment of immune cells due to
the localized foreign body response to the material [140]. The initiation of cancer
metastasis is associated with systemic alteration of immune responses, which we
hypothesize also alters the composition of the foreign body response [141]. In the
context of cancer progression, the immune response at an implanted microporous
polymer scaffold would acquire immunosuppressive trademarks, thus mimicking the
properties of disease-targeted organs. We propose to analyze the immune cell com-
position and phenotype to draw correlations with disease progression, while sparing
vital organs or other sites from invasive sampling. For cancer metastasis, this scaf-
fold could advance disease detection capabilities by providing a predefined site that
indicates an altered immune environment and disease progression in vital organs [2].
Identifying early metastatic events has the potential to inform a new generation of
therapeutic approaches that target the earliest stages of metastatic disease.
5.4 Results
5.4.1 Metastatic disease alters gene expression at implants as a function
of disease severity
We performed a high-throughput gene expression analysis of immune pathways
to characterize the dynamics at a biomaterial implant that recruits metastatic cells,
throughout the process of disease progression. We and others have shown that
metastatic tumor cells colonize microporous implants, yet are vastly outnumbered by
other cell types including stromal, immune, and epithelial cells [20, 21, 22, 130, 131].
Microporous implants (5-mm diameter, 2-mm thickness, interconnected 250-425 mm
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Figure 5.2: Microporous polymer scaffolds support host tissue integration when im-
planted, which is then progressively modified as a function of disease burden
and presents unique dynamics compared with blood. (A) PCL scaffolds and ex-
perimental timeline for scaffold implantation, tumor inoculation, implant biopsies, and
high throughput gene expression analysis. (B) and (C) Representative macroscopic and
SEM images of PCL scaffold illustrating microporous architecture. Scale bar, 500 µm
and interconnected 250425 µm pores. (D) DAPI staining illustrates dense and uniform
cellularity throughout the implant. Scale bar, 500 µm. Highlighted area (dashed box)
indicates region of higher magnification (E). Scale bar, 100 µm. (F) Progressive gene
expression changes in tissue biopsied from implants during metastatic disease course.
BALB/c mice were implanted with microporous polymer implants (day -14), then in-
oculated with syngeneic 4T1 tumor cells at day 0. Implants were biopsied at days 7,
14, and 21 and tissue was analyzed with a high-throughput qRT-PCR platform (OA,
632 target and 16 reference genes). The heatmap illustrates unsupervised hierarchal
clustering of the 10-gene panel,with expression levels for each gene depicted as stan-
dardized data (n=14 per condition). Cohort size at days 7 (n=3), 14 (n=8), and 21
(n=3) represent different mice as biological replicates. (G) BALB/c leukocytes were iso-
lated from blood of tumor-bearing mice, gene expression profiled, and compared against
tumor-free and implant-free control mice. Many of the genes in the panel showed sig-
nificant differences in the same directionality as those in the implant. (H) The heatmap
shows differences in dynamics between the implant to blood gene expression ratio and
the goodness of fit for this relationship between days 7 and 21. Fit for the regression
analyses was determined by normalized root mean squared error, where negative values
indicate a worse fit and a value of 1 indicates a perfect fit. S100a9, S100a8, Pglyrp1,
and Ltf had the worst fits when comparing implant with blood. Bmp15 is not shown
as it was not measurable in blood.
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Figure 5.3: Experimental designs and OpenArrayTM output for select genes with high
fold-change and predictive value. (A) Results from OpenArray for TB mice at
Days 7 (n=3), 14 (n=8), and 21 (n=3) along with time-matched TFC mice (n=14).
(B) Results from OpenArray selected for fold change TFC or TB. For panels (B)-(C)
mice are indicated on x-axis and genes are indicated on y-axis with clustering done via
Euclidian distance and average linkage. Genes indicated in red text on the y-axis were
selected for the smaller 10-gene panel analysis is subsequent studies.
pores) composed of PCL (Fig. 5.2A and B), were inserted into dorsal subcutaneous
space of BALB/c mice to allow for tissue ingrowth. Microporous PCL scaffolds (Fig.
5.2C) facilitate the longitudinal studies herein by provide greater implant stability
compared with more rapidly degradable polymers like poly(lactide-co-glycolide) [22].
This microporous architecture facilitated cell colonization throughout the thickness
of the implant (Fig. 5.2D and E). After 2 weeks, mice were orthotopically inocu-
lated (day 0) with triple-negative 4T1 tumor cells. At weekly intervals (days 7, 14,
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and 21), tissue from implants was biopsied and changes in the gene expression were
screened via a high-throughput qRT-PCR platform, OA (Fig. 5.2A). This screening
assessed the expression of 632 target and 16 reference genes per sample in parallel
(Fig. 5.3A). Gene expression from the biopsied implants of tumor-bearing mice was
compared against time-matched tumor-free control mice that had implants yet were
not inoculated with 4T1 cells. Altered expression was observed for 113 genes follow-
ing tumor inoculation. To focus our studies, a panel of 10 genes was identied on the
basis of fold change (Fig. 5.3B), level of signicance (FDR corrected), and expres-
sion stability. The 10 target genes (Fig. 5.2F; Fig. 5.4A) were normalized against
an average expression of 5 reference genes. As a function of disease progression
(Fig. 5.4B), expression increased for 7 of the 10 genes within the implant, includ-
ing: S100 Calcium Binding Protein A8 (S100a8 ), S100 Calcium Binding Protein A9
(S100a9 ), Peptidoglycan Recognition Protein 1 (Pglyrp1 ), Lactotransferrin (Ltf ),
Cathelicidin Antimicrobial Peptide (Camp), Elastase 2 (Ela2), Chitinase (Chi3l3).
Expression decreased for 3 of the 10 genes within the implant, including: Bone Mor-
phogenetic Protein 15 (Bmp15 ), C-C Motif Chemokine Ligand 22 (Ccl22 ), and C-C
Motif Chemokine Receptor 7 (Ccr7 ). Unsupervised hierarchical clustering of the
expression of these genes in the implant-derived tissue produced a separation be-
tween tumor-bearing and tumor-free control cohorts. Over time, the gene expression
in the tissue inltrate of tumor-bearing mice progressively separated from tumor-free
controls with day 7 expression being most similar to tumor-free mice. No structured
or time-based organization was observed in the gene expression from the tumor-free
controls, presumably due to the microenvironment stability in healthy mice. Cluster-
ing also identied distinct gene groups (i.e., S100a8/S100a9/Pglyrp1 ) that displayed
similar expression patterns.
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Figure 5.4: Statistical plots to support heatmaps in main text and supplementary ma-
terials. (A) Box plots for gene panel heatmap in Fig. 5.2F show the median, 25th-
75th percentiles and most extreme data points that were not considered outliers (out-
liers are visually indicated by red ). TB cohort expression is centered relative to the
time-matched TFC cohort median. Scale depicts the log2-transformed fold change.
A two-way MANOVA showed a significant interaction effect between condition and
time (Pillais Trace=1.276, F(20,28)=2.465, p=0.014). Post hoc univariate ANOVA
showed significant differences within the f diseased cohort over time (indicated by #,
df=(2,22), p<0.05). Simple effects analysis showed significant differences between dis-
eased and time-matched TFC (indicated by , ida´k adjusted p<0.05 adjusted). (B)
Tumor growth curve for 4T1 mice starting at Day 7, with a power regression line, er-
ror bars are standard deviation. (C) Box plots of gene expression to support the data
in the C57BL/6-Lu.2 heatmap in Fig. 5.5B. indicates significance (Dunn-Sˇida´k cor-
rected to p<0.005) from independent two-tailed t-tests comparing TB to TFC (n=5 per
condition). (D) Box plots of gene expression for blood data to support the heatmap
found in Fig. 5.2. Tumor-bearing Implant Free Controls (IFCs) are shown to illustrate
that the implants do not alter the gene expression of blood leukocytes. A two-way
MANOVA showed a significant interaction effect between condition and time (Pillais
Trace=2.527, F(36,40)=1.907, p=0.024). Post hoc univariate and simple effects analy-
sis showed significant differences within the diseased cohort over time as indicated as #
(df=(2,15), p<0.001) and indicates significant differences compared to time matched
controls (Sˇida´k adjusted p<0.05 adjusted). (E) Gene expression data from the lung
tissue heatmap in Fig. 5.5A. indicates significance (Dunn-Sˇida´k corrected to p<0.005)
from independent two-tailed t-tests comparing TB to TFC (n=4 per condition).
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The 10-gene panel was then analyzed in blood leukocytes isolated from blood at
multiple time points following tumor inoculation to identify correlations or unique
dynamics in synthetic niche. Liquid biopsies represent a relatively accessible source
to analyze the intermediary stages of metastasis that occur between the primary
tumor and distant metastatic sites. Most genes (except Bmp15 ) analyzed in the
implant-derived tissue were expressed in the blood (Fig. 5.2G; Fig. 5.4C), yet their
expression dynamics differed from those of the implant. This difference was par-
ticularly evident for the genes S100a9, S100a8, Pglyrp1, and Ltf. At the implant,
expression of these genes progressively increased over time, which aligned with the
progression of disease. In the blood, expression of these genes was stable and lacked a
correlation with disease progression, illustrated by a goodness-of-t analysis in which
S100a9, S100a8, Pglyrp1, and Ltf had the poorest alignment between the implant
and blood (Fig. 5.2H). In contrast, gene expression for Ela2 and Camp progressively
increased in both the implant and blood. Collectively, the data acquired from blood
does not directly correlate with the synthetic niche, indicating that synthetic niche
provides distinct information that has the potential to complement liquid biopsy.
5.4.2 Disease-driven differences at the implant have unique dynamics
and are reective of distal organs
The 10-gene panel was analyzed in diseased lung tissue to determine whether
the synthetic niche correlates with native metastatic sites in distal organs. The
lung is normally the primary metastatic site for 4T1 cells, and we thus analyzed
lung biopsies from tumor-bearing and tumor-free control mice for comparison with
synthetic niche. The gene expression patterns for the 10-gene panel in the lung
at day 21 following tumor inoculation (Fig. 5.5A; Fig. 5.4D) was highly aligned
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Figure 5.5: Tissue biopsied from implants is indicative of diseased lung. (A) BALB/c
mice orthotopically inoculated with 4T1 tumor cells at day 0 had lung tissue biopsies
taken and qRT-PCR analyzed at day 21 from tumor-bearing and tumor-free control
mice. Heatmap of gene expressions from lung tissue of tumor-free control and tumor-
bearing mice. Organization was based on unsupervised clustering of samples and genes.
(B) Tissue biopsied from implants in C57BL/6 was analyzed for gene expression in
tumor-free and tumor-bearing mice that were inoculated with a lung-tropic, syngeneic
metastatic cell line. C57BL/6 mice were implanted with microporous PCL scaffolds
(day -14) and then orthotopically inoculated with a metastatic derivative (developed
through serial inoculations of explanted lung metastases) of the E0771 syngeneic line
(day 0). At day 14, scaffolds were biopsied from tumor-bearing and tumor-free control
mice. Heatmap of gene expressions for a 10-gene panel normalized to reference genes,
centered on the healthy tumor-free control median, and standardized. Organization is
based on unsupervised clustering of samples and genes.
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with that observed in the implant. Notable is that all 7 genes upregulated in tissue
biopsied from synthetic niche are clustered in the lung data. Similarly, the 3 genes
downregulated in the tissue biopsied from implants are clustered in the lung data.
These measurements of tissue taken from the lung were consistent with data from
other studies regarding metastatic niche development and the phenotype of MDSCs
in distal tissues during metastasis [137]. Collectively, the gene expression patterns
of the synthetic metastatic niche reect the patterns observed in native metastatic
niche.
We developed a lung-tropic tumor cell line for C57BL/6 as an additional im-
munocompetent model of lung-biased metastasis to determine whether the expression
panel may reect lung metastasis. To match the aggressive and lung-tropic metastasis
of the BALB/c-4T1 model, we developed an aggressive variant of the E0771 cell line
through serial inoculation of lung metastases. This aggressive and lung-tropic E0771
variant, denoted as Lu.2, was inoculated in C57BL/6 mice implanted with the poly-
mer scaffolds. This experiment also used an orthotopic inoculation of tumor cells
into the mammary fat pad, which maintained the experimental design of a primary
tumor conditioning distal sites and spontaneous metastasis. The C57BL/6-Lu.2 had
similar gene expression changes and clustering to the lung tissue from the BALB/c-
4T1 model (Figs. 5.2C and 5.5A), with 80% (8/10) of altered genes progressing in a
similar direction (Fig. 5.5B; Fig. 5.4E). The two genes that demonstrated a differ-
ence in expression (Camp and Chi3l3) may be due to the slower progression of disease
that we observed in the B6-Lu.2 model, yet additional studies would be necessary
to fully understand the impact of mouse strain and cell line metastatic potential on
distal conditioning. Our data illustrates that the synthetic niche consistently mimics
and serves as a sentinel for metastatic conditioning of lungs.
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Figure 5.6: Select innate immune populations drive phenotypic changes within the syn-
thetic niche. At day 14, immune populations within the scaffolds of tumor-free control
(TFC) and tumor-bearing (TB) mice were profiled by scRNA-seq, with a focus on the
10-gene panel derived from analysis of the whole microenvironment. (A) T-distributed
Stochastic Neighbor Embedding (tSNE) plot of innate and adaptive immune cells ana-
lyzed in implants during disease progression. (B) Heatmap and unsupervised hierarchi-
cal clustering of aggregated gene expression of the total immune cell population in the
tumor-bearing models. This data represents the expression level of a gene in a specific
cell type as compared with other cell types (e.g., cumulative MDSCs express the highest
amount of S100a8 and S100a9 compared with all other cell types). (C) Violin plots of
single-cell gene expression from tumor-free control and tumor-bearing mice including
B cells, DCs, macrophages, monocytes, neutrophils, natural killer (NK) cells, and T
cells. Each dot represents the gene expression (x-axis) of a single cell within a cell
type and health state (tumor-bearing or tumor-free control; y-axis). Bmp15 is absent
as it was undetected using scRNA-seq. (D) and (E) Immune cells adoptively trans-
ferred from tumor-bearing mice readily infiltrate implants of tumor-free control and
tumor-bearing mice. Gr1+Ly6G−and Ly6G+ immune cells were isolated from spleens
of tumor-bearing mice through magnetic-activated cell sorting, then labeled with DiO
orDiD, respectively. Labeled immune cells were adoptively transferred into tumor-free
control or tumor-bearing mice implanted with scaffolds. For tumor-bearing mice, tu-
mors were inoculated 7 days prior to adoptive transfer, where approximately 30 tumor
cells were expected in implants. An injection of PBS was used as an unlabeled con-
trol to establish the analytical background [22]. Adoptively transferred DiO-labeled
Gr1+Ly6G−cells (D) and DiD-labeled Ly6G+ cells (E) readily trafficked into implants
in tumor-free control and tumor-bearing mice. One-way ANOVA and post hoc Sˇida´k
multiple comparisons analysis with significance indicated as ∗, P<0.01; ∗∗∗, P<0.0001;
n.s., not significant.
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5.4.3 Select immune populations dictate alterations in the implant mi-
croenvironment during metastasis
We next investigated the gene expression of innate and adaptive immune cells (Fig.
5.6A) within implants during cancer metastasis to determine the cell types driving
metastatic conditioning of the synthetic niche. Single-cell RNA-sequencing (scRNA-
seq) was employed to investigate cell-specic gene expression. Our data supports pre-
vious studies that MDSCs are a driving force of immunosuppressive S100a8/9 [137]
MDSCs had increased expression of S100a8, S100a9, Pglyrp1, and Ltf relative to the
other cell types (Fig. 5.6B). Specically, emphPglyrp1 was 1.8-fold higher in MDSCs
than other neutrophils from implants of tumor-bearing mice. The scRNA-seq data
are consistent with our previous data, showing an inux of MDSCs to the implant,
and current literature on MDSC phenotype [142]. Interestingly, when the gene ex-
pression was normalized to the number of cells in each population, a phenotypic shift
was observed. S100a8 was signicantly upregulated in dendritic cells (DC) of tumor-
bearing mice and S100a8 and S100a9 were signicantly upregulated in macrophages
of tumor-bearing mice, relative to their tumor-free counterparts (Fig. 5.6C; Fig.
5.7A and 5.7B). This phenotypic shift in antigen-presenting cells, which reside as
sentinels in tissues, suggests that multiple branches of the myeloid lineage are in-
uenced by primary tumor conditioning of distal sites [143]. In our data, diseased
neutrophils cluster closely with MDSCs as they are also a source of S100a8, S100a9,
Pglyrp1, and Ltf. However, individual neutrophils did not signicantly change their
expression of these genes, yet overall increases from neutrophils at the implants were
observed because of their increased cell numbers following the onset of metastasis
(Fig. 5.6C). The scRNA-seq data indicates that the genes most associated with
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MDSC phenotype (Fig. 5.6B) were also those genes that poorly aligned with blood
leukocyte gene expression (Fig. 5.2H). Perhaps this is supported by previous studies
showing that MDSCs can activate within metastatic niche distal sites [135], similar
to our scRNA-seq data showing that a phenotypic shift occurs in antigen-presenting
cells within the synthetic niche (Fig. 5.6C). This data on phenotypic shift of myeloid
lineage cells in tissue biopsied from implants underlies the function of synthetic niche.
Figure 5.7: Additional scRNA-seq plots of the gene panel analyzed in Fig. 5.6. (A)
Heatmap of fold-change between scaffolds in tumor-bearing mice and tumor-free con-
trols. Data is analogous to that presented in Fig. 5.6C and Fig. 5.7B violin plots.
(B) Violin plots of single-cell gene expression from TFC and TB mice including B cells,
dendritic cells (DCs), macrophages, monocytes, neutrophils, natural killer (NK) cells,
and T cells. Each dot represents the gene expression (x-axis) of a single cell within a
cell type and health state (TB or TFC, y-axis). Bmp15 is absent as it was undetectable
by scRNA-seq.
The trafficking of innate immune cells to implants was investigated for its de-
pendence on primary tumor conditioning of the implant. We adoptively transferred
puried Gr1+Ly6G−and Ly6G+ cells (isolated from tumor-bearing mice) into tumor-
free control and tumor-bearing mice that had implanted scaffolds. Gr1+Ly6G−and
Ly6G+ cells were labeled prior to transfer with DiO and DiD lipophilic dyes, respec-
tively. Scaffolds were analyzed for labeled immune cells at 36 hours after the transfer.
Both labeled immune cell populations were present in implants of the tumor-free
control and tumor-bearing mice at an equal order of magnitude. Compared with
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PBS controls, transferred Gr1+Ly6G−cells were increased by 8.4-fold and 7.9-fold
in tumor-free control and tumor-bearing mice, respectively (Fig. 5.6D). Transferred
Ly6G+ cells were increased by 31-fold and 55-fold in tumor-free control and tumor-
bearing mice, respectively (Fig. 5.6E). These results suggest that the foreign body
response to the material largely determines immune recruitment to the scaffold, as
supported by previous studies [20, 134], and that the preexisting condition of the
implant does not selectively control immune cell trafcking at the implant. Thus, the
similarities in trafcking and phenotypic shifts in the scRNA-seq data illustrate that
the synthetic niche provides both a predened site for disease-conditioned immune
cells to aggregate, then further differentiate into metastasis-supportive populations.
5.4.4 Gene expression signatures monitor disease progression
We next developed a scoring system from our 10-gene panel that represented the
progression of metastatic conditioning in tumor-bearing mice. We applied computa-
tional approaches to derive single-metric scores based on gene expression signatures
from the tissue of biopsied implants, and thereby develop a predictive model for
the probability that a mouse was either tumor bearing or a tumor-free control (Fig.
5.8). The computational reduction of gene expression signatures from primary tu-
mor tissues to single-metric scores and predictions has guided clinical management of
patients with breast cancer [144]. Two computational techniques were investigated
in parallel (Fig. 5.9) as a spectrum of regression and modeling approaches provides
a more robust interpretation of data and biological networks [145]. First, data di-
mensionality was reduced via an unsupervised matrix factorization (singular value
decomposition, SVD) [146], which linearly transformed the data into eigengenes and
eigenarrays that indicate gene signicance and sample grouping, respectively. The
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Figure 5.8: Gene expression signatures reduced to scoring metrics and diagnostic pre-
dictions. (A) and (B) Gene expression from analysis of implant-derived tissue was
reduced to an unsupervised scoring metric through SVD, which was converted to a
score by calculating Euclidean distance from the tumor-free control centroid to each
sample. Scores were scaled between 0 and 1. (C) In parallel, gene expression data were
used to train a bootstrap aggregated (bagged) decision tree ensemble with leave-one-out
cross-validation to predict the likelihood that a mouse was tumor bearing. (D) Plot of
the SVD score versus the bagged tree prediction. Dashed and solid line ellipses indicate
the 99.9% confidence intervals for tumor-free control (TFC; n=14) and tumor-bearing
(TB; n=14) cohorts, respectively. Filled ellipses indicate average and SEM for bagged
tree and SVD data at days 7 (n=3), 14 (n=8), and 21 (n=3). A two-way MANOVA
showed a significant interaction effect between condition and time [Pillai trace=0.568,
F(4,44)=4.361, P=0.005]. Post hoc univariate ANOVA showed significant differences
within the diseased cohort over time [indicated by #, df=(2,22), P<0.001]. Simple
effects analysis showed significant differences between tumor bearing and time-matched
tumor-free controls (indicated by ∗, Sˇida´k adjusted P<0.05).
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Figure 5.9: Experimental timeline, gene expression analysis, singular value decomposi-
tion, and bagged decision tree analysis and computational pipelines. Map of
computational processes and the data outputs that are represented in the manuscript.
For example, the calculation of the Euclidean distance from the principle components
of the singular value decomposition (SVD) represented in Fig. 5.8B can be traced back
through its processing steps to the total RNA isolation, quality control, and cDNA
synthesis.
SVD separation of the samples in three-dimensional subspace (Fig. 5.8A) estab-
lished a scoring metric by setting a reference point at the centroid of the tumor-free
controls and calculating Euclidean distance to each sample data point (Fig. 5.8B;
x-axis of 5.8D), scores are scaled between 0 and 1. Second, supervised machine
learning created a predictive model via a bootstrap aggregated (bagged) decision
tree ensemble (i.e., random forest) [147], which used a forest of decision trees based
on a random selection of a gene from the 10-gene panel to predict a mouse status
as tumor free or tumor bearing. For each sample, a prediction score (Fig. 5.8C; y-
axis of 5.8D) was determined via leave-one-out analysis. In all models, the scores in
tumor-bearing mice increased over time and corresponded with disease progression,
while the scores in tumor-free control mice remained consistent (Fig. 5.8D). Thus,
the metastatic conditioning of the implant was formulated into a trained model for
monitor disease progression.
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5.4.5 Monitor response to surgical excision and early identication of re-
sponders
We subsequently investigated the regression of disease following therapy to test
and validate the disease-monitoring capabilities of the synthetic niche. Gene expres-
sion of synthetic niche was proled following excision of the tumor-bearing mammary
gland. This procedure (analogous to a mastectomy in humans) was chosen as the
intervention based on the role of surgery as a rst-line treatment for breast cancer.
We have previously reported that surgery alone in mice receiving scaffolds resulted in
40% long-term survival, while the remaining mice recurred [22]. Following synthetic
niche proling, samples were then classied on the basis of the model developed in Fig.
5.8. Note, this study serves as validation because the trained model is based on
progression of disease burden, while the test analysis is based on disease regression.
Fourteen days following 4T1 tumor inoculation in BALB/c mice, tissue from the
implant was biopsied (day 0 in Fig. 5.10A) and then immediately followed by an
excision of the tumor-bearing mammary gland. Tumor-free control mice had a sim-
ilar excision of the mammary gland. Implant biopsies were performed at weekly
intervals following mammary gland excision (days 7, 14, and 21 post-excision in Fig.
5.10). Gene expression from the biopsies was quantied, and scores were derived from
tumor-free control or tumor-bearing mice. Scores for each tumor-bearing animal
showed a redirection toward the tumor-free control baseline 7 days after surgery
for all mice (Fig. 5.10B). This difference was most evident at day 7 for the SVD
(Fig. 5.10C) and at day 21 for the bagged tree prediction (Fig. 5.10D), with this
difference originating from the distinct weighting of specic genes in the two computa-
tional approaches. We noted increased variability of scores at later time points with
the SVD, which prompted an investigation of these metrics as a function of outcome.
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Figure 5.10: Primary tumor excision redirects signature and score trajectories, which
predicts therapeutic efficacy. (A) Mice with an array of implants and a primary
tumor in their 4th mammary fat pad (n=15 mice) had an implant surgically biopsied,
then immediately had their primary tumor resected along with the surrounding fat
pad (day 0, tumor burden equivalent to day 14 in Figs. 5.2 and 5.6). Tumor-free
control (TFC) mice (n=7) received sham inoculation with PBS and a mammary gland
excision. All mice where then monitored by weekly (days 7, 14, and 21) biopsy of
tissue from the implant, then analyzed by qRT-PCR and reduction to a predictive
score. (B)-(D) Signature analysis using the SVD and bagged tree algorithm that
had been trained on the disease-progression group (Fig. 5.8) was used to classify
each sample. Both SVD and bagged tree exhibited downward trends in the tumor-
bearing cohort (n=15) following therapeutic tumor resection. Next, the analysis was
stratified on the basis of classification as therapy resistant (n=9) or responsive (n=6),
as determined by survival monitoring following excision of the primary tumor. (E)-
(G) The predictive scores indicated a significant divergence between the resistant and
responsive mice. Filled ellipses indicate the average and SEM for the bagged tree and
SVD data at days 0, 7, 14, and 21. The cohort size for each group was decreased by
one at day 21 due recurrence and animal censorship. For longitudinal data, statistics
were performed via a linear mixed model. Post hoc simple effects analysis indicates
significant differences (P<0.05) between tumor-free control (∗) and tumor bearing
(TB; collective, not stratified by outcome), tumor bearing and tumor bearing day 0
(preexcision; ), tumor-free control and resistant (†), tumor-free control and responsive
(), and resistant and responsive following significant (; P<0.05) or trending (P<0.1)
interactions in a two-way ANOVA.
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Figure 5.11: Gene expressions corresponding to the post-therapeutic signature analysis
shows a cumulative regression toward a tumor-free state following tumor
resection and a subsequent bifurcation between several genes as a function
of therapeutic outcome. (A) For the 7 genes that showed an increased expression in
the metastatic onset model (Fig. 5.5), there was an organized regression in expression
1 week after therapy. Tumor-free control (TFC), n=7; tumor-bearing (TB) mice,
n=15. (B)-(E), Radar plots illustrate the bifurcation of specific genes as a function of
therapeutic outcome, as determined by survival monitoring following excision of the
primary tumor. While the decrease in expression continued for several genes, other
genes like S100a8, S100a9, Pglyrp1, andLtf showed a rebound and increase in the
resistant cohort after the initial decrease. tumor-free control, n=7; resistant, n=9; and
responsive, n=6.
Scores were stratified on the basis of survival or recurrence outcomes (Fig. 5.10E-
G). For mice that survived long-term post-excision, the regression toward the tumor-
free control baseline continued over the subsequent 2 weeks (days 14 and 21 post-
surgery), with no signs of recurrence through day 48. However, for the mice that
developed disease recurrence, the scores remained signicantly elevated above the
tumor-free control baseline and signicantly deviated from the scores of mice that
survived long term. In the predictions obtained from the bagged decision tree, the
average scores for mice that survived consistently indicated a lower degree of dis-
ease conditioning. The redirection in score and prediction trajectories of Fig. 5.10
is attributable to specic changes in gene expression. All genes from the panel with
increased expression during tumor progression (S100a8, S100a9, Pglyrp1, Camp, Ltf,
Chi3l3, and Ela2 ) regressed toward the tumor-free control baseline following tumor-
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bearing mammary gland excision (Fig. 5.11A). Interestingly, the three genes strongly
associated with MDSC cell phenotype in our scRNA-seq data (S100a8, S100a9, and
Pglyrp1 ; Fig. 5.6B), also demonstrated a pronounced separation between mice that
remained disease free and those animals that developed a recurrence (Fig. 5.11B-E;
Fig. 5.12A-K). An interesting connection between data in Figs. 5.2F, 5.2H, 5.8B,
and 5.11A-E is that S100a8, S100a9, Pglyrp1, and Ltf cluster together during disease
progression, have the weakest correlation with blood, are upregulated in MDSCs, and
are the earliest and most consistent predictors of survival in the therapeutic model.
Results from the signature analysis, reduction to single-metric scores, and the gene
expression components demonstrate that tissue from biopsied implants are a plat-
form for monitoring context-specic pathological states.
5.5 Discussion
The synthetic metastatic niche is based on engineering a tissue within a porous
scaffold that is inserted subcutaneously and is thus readily accessible for analysis, al-
lowing for longitudinal monitoring without risk to a solid organ. Following treatment
with surgery, chemo- and/or radiotherapy, scaffolds would be implanted into patients
with aggressive cancer variants, who are at high risk for disease recurrence. Insertion
and biopsy of a synthetic niche using a trocar would be comparable with procedures
using a CNB. The microporous scaffold supports cell inltration from the host, which
becomes vascularized within days [148]. In addition to the broblasts and endothelial
cells, the biomaterial scaffold elicits a foreign body response that recruits immune
cells from the vasculature. Immune cell inltration is highly dynamic during the acute
phase (1-2 weeks after implantation) and is followed by a chronic phase that is rel-
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Figure 5.12: Additional data from post-excision model demonstrating the cohort sur-
vival curve and gene expression trajectories. (A) Kaplan-Meier survival anal-
ysis comparing TFC and TB mice that received mammary gland excisions. (B)-(K)
Time course analysis for 10 gene panel. Error bars in line plots for gene expression
and signature trajectory indicate SEM. The cohort size for each group is decreased by
one at Day 21 due recurrence and animal censorship. For longitudinal data, statistics
were performed via a linear mixed model. Post hoc simple effects analysis indicates
significant differences (p<0.05) between (∗) TFC and resistant, (‡) TFC and respon-
sive, (&) resistant and responsive, (#) responsive and responsive Day 0 (pre-excision),
and ($) resistant and resistant Day 0 (pre-excision) following significant (p<0.05) or
trending (p<0.1) interactions in a two-way ANOVA.
atively stable. However, as the health status of the host changes, the immune cells
and acellular material in the circulation may be altered, which alters recruitment
to the scaffold and transforms the immune composition at the synthetic niche from
that of a healthy individual to reflect the diseased state. This relationship between
the foreign body response and disease state has emerged recently, with observations
in the context of diabetes and neoplasia [138, 139]. In the work focused on neopla-
sia, Oliva and colleagues demonstrated that tissue adhesives perform differently in
healthy, inamed, and neoplastic colon tissue, which were then used to inform the
synthesis of disease-specic adhesives [138]. Our data builds on these observations by
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demonstrating that the immune pathways in tissue localized at biomaterial implants
may be exploited as a cancer diagnostic platform.
Changes in the gene expression of tissue biopsied from implants of tumor-bearing
mice suggest the adoption of an immunosuppressive and hospitable environment
for tumor cells, which is reflective of metastatic niche biology and primary tumor
conditioning of distant vital organs. The increases in S100a8/9 are hallmarks of
premetastatic and metastatic niche formation in metastasis-targeted organs (e.g.,
lungs) and MDSC immunosuppressive functionality [137]. Accordingly, S100a8/9
expression leads to T-cell inhibitory/cytotoxic byproducts (e.g., reactive oxygen
species) and tumor cell proliferation [149, 150]. Others have shown that tumor
cells, specically 4T1 cells, lack production of S100a8/9 [151], thus our results reect
changes in immune cell dynamics and not the presence of metastatic tumor cells. An
interesting discovery was that S100a8/9 was also upregulated in macrophage and
DC populations, supporting that multiple myeloid cell lineages are involved estab-
lishing the metastatic niche. Unlike the increase in S100a8/9, the increase in Pglyrp1
has not yet been associated with the metastatic niche, although Pglyrp1 expression
correlation with S100a8/9 was previously associated with bone marrow-derived gran-
ulocytic MDSCs and Th17 to regulatory T (Treg) cell transdifferentiation [152, 153].
Increases in Ela2, Camp, and Ltf had the greatest overall magnitude changes within
the implant tissue at day 21. Ltf and Camp are upregulated in granulocytic MDSCs
as compared with neutrophils, and increased levels of Ela2 and Camp have been
identied as drivers of metastasis, with Ela2 associated with poor clinical outcomes
and endocrine treatment failure [142, 154]. Chi3l3 expression progressively increased
in the tissue inltrate, and this finding is supported by recent reports that chitinase-
knockout mice had decreased metastasis [155]. A decrease in Ccr7 would limit the
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Figure 5.13: Kaplan-Meier survival curves correlated with high and low gene expression
from breast cancer patient samples. (a) Microarray (GEO via KMPlot) and prog-
nosis data were queried for genes selected for the 10-gene panel derived from tissue
within implants to determine the expression level relevance in primary tumors on the
clinical outcome of systemically untreated breast cancer patients (n=818). Kaplan-
Meier plots indicate as separation of two profiles separating high and low gene ex-
pression that are automatically divided by the median expression of the genes for all
samples. Plots indicate the Hazard Ratio (HR) which is highest for S100a9 and lo-
grank significance comparing high and low expression as a function of recurrence-free
survival. FDR 10% corrected significance (p<0.011) and FDR 5% corrected signifi-
cance (p<0.00099). (b) Metrics on overall survival (n=379 patients) were calculated in
the same manner as that for recurrence-free survival. FDR 10% corrected significance
(p<0.0123) and FDR 5% corrected significance (p<0.005)
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chemoattraction of T cells, reecting the decrease in CD8+ and CD4+ T cells in tissue
at days 14 and 21, respectively [22, 156]. Ccl22 expression can be upregulated in
metastatic target organs and attracts Tregs in oncogenesis, thus the decrease in Ccl22
expression during disease progression was novel and not anticipated [157]. Data ac-
cessed from a gene expression repository suggests that expression of S100a8, S100a9,
Pglyrp1, and Camp in the primary tumors of patients with breast cancer is prognos-
tic, which points toward some conserved biological mechanisms (Fig. 5.13A and B),
yet these primary tumor measurements are limited to a single predictive measure
and do not facilitate the monitoring of oncogenic changes over time. Collectively,
data obtained from implants in the BALB/c-4T1 metastatic model indicate that the
scaffold is conditioned by the primary tumor, leading to increased expression of genes
associated with an immunosuppressive microenvironment.
Analysis of the scaffold provides data relevant to the elusive metastatic niche that
is distinct from the information that obtained from a liquid biopsy. Information ob-
tained from the metastatic niche could be used to generate tools that enable compre-
hensive analysis of the metastatic cascade to permit early detection. Primary tumor
and sentinel lymph node data are attainable from tissue biopsies but are limited
to providing only early stage disease findings. Liquid biopsies have utility, yet may
reflect an intermediate or potentially clinically noncontributory step in the disease
process. Cell migratory events, particularly events involving immune cells leaving
the vascular and entering distal tissues, are associated with phenotypic changes. As
the formation of the metastatic niche is stochastic in distal organs, the ability to
predetermine the location of the metastatic niche enables the analysis of the mi-
croenvironments that support the survival of disseminated tumor cells. Importantly,
for the 4T1 metastatic breast cancer model, this data showed that the conditioning
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of the implant microenvironment was similar to the conditioning of the lung. In-
terestingly, the gene panel had several common responses in two distinct models of
breast cancer metastasis to the lung. Thus, these findings point toward the develop-
ment of an environment that can induce a common lung-tropic cellular phenotype
in recruited cancer cells [158]. We do not anticipate that this implant replicates
the biology of the lung, yet is capturing common aspects of metastatic condition-
ing. These results highlight the spectrum of immune states that sites distal from a
primary tumor exhibit following therapy and during cancer progression. Through
the targeting of early immunologic events using immune modulatory agents, these
dynamics could potentially be exploited [159]. In addition, these treatments could
be used in conjunction with anticancer therapies that focus on the cellular weak-
nesses gleaned from the analysis of tumor cells captured within the scaffold. The
expectation that combinatorial approaches would be necessary to address different
cancer subtypes will help to realize the promise of personalized medicine.
Analysis of the scaffold following surgical excision of the primary tumor allowed
for monitoring of response to this therapy, and stratified the tumor-bearing treat-
ment group based on survival outcomes. Predictive scores were derived from gene
expression signatures to track disease status and enable longitudinal monitoring of
individual mice before and after surgical treatment. One of the most interesting
observations was the sharp regression in tumor-promoting gene expression in the
implants following cancer excision of the tumor-bearing mammary fat pad. On the
basis of scRNA-seq data, this rapid change in gene expression likely results from
changing immune cell populations or altered phenotypes within the implant. This
dynamic nature of immune cells at the implant underpins the concept of the synthetic
niche, which could inform the initiation of novel therapeutic interventions. In the last
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year, novel therapies have become available for the treatment of hormone insensitive
and HER2 receptornegative breast cancer. Olaparib, a PARP inhibitor, has shown
efficacy in extending progression-free survival for patients with metastatic, BRCA
mutationpositive, and triple-negative breast cancer [160]. In addition, an anti-PD-L1
antibody, atezolizumab, was also recently found to be efficacious in extending survival
for patients with PD-L1expressing metastatic triple-negative breast cancer [161]. Ac-
celerating the initiation time of these promising treatments, through early-detection
diagnostic platforms, could improve disease-specic outcomes by allowing therapeu-
tics to function when the burden of metastatic disease and heterogeneity of cancer
mutations are relatively low. Furthermore, the niche can be analyzed for the pres-
ence of immunosuppressive macrophages and DCs, which presents unique diagnostic
avenues and therapeutic targets for tumors that are driven by these myeloid subsets
and complements efforts to characterize and overcome MDSC immunosuppression.
The application of tissue engineering for cancer diagnostics represents a novel
approach to engineer a system that reports on early metastatic sites. Our data in-
dicate the ability to capture disease progression or regression, suggesting that the
foreign body response has the potential to capture both immune activation and sup-
pression, which may enable their application to a range of immunologic disorders.
Collectively, our data indicate that the tissue within implants is dynamic, with a
context-dependent prole that reects disease course and response to tumor excision.
Broadly, the concept of synthesizing tissues that are difcult to assess, such as the
lung or central nervous system tissue, may enable diagnostics that have broad appli-
cation for monitoring immunologic diseases.
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5.6 Materials and Methods
5.6.1 Microporous PCL scaffold fabrication
Poly(-Caprolactone) (PCL) microspheres were prepared by emulsifying (homoge-
nization at 10,000 rpm for 1 minute) a 6% (w/w) solution of PCL (Lactel Absorbable
Polymers) in dichloromethane in a 10% poly(vinyl alcohol) solution, which was then
stirred in DI water for 3 hours. Particles were collected by centrifugation, serially
washed with MilliQ filtered water, then lyophilized. Salt porogen (NaCl) with a
size range of 250-425 m was selected through sieving. PCL microspheres and NaCl
were then mixed in a 1:30 (w/w) ratio and pressed at 1,500 psi in a stainless-steel
die (International Crystal Laboratories) for 45 seconds. The volume and die size
used results in a PCL/NaCl disc that is 5 mm wide and 2 mm thick (Fig. 5.2A).
PCL/NaCl discs were heated on disinfected glass slides to 135◦C for 5 minutes per
side. NaCl was then removed via leaching in MilliQ water for 1.5 hours. The result-
ing microporous PCL scaffolds were disinfected in 70% ethanol then serially rinsed
in sterile filtered MilliQ water. Scaffolds were dried on a sterile gauze and stored at
-80◦C until time of implantation.
5.6.2 Animals and scaffold implantation
Microporous PCL scaffolds were implanted in the subcutaneous space of female
mice to facilitate cellular infiltration and development of a foreign body response for
subsequent isolation and analysis. All animal studies were performed in accordance
with institutional guidelines and protocols approved by the University of Michigan
Institutional Animal Care and Use Committee. Female mice of the BALB/c and
C57BL/6 strains were purchased from Jackson Laboratories at an age of 8 weeks.
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For implantation, mice were administered the analgesic Carprofen (5mg/kg) prior
to and 24 hours after surgery. Mice were anesthetized under isoflurane (2.0-2.5%)
and assessed by toe pinch reflex for level of sedation. The upper dorsal area above
the scapula was then shaved and prepared using betadine and ethanol swabs. An
incision (approximate 7-10 mm from anterior to posterior) was made in the upper
dorsal area. A subcutaneous cutdown created a pocket in the lateral direction on the
left and right sides of the mouse. A single scaffold was then inserted into each pocket.
Two scaffolds were implanted for mice used to identify the initial gene expression
changes and develop a signature. The incision line in these mice was closed with 7
mm stainless-steel wound clips (Roboz Surgical Instrument Co.). An array of eight
scaffolds was implanted in mice used for longitudinal monitoring of disease course af-
ter therapy. Skin in these mice was closed with suture (MONOCRYL-poliglecaprone
25, Ethicon, Inc.).
5.6.3 Metastatic tumor cell lines and animal inoculation
Orthotopic inoculation of tumor cells was performed 2 weeks after scaffold im-
plantation. 4T1-luc2-tdTomato cells were obtained from Perkin Elmer which had
been authenticated previously via short tandem repeat (STR) and comparison with
ATCC STR database. E0771 GFP+ cells were a kind gift from the Laboratory of
Gary and Kathryn Luker at the University of Michigan Center for Molecular Imag-
ing. To develop a more aggressive metastatic cell line, we employed a serial inoc-
ulation strategy that began when a C57BL/6 mouse inoculated with the parental
line exhibited secondary metastatic growths at many sites including: lung, brain,
mesentery, and diaphragm. Cells derived from the original lung (Lu.1) and brain
(Br.1) metastases were then inoculated via intracardiac injection, which resulted in
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Figure 5.14: Scaffolds from (A) left and (B) right side of a mouse inoculated with
parental E0771 which developed a high metastatic burden which metas-
tases present in the (C) brain and (D) lungs. Metastatic lines Br.1 and Lu.1
were derived from the tumor cells from these brain and lung metastases, respectively.
Serial inoculation via intracardiac injection and isolation of developed metastases (E)
indicated a propensity for the lung derived metastases have an organotropic bias to-
ward lung tissue. (F) Confirmation of fluorescent tumor cells in the scaffolds from
(A)-(B) was verified by fluorescent microscopy of scaffold tissue sections. (G) In vivo
imaging of Br.1 and Lu.1 line 11 days following intracardiac inoculation.
brain and lung metastases that were again isolated as Lu.2 and Br.2. Both Lu.1
and Lu.2 showed a stronger inclination for metastatic colonization of the lung (Fig.
5.5E), similar to reports on 4T1 phenotype. 4T1-luc2-tdTomato (BALB/c) or E0771
Lu.2 (C57BL/6) syngeneic tumor cells were orthotopically inoculated at a density of
40,000 cells/µL for a total of 800,000 in 20 µL of sterile Dulbeccos phosphate buffer
saline (DPBS; Gibco). Inoculation was performed by making a small incision (5 mm
dorsal to ventral) above the 4th right mammary fat pad. The mammary fat pad was
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exposed, injected, then the skin was closed with tissue adhesive (3M VetbondTM).
Tumor measurements were taken daily, starting at Day 7, and calculated with the
conventional ellipsoid equation (width2*length)/2.
5.6.4 Biopsies tissue of scaffold, blood, and lung tissue
Biopsies of tissue from microporous scaffolds, leukocytes from blood, and lung
tissue were isolated to study gene expression changes due to disease progression. Mi-
croporous scaffolds that had been implanted for either 7, 14, or 21 days following
inoculation of primary tumors (as indicated in figures) were surgically biopsied fol-
lowing isoflurane (2.0-2.5%) sedation by making an incision adjacent to the implant
site and removing the implant without taking surrounding tissue. Using this surgical
biopsy ensure we sampled the implant and eliminated caveats associated with biop-
sies of regenerated tissue in the implant, yet this aspect would need to be analyzed
for translation. For core-needle biopsy (CNB) of the implant, a disposable CNB tool
(Bard R© Mission R© Disposable Core Biopsy Instrument) was inserted through the
skin and used to isolate a portion of the implant and infiltrating tissue (Fig. 5.15B),
which enables minimally invasive retrieval of samples. Leukocytes were isolated
from blood via an intracardiac blood draw stabilized by EDTA. Erythrocyte lysis in
EDTA-treated blood samples was performed with Ammonium-Chloride-Potassium
(ACK) Lysing Buffer (Gibco) with serial washes in DPBS. Lung tissue from time-
matched healthy control and tumor-bearing mice at Day 21 were isolated for endpoint
comparative analysis following euthanasia.
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Figure 5.15: Implant microenvironment exhibits good tissue ingrowth and facilitates
surgical and core-needle biopsies to acquire RNA for transcriptomic or
gene expression analysis. (A) A surgically-biopsied implant illustrating the intact,
frozen condition prior to RNA isolation and RT-qPCR assessment. (B) A sample
derived from a scaffold using a core needle biopsy (CNB, Bard R© Mission R© Disposable
Core Biopsy Instrument) which enables minimally invasive retrieval of samples, similar
to clinical approaches for sampling suspicious tissue. In both samples tissue ingrowth
into the microporous structure is evident but especially in the CNB as the cutting
plane transected the inner core of the implant. Scaffolds as shown are in -80circC
frozen state. Diameter of the black background circle is 7.5 mm. (C) Comparing
the RNA isolated from the full surgically biopsied scaffold compared to the CNB
sample, there is a significant -1.812 log-transformed fold change, but sufficient material
for numerous gene expression assessments (RT-qPCR, RNAseq, etc.) with the CNB
samples containing an average of 4376 ng of total RNA. indicates differences between
surgically biopsied and CNB samples from an unpaired t-test (p<0.05, n=8).
5.6.5 Surgical resection of primary tumor and longitudinal tracking
To test the responsiveness of the tissue biopsied from implants to therapeutic
treatment mammary gland removal was performed on the 4T1 primary tumor that
had been inoculated in the 4th right mammary fat pad of BALB/c mice. In this
model, the primary tumor was resected 14 days after inoculation, which aligns with
the time point for the initial set of experiments to study the progressive changes in
the tissue within implants as a function of disease course. The skin above the primary
tumor was prepared by swabbing with betadine and ethanol. A dermal incision was
made adjacent to the primary tumor for the length of the primary tumor and mam-
mary fat pad (approximately 1 cm). Large vessels surrounding the primary tumor
were cauterized using a Gemini Cautery System (Roboz Surgical Instrument Co.).
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Iris scissors were used to cut connective tissue to separate the mammary fat pad
and contained primary tumor from the superficial dermal and underlying body cav-
ity wall. The dermal incision was closed using suture (MONOCRYL-poliglecaprone
25, Ethicon, Inc.). Following tumor resection and mammary gland removal, animal
health was monitored daily for activity and responsiveness, including posture, mo-
bility, body weight, grooming behavior, and respiratory conditions. Animals were
euthanized if found in a moribund condition or when a primary tumor regrowth was
positively identified.
5.6.6 RNA isolation, purity, integrity, and cDNA synthesis
Total RNA was isolated from tissue biopsied from implants, lung tissue, and
leukocytes from blood. Frozen (-80◦C), surgically biopsied scaffolds were immersed
in monophasic solution of phenol and guanidine isothiocyanate (TRIzol R© reagent,
Thermo Fisher Scientific, Waltham, MA) at 4 ◦C, then homogenized with a rotor sta-
tor homogenizer (T25, S25N8GST dispersing element, IKA R© Works, Inc.). Samples
were then centrifuged at 10,000g to remove particulate, and the TRIzol R© containing
genomic content from the scaffold was then processed in a silica-based matrix spin
column (Direct-zolTM RNA Miniprep Plus, Zymo Research Corp., 110 Irvine, CA)
with DNase I treatment to isolate total RNA. Concentration (modified Beer-Lambert
at 260nm) and purity (260nm/280nm absorbance ratio) of the RNA isolation was
assessed by light absorbance via a NanoDrop 2000c (Thermo Fisher Scientific). Addi-
tionally, RNA integrity number (RIN) analysis was obtained through RNA fragment
analysis (RNA 6000 Nano Kit on a 2100 Bioanalyzer, Agilent Technologies, Inc.,
Santa Clara, CA). RIN for samples used in high-throughput RT-qPCR ranged from
8.2-9.7. Generation of first strand cDNA was performed through reverse transcrip-
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tion (RT, SuperScript
TM
VILO
TM
cDNA Synthesis Kit, ThermoFisher Scientific).
For all RT-qPCR of tissue biopsied from implants, RT was performed with an RNA
concentration of 200 ng/µL. cDNA was either used immediately for RT-qPCR or
stored at -80◦C. Frozen lung tissue biopsy RNA was isolated in similar fashion to
implants with RT performed at an RNA concentration of 200 ng/µL. Blood leuko-
cyte RNA was isolated by thoroughly mixing blood leukocytes following ACK lysis
in TRIzol, then processing for RNA and performing RT at 100 ng/µL due to limited
quantities of total RNA. RNA concentration was increased to 200 ng/µL (niches and
lungs) or 100 ng/µL (blood) using a RNA clean-up kit (RNA Clean & Concentrator-
5, Zymo Research Corp.) for samples below these thresholds.
5.6.7 OpenArrayTMhigh-throughput RT-qPCR
Tissue biopsied from implants was analyzed for gene expression with OpenArray R©
(OA), a high-throughput RT-qPCR platform that analyzes 648 genes per sample in
parallel, in accordance with the standard OA protocol. All materials used in this
section were purchased from Thermo Fisher Scientific. Briefly, the genes for this
study were focused on the immune pathways and included a panel of 16 reference
(housekeeping) genes per sample (Applied BiosystemsTM TaqManTM OA Mouse In-
flammation Panel, Cat. No. 4475393). cDNA from tissue biopsied from implants
in tumor-free healthy controls (n=14 total tumor-free control) and tumor-bearing
mice (n=14 total tumor-bearing) across the three time points of 7 (n=3), 14 (n=8),
and 21 (n=3) days were mixed with 2X TaqMan R© OA Real-Time Master Mix then
loaded onto the OA panels via a robotic OA AccuFillTM System in an order that
staggered conditions and time points across the panels analyzed. The OA RT-qPCR
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run (QuantStudio 12K Flex Real-Time PCR System, ThermoFisher Scientific) and
sample quality control were performed by the Affymetrix Group at the University of
Michigan DNA Sequencing Core. In accordance with OA standard operating proce-
dure, Cq was calculated as Crt, a curve-specific method.
5.6.8 Analysis of gene expression and selection of genes of interest
Gene expressions from OA was screened to identify genes of interest during dis-
ease course. First, genes with insufficient data within samples (missing greater than
4/14 per cohort or 2/3 per time-point) were dropped from the study, resulting in 559
genes for full analysis. Next the 16 reference genes were ranked according to their
expression stability compared to each other and as a function of experimental design
(NormFinder Algorithm), which led to the selection of Gapdh, Tbp, Ywhaz, Hmbs,
and Ubc. ∆Cq values were calculated against the average of the reference genes,
centered on median of time-matched tumor-free controls, then standardized for clus-
ter and multivariate statistical analysis. From ∆Cq data fold change, significance
(uncorrected p and false-discovery rate corrected q), at Days 7, 14, and 21 were cal-
culated. For computational analysis ∆Cq values are log2 transformed and centered
on the healthy, tumor-free control time-matched median as reflected in the figure box
plots, which show the median, 25th-75th percentiles and most extreme data points
not considered outliers (outliers are visually indicated by +). Management of non-
detects within the OA data was handled in two manners: for multivariate statistical
analysis non-detects were interpolated based on the ∆Cq average across all cohorts
and time points, and for signature construction non-detects were interpolated based
on the ∆Cq average for a specific cohort at a specific time point.
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5.6.9 10-gene panel RT-qPCR analysis in 96-well format
Experiments for signature validation, analysis of blood, lung and post-excision
monitoring was performed by RT-qPCR analysis in 384-well and 96-well plate for-
mats using matched Taqman R© probes from the OA platform (see Supplementary
Data 1 for probe details). Like the OA RT-qPCR, samples were staged within plates
alternating between tumor-free control and tumor-bearing. The same 5 reference
genes (Gapdh, Tbp, Ywhaz, Hmbs, Ubc) were run in parallel with the 10 target genes
of interest (Bmp15, Camp, Ccl22, Ccr7, Chi3l3, Ela2, Ltf, Pglyrp1, S100a8, S100a9 )
for all studies in BALB/c mice. Ywhaz and Ubc were only used for the C57BL/6-
E0771 analysis due to poor detection and poor stability in Gapdh, Tbp, and Hmbs
reference genes. Analysis was performed on a CFX ConnectTM Real-Time PCR
Detection System (Bio-Rad Laboratories, Inc., Hercules, CA) with CFX Manager
Software that calculated the Cq values based on the regression analysis mode, which
applies a multivariable, nonlinear regression model to each well trace. For signature
computation and multivariate statistics, non-detects were interpolated based on Cq
average across all cohorts and time points to limit predictive bias, which could be
exaggerated by use of a static, arbitrary ∆Cq. Non-detects were left blank for uni-
variate, multiple comparison, and linear mixed model analysis. The gene expression
dynamics of tissue biopsied from implants and blood gene expression dynamics were
compared by goodness of fit using a normalized root mean square error cost function
on a linear polynomial curve fit between Days 7, 14, and 21. Cohort centering was
used to align the longitudinal data from the therapy study for subsequent signature
analysis. The median of the therapy cohorts Day 0 pre-excision was centered on the
OA Day 14 data median, which was experimentally equivalent. The calibration fac-
tor used for aligning therapy cohorts Day 0 to OA Day 7 was applied to all successive
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time points.
5.6.10 Single-cell RNA-seq of immune cells in tissue biopsied from im-
plants
Scaffolds were implanted in BALB/c mice 14 days before the mice were inoculated
with 4T1 metastatic triple negative breast cancer cells in the fourth right mammary
fat pad. After an additional 14 days, the scaffolds were removed and digested in
order to obtain a single-cell suspension. Erythroblasts were lysed through sequen-
tial exposure to 0.2% NaCl and 1.6% NaCl. The cells were prepared for single-cell
sequencing using Drop-Seq.
mRNA was collected from each cell and subsequently converted to cDNA before
being taken through tagmentation and PCR. Sample quality and DNA concentra-
tion were assessed with a Bioanalyzer 2100 before submission to the DNA Sequencing
Core at the University of Michigan. Samples were pooled and sequenced on the Illu-
mina HiSeq-4000. The final reads were mapped to the mm10 mouse reference genome
to quantify gene expression and a read-count matrix was assembled. Single-cell gene
expression was conducted using Seurat, an 180 open source program in R developed
by the Satija lab at the New York Genome Center. The matrix was filtered, nor-
malized and scaled before using PCA and tSNE to identify clusters. Identification
of each cluster was conducted using known cell markers.
5.6.11 Adoptive transfer and implant trafficking analysis of Ly6G+ and
Gr-1+ Ly6G−immune populations
Splenocytes were isolated from 4T1 tumor-bearing BALB/c mice. G-MDSCs
(Ly6G+) and M-MDSCs (Gr1+ Ly6G-) were taken from splenocytes by magnetic
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bead separation using the Myeloid-Derived Suppressor Cell Isolation Kit (Miltenyi
Biotec). G-MDSCs and M-MDSCs were labeled with lipophilic membrane dyes DiD
and DiO (ThermoFisher), respectively. Cell staining was performed at a concen-
tration of 2E6 cells/mL in 5µM dye solution at 37◦C for 20 minutes. Cells were
quantified after staining, and 5E6 live labeled G-MDSCs and 5E6 live labeled M-
MDSCs were injected i.v. into disease-free or Day 7 tumor-bearing recipient mice.
Recipient BALB/c mice had been implanted with scaffolds 21 days prior to adoptive
transfer of labeled cells. Scaffolds were isolated 36 hours after adoptive transfer, and
labeled G-MDSCs and M-MDSCs in the scaffold were quantified by flow cytometry.
5.6.12 Gene expression dimensionality reduction and classification
Genes of interest were identified based on fold-change, level of significance, and
expression stability over time. Expression stability was defined as a continuous tra-
jectory for the expression of a gene. Panel selection was confirmed by an Elastic Net
regularization, which identified how predictive a gene was of the tumor-bearing state,
irrespective of timepoint. Elastic Net regularization, a variation of the LASSO (least
absolute shrinkage and selection operator) algorithm with an α=0.1 and leave-one-
out cross validation, was employed using the Matlab lasso function on the ∆Cq of
the 559 genes with sufficient data. This data indicated the predictive nature of genes
for tumor-bearing classification at specific time points (Fig. 5.15B). Clustering of
samples was performed with the Matlab clustergram function on standardized ∆Cq
data. Dendrograms indicate clustered genes and samples, in which samples are indi-
cated on the x-axis and genes expressed are indicated on the y-axis with a complete
linkage and a display range of -3.5 to +3.5. Unsupervised dimensionality reduction
was performed using singular value decomposition (X=USVT) with the Matlab svds
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Figure 5.16: Gating scheme for flow cytometry analysis of adoptive transferred cells.
These plots indicate the (A) cells and (B) singlet gating prior to (C) gating for DiO
and DiD fluorescent lipophilic dyes. Axes in(c) are identical to those in panels (D)-
(F). Numbers on plots indicate percentage of gated cells in comparison to (A) total
events, (B) gated cells, and (C) single cells. Representative flow cytometry plots
and gating for (D) PBS injected control mice and adoptively transferred Ly6G+ and
Gr1+Ly6G−populations into (E) TFC and (F) TB mice.
function on the 10-gene and 4-gene panels standardized ∆Cq values centered on the
time-matched tumor-free controls. The first 3 principle components (PCs) were com-
puted from the first 3 left singular vectors (columns of U, eigenassays) and singular
values (diagonal matrix S). Unsupervised separation of the samples was visualized
by plotting the PCs in 3D scatter, which was quantified by calculating the Euclidean
distance in PC1 and PC3 to each sample from the centroid of all the tumor-free
controls. Distance calculations were scaled between 0 and 1. A supervised machine
learning algorithm, bootstrap aggregated (bagged) decision tree ensemble (i.e., Ran-
dom ForestTM), was used to construct a predictive model based on the 10-gene and
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4-gene panels standardized ∆Cq values centered on the time-matched tumor-free
controls. The model was constructed using the Matlab core fitcensemble function
with the Bag method. Decision tree depth was limited by the number of splits to 1.5
times the number of input predictors (genes). The number of learning cycles for final
model was set to 250 cycles. A partitioned model and leave-one-out cross-validation
was performed using the Matlab crossval and kfoldPredict functions, which returned
the posterior probability for classification of each sample.
5.6.13 Statistics
This section details the statistical tests used to evaluate the hypotheses. Error
bars are defined within figure legends, with all line plots indicating standard error of
the mean. The exact n for each test is detailed in the legends along with the meth-
ods for multiple comparisons corrections. All n throughout the manuscript indicate
biological replicates from different mice. During the initial screen of the OA data
and selection of genes of interest, a false-discovery rate corrected two-tailed t-test
using a linear step-up procedure to account for all genes analyzed (559 total follow-
ing elimination of genes that did not contain sufficient sample) contrasted samples
from tumor-bearing mice and healthy time-matched tumor-free controls. These tests
were carried out in Matlab using the mattest and mafdr functions. All statistical
indicators within the manuscript were computed using packages and syntax in the
Statistical Package for the Social Sciences (SPSS, International Business Machines
Co., Armonk, NY). Multiple comparisons analysis for comparisons with an individ-
ual time point were compared via an independent Students two-tailed t-test with
Dunn-Sˇida´k correction for multiple comparisons resulting in a p<0.0051 being con-
sidered significant. Two-way multivariate analysis of variance (MANOVA) for genes
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of interest and reduced dependent variables (SVD score or bagged tree prediction)
were performed within the generalized linear model (GLM) syntax package using the
BY command for condition and time. First, Pillais Trace statistic (p<0.05) was used
to determine MANOVA significant interaction effects. Second, fixed-effects ANOVA
was used to assess univariate interaction effects. Last, following determination of
multivariate and univariate interaction effects, a post-hoc simple effects analysis was
computed with Sˇida´k correction from an initial p<0.05 for multiple comparisons to
determine within groups over time and between groups at Days 7, 14, and 21. To
analyze the differences within mice tracked longitudinally before and after a ther-
apeutic tumor excision a Linear Mixed Model (LMM) was employed. The SPSS
syntax for the LMM is available in the prepress repository. First, two-way ANOVA
within the LMM was assessed for significant (p<0.05) or trending (p<0.1) interac-
tions. Last, post hoc simple effects analysis indicated significant differences (p<0.05)
within groups over time and between groups at Days 7, 14, and 21. Within the fig-
ures the focus for within group effects was how the gene expression, SVD, or bagged
tree data changed from pre-excision (Day 0) to post-excision (Days 7, 14, and 21).
5.6.14 Breast cancer patient microarray Kaplan-Meier correlation
A repository of human patient microarray data was analyzed for gene expressions
correlations with high or low gene expression and patient recurrence free survival
(RFS). Microarray data from Gene Expression Omnibus (GEO) via Kaplan-Meier
Plotter (KMPlot, kmplot.com/analysis/) and prognosis data were queried for the
10-gene panel from the implant-derived data to determine the expression level rel-
evance in primary tumors on the clinical outcome of systemically untreated breast
cancer patients. Separation of high and low gene expression profiles was automat-
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ically divided by the median expression of the genes for all samples – n = 818 for
recurrence-free survival and n = 379 for overall survival. Redundant and outlier
microarrays were excluded, and only breast cancer patients that were systemically
untreated were included. Data outputs for Hazard Ratio (HR) and logrank signifi-
cance are indicated in plots with multiple comparisons corrected using the KMPlotter
tool for false-discovery rate (FDR) with FDR 10% corrected significance FDR 5%
corrected significance.
5.6.15 Protocol and material availability
Many of the experimental protocols including scaffold fabrication, RNA isolation,
and RT-qPCR follow previously published or manufacturer recommended guidelines
and additional specifics are available from authors. The lung-topic Lu.2 cell line
derived from the parental E0771 tumor cell line is available from the authors.
5.6.16 Data availability
OpenArrayTM raw Cq, ∆Cq, and ∆∆Cq data is prepared for deposition in the
National Center for Biotechnology Information (NCBI) Gene Expression Omnibus
(GEO). OA .eds files are available from authors upon request if access to quality
controls (e.g., Cq confidence), amplification plots and Cq indicators are desired. All
other data supporting the findings in this study are available within the paper and
the supplementary data files. Single cell RNA-seq metadata, raw data, and processed
data will be deposited in the ArrayExpress according to the Annotare sequencing
template for single-cell submission. This includes cell-gene count matrix, cluster
identifications, markers for identification, and the compressed raw sequence read
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files in the fastq.gz format. ArrayExpress and GEO repositories comply with MIN-
SEQE and MIAME, respectively.
5.6.17 Code availability
Code that used built-in Matlab packages is available in the supplementary data
files alongside the raw data. The Matlab code and data output is available as the .m
file but has been converted to an html with table of contents to simplify review of
computational steps. SPSS syntax used for statistical analysis is available alongside
the statistical outputs with full descriptive statistics and indications of significance
or trends. The data output is organized by sheet to reflect each statistical analy-
sis for the OA gene expression MANOVA, OA signature MANOVA, C57BL/6-Lu.2
model multiple comparisons t-tests, LMM output for excision 10/4-gene signatures
and gene expression data, blood MANOVA, and lung multiple comparisons. The
.xlsx output is in the supplementary data files alongside the raw data and code.
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CHAPTER VI
The Role of Gr-1+ Cells at Metastatic Sites Changes with
Disease Progression
6.1 Authors
Yining Zhang, Jing Wang, Sophia M. Orbach, Ravi M. Raghani, Jacqueline S.
Jeruss, Lonnie D. Shea
6.2 Abstract
Myeloid-derived suppressor cells (MDSCs) have been shown to contribute to the
lack of response for a number of immunotherapies for cancer. As such, they present
potential as diagnostics and therapeutic targets. The phenotype of MDSCs has been
well-characterized in vitro and within various tissues, though relatively little is known
about their dynamics and behavior specifically at metastatic sites. Herein, we used
polymer scaffolds to investigate the phenotypic changes that Gr-1+ cells undergo
throughout metastatic disease progression. Porous polymer scaffolds implanted into
tumor-bearing mice recruit immune cells and subsequently metastatic tumor cells,
forming a microenvironment that has been shown to reflect the disease state of the
animal. These scaffolds provide a pre-defined location for metastatic events, which
can be used to isolate Gr-1+ cells for further study. We observed that the phenotype
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of Gr-1+ cells across different tissues change with disease progression, and found that
the changes observed at the scaffold are more similar to the metastatic lung than to
the spleen.
6.3 Introduction
Recent advances in the understanding of immune-tumor cell interactions has led
to the development of immunotherapies such as immune checkpoint blockade, CAR
T cells, and cancer vaccines. The efficacy of these therapies rely on their ability to
induce or improve the CD8+ T cell capacity for killing of tumor cells. However, it
has been shown that the presence of pro-tumor innate immune cells suppresses T
cell function, limiting the efficacy of these the therapies. Myeloid-derived suppressor
cells (MDSCs), in particular, have been identified as a major contributor to the
observed immunosuppression. MDSCs are a heterogeneous population of immature
innate cells. In mice, they are identified by their surface markers CD11b and Gr-1
(Ly6C/Ly6G).
The role of Gr-1 cells has been extensively studied in the past decade, especially
in the context of developing methods of counteracting their immunosuppression [4, 5,
7, 13]. Several studies have reported the different roles of distinct MDSC populations
in aiding metastatic seeding, niche maintenance, and primary tumor growth [4], as
well as the tissue-dependence of MDSC phenotype [5].
We hypothesized that Gr-1+ cells at metastatic sites are also functionally distinct
from those within the spleen, and that the phenotypes of Gr-1+ cells change with
disease progression across different tissues. Due to the challenges of studying Gr-
1+ cells in situ and longitudinally, the changes in Gr-1+ cell phenotype over time
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remains largely unexplored.
Polymer scaffolds that recruit immune and tumor cells in vivo have been used
to study metastatic cells [20, 21, 22, 134], and the microenvironment at the scaffold
has been shown to reflect the disease state of the animal [159]. These scaffolds
recapitulate many aspects of metastatic sites, and are thus likely to recruit Gr-1+
cells that are functionally similar to those at metastatic sites.
In this study, we investigate whether the MDSCs responsible for early metastatic
events are phenotypically distinct from those that persist at later timepoints, and
utilize the scaffold to further investigate Gr-1+ cells at metastatic sites. Anti-Gr-1
antibody (RB6-8C5), which depletes Gr-1+ cells, has been utilized to assess the func-
tional contribution of Gr-1+ cells in cancer, and has been explored as a therapy [162].
Here, we also use antibody depletion at various timepoints throughout disease pro-
gression to investigate the disease state-dependence of Gr-1+ cells phenotype.
6.4 Results
6.4.1 Tissue-specific and time-dependent functional phenotype of Gr-1+
cells
We first investigated the phenotypes of tumor-induced Gr-1+ cells within various
tissues and disease states in vitro. We assessed the tissue-specific differences of Gr-
1+ cells isolated from different organs with a trans-endothelial tumor cell migration
assay. Conditioned media was collected from Gr-1+ cells of the spleen, lung, and
scaffold of tumor-bearing mice, and tumor cell migration across an endothelial cell
layer toward the conditioned media was studied. Conditioned media generated from
Gr-1+ cells isolated from the lung and the scaffold induced migration of tumor cells,
whereas those from the spleen and tumor free control did not (Fig. 6.1), indicating
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differential secretion of chemoattractants and/or other factors that are able to di-
rectly influence tumor cells.
Figure 6.1: Gr-1+ cell secreted factors induce transendothelial migration. A)
Transendothelial migration assay design. B) Microscopy images of tumor cells (green)
that have migrated across the endothelial transwell cell layer toward conditioned media
isolated from Gr-1+ cells within spleen, lung, and scaffolds of tumor-bearing mice.
Changes in Gr-1+ cell phenotype and their interactions with anti-tumor immune
cells as functions of disease state were also investigated. The ability of these cells to
inhibit T cell proliferation was assessed with a T cell suppression assay. Gr-1+ cells
isolated from organs at day 3 (pre-metastatic) or day 10 (early metastatic) time-
points were cocultured with stimulated T cells and subsequent T cell proliferation
was quantified by flow cytometry (Fig. 6.2A). A decrease in suppressive capacity of
lung Gr-1+ cells was seen at day 10 post inoculation compared with day 3, yet this
change not observed in the other tissues (Figs. 6.2B and C).
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Figure 6.2: Suppression of T cell proliferation by Gr-1+ cells. A) Schematic of T cell suppres-
sion assay. Suppression of B) CD4+ T cell and C) CD8+ T cell proliferation following
coculture with Gr-1+ cells.
6.4.2 Depletion of Gr-1+ cells on disease progression
Next, systemic depletion with anti-Gr-1 antibody was employed to study the
contribution of Gr-1+ cells to disease progression and metastasis to in vivo. At
both the pre-metastatic and early metastatic time points, anti-Gr-1 was able to
deplete Gr-1+ cells systemically and within tissues, though a fraction was detectable
in the primary tumor with early metastatic treatment (Fig. 6.4). An intracardiac
model wherein labeled tumor cells were injected into circulation following anti-Gr-1
treatment (Fig. 6.4A) did not indicate a difference in tumor cell accumulation at the
scaffold (Fig. 6.4B) or the lung (Fig. 6.4C).
To examine the influence of Gr-1+ cells on survival, tumor-bearing mice were
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Figure 6.3: Anti-Gr-1 depletes Gr-1+ cells completely within tissues. Following anti-Gr-1
treatment at (A) pre-metastatic and (B) early metastatic timepoints, Gr-1+ cells were
no longer detectable in nearly all tissues evaluated.
treated with anti-Gr-1 antibody at pre-metastatic (day 1, 4), early metastatic (day
7, 10), or late metastatic (day 14, 17) (Fig. 6.5A). Anti-Gr-1 treatment at the
pre-metastatic timepoint resulted in increased metastasis and reduced survival time,
while no survival benefit was observed with early-metastatic treatment (Figs. 6.5B
and C). Late-metastatic treatment resulted in death of the animals within hours of
injection, possibly due to massive cell loss that compromised organ function.
6.4.3 Tissue-specific and disease state-dependent gene expression changes
in Gr-1+ cells
Gene expression analysis by RNA-seq was employed to assess transcriptomic dif-
ferences between Gr-1 cells at the various disease states and within different tissues
(Fig. 6.6A). Gr-1+ cells were isolated from the lung, spleen, and scaffolds of tumor-
bearing mice by antibody-based magnetic bead separation (MACS) at days 3, 10,
and 17 post inoculation. Principal component analysis delineated organs into sepa-
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Figure 6.4: Intracardiac injection of Gr-1 cells following anti-Gr-1. (A) Schematic of intracardiac
injection model for assessing tumor cell recruitment. (B) Quantification of tumor cells
in scaffolds by flow cytometry. (C) Quantification of relative tumor cell abundance in
the lung by IVIS.
rate populations, though overlap is observed for cells from the spleen at day 0 and
day 3 post inoculation with cells from the lung at day 10 (Fig. 6.6B). Changes
in pathway regulation over time was also examined using GSEA, and hierarchical
clustering indicated that Gr-1+ cells from scaffolds and lungs clustered more closely
together than with the spleen (Fig. 6.7).
The most highly differentially-expressed pathways were identified and are shown
in Figure 6.8. Cells within all three tissues showed a decrease in proliferation path-
ways from day 3 to day 10, and an increase from day 10 to day 17. The scaffold
exhibited relative upregulation in inflammation pathways from day 3 to day 10, as
well as a subsequent downregulation in those pathways from day 10 to 17. This trend
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Figure 6.5: Anti-Gr-1 exacerbates disease progression depending on time of treatment.
Mice were treated with 2 doses of anti-Gr-1 antibody starting at day 1 (pre-metastatic,
day 7 (early metastatic), or day 14 (late metastatic). B) Pre-metastatic treatment re-
sulted in accelerated disease progression compared with the untreated cohort. Animals
treated at the late metastatic timepoint died following the first dose. C) An increase
in lung metastasis was observed with pre-metastatic treatment.
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Figure 6.6: Gene expression comparisons made and principal component analysis of
RNAseq data for each organ and timepoint.
was also observed in the spleen, though not in the lung. In addition, downregulation
of T cell-related pathways was observed in the spleen throughout disease progression,
while the lung and scaffold remained relatively unchanged.
6.5 Discussion
MDSCs, or Gr-1+ cells, are an important part of the tumor microenvironment
and have been shown to be involved in metastatic processes by promoting tumor
growth and migration while inhibiting anti-tumor immune cell function [4, 5, 13].
As such, there has been much interest in using these cells for diagnostics as well as
therapeutic targets [96, 162]. Much of what is known about the phenotype of Gr-1+
cells is the result of in vitro functional assays, which often don’t take into account
the dependence of cell phenotype on the tissue of origin. It has been shown that
Gr-1+ cells within the spleen is functionally distinct from those within the primary
tumor [163]. In this study, we used biomaterial scaffolds that recapitulate metastatic
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Figure 6.7: Gene Set Enrichment Analysis of gene expression changes in Gr-1+ cells
over time and hierarchical clustering.
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Figure 6.8: Changes in select gene sets of interest for Gr-1+ cells.
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sites to be able to more readily isolate and study Gr-1+ cells at metastatic sites at
various timepoints throughout disease progression.
We first compared conditioned media generated from Gr-1+ cells of different tis-
sues, and observed that cells from the lung and scaffold were able to recruit tumor
cells in a transendothelial migration assay while those from the spleen were not. This
difference is likely due to the secretion of different factors, which has previously been
described between the spleen and tumor [163]. Of note, no changes in the ability to
suppress T cell proliferation was observed over time in the spleen and scaffold, while
there was a decrease in suppressive function at the lung.
We also employed RNA-sequencing to better understand the phenotypic differ-
ences between Gr-1+ cells isolated from different organs and at different disease
states. Pathway analysis was used to identify differences in proliferation, inflamma-
tory function, and T cell interactions across the tissues and over time, adding to what
is already known about functional differences between Gr-1+ cell subsets. These re-
sults also indicate that Gr-1+ cells that are recruited to the scaffold are more similar
in phenotype to those at the metastatic lung than to those at the spleen, which sug-
gests that the scaffold site can be used as a surrogate for studying metastatic sites
in situ.
As MDSCs are being explored as diagnostics for cancer and metastasis, better
understanding of Gr-1+ cell function is needed. This study highlights the need to
consider tissue of origin as well as disease state when assessing the function of MD-
SCs for diagnostics and treatment. Of note, depletion of Gr-1+ cells at early disease
states exacerbated disease and increased metastatic burden, and no therapeutic ben-
efit was observed in any treatment group. In addition, treatment with anti-Gr-1
resulted in the death of all animals within the cohort upon late metastatic treat-
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ment. These observations stand in contrast with the therapeutic benefit that been
previously reported with targeting Gr-1+ cells [162, 164]. As such, this study also
brings to light the severe off-target effects that can potentially occur when broadly
targeting Gr-1+ cells.
6.6 Materials and Methods
6.6.1 Scaffold fabrication and implantation
Poly(-caprolactone) (PCL) microparticles, 4-8 um in diameter, were first syn-
thesized prior to scaffold fabrication. PCL was dissolved in DCM at 6 w/w% at
4C overnight and mixed with 10 w/v% poly(vinyl alcohol) (PVA; 80% hydrolyzed,
MW 9-10k; Sigma Aldrich) solution in water at 3:20 PCL:PVA volume ratio. The
solution was then homogenized at 10,000 rpm for 1 minute to form the micropar-
ticles and immediately mixed with deionized (DI) water. The mixture was stirred,
and the solvent was evaporated overnight. Microparticles were then washed 3 times
with centrifugation and resuspension in DI water prior to lyophilization and long-
term storage in a desiccator. Microparticles were used to fabricate 5 mm scaffolds
as previously described [22]. Briefly, 2.5 mg of PCL microparticles was mixed with
75 mg of NaCl and pressed into a disc. Scaffolds were then melted 60◦C and salt
was leached from the scaffolds in MilliQ water. Leached scaffolds were disinfected
in sterile-filtered 70% ethanol, rinsed in sterile MilliQ water, then dried and stored
at -80◦C. Frozen scaffolds were left on dry ice until implantation into the dorsal
subcutaneous space. Each animal received 4 scaffolds. All animal procedures were
performed in accordance with guidelines set by the Institutional Animal Care and
Use Committee and Animal Care and Use Office at the University of Michigan. Mice
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were anesthetized with 2% isoflurane during surgical procedures and received peri-
and post-operative carprofen intraperitoneally at 5 mg/kg (Zoetis Inc.).
6.6.2 Tumor cell culture and inoculation
4T1-luc2-tdTomato cells (Perkin Elmer) were expanded in RPMI 1640 + Gluta-
MAX (Thermo Fisher Scientific) with 10% FBS for 5 days at 37◦C and 5% CO2 prior
to inoculation. Cells were removed from culture flasks by incubation with trypsin
for 10 minutes at 37◦C and resuspended in RPMI 1640. Cells were then pelleted
by centrifugation at 300 x g and washed with DPBS, and resuspended at 1 x 107
cells/mL of DPBS. Orthotopic tumor inoculations were performed by injection of 5 x
105 tumor cells resuspended in 50 µL DPBS (Life Technologies) into the fourth right
mammary fat pad of 8- to 10-week-old female BALB/c mice (Jackson Laboratory).
The cell line was confirmed to be pathogen free and authenticated by short tandem
repeat DNA analysis and compared to the ATCC STR profile database (DDC Med-
ical). For scaffold-implanted mice, tumor inoculation was performed 14 days post
implant to allow for initial wound healing and tissue infiltration [22].
6.6.3 Gr-1+ cell depletion and survival studies
Mice were treated twice with 100 ug of InVivoMab anti-mouse anti-Gr-1 (anti-
Ly6C/Ly6G) antibody (clone RB6-8C5, Bio X Cell). Pre-metastatic treatment oc-
curred on days 1 and 4 post tumor inoculation, early metastatic treatment occurred
on days 7 and 10, and late metastatic treatment occurred on days 14 and 17. Anti-
body was diluted in DPBS to a final concentration of 1 mg/mL immediately prior
to i.p. injection. For survival studies, mice were monitored for tumor size and body
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conditioning. Mice were euthanized if any of the following criteria were met: tumor
size of > 2 cm in any dimension, ulceration of more than 50% of the visible tumor
area, partial paralysis due to tumor invasion of hind limb muscle, labored breathing,
ascites, lethargy, or visible weight loss.
6.6.4 Intracardiac injection model of metastatic seeding
In the intracardiac model, mice were implanted with scaffolds as described above
and inoculated with unlabeled 4T1 tumor cells, which were cultured as described
above. Anti-Gr-1 was administered i.p. on days 3 and 6 post inoculation, following
the formation of a primary tumor comprised of unlabeled 4T1 cells. 106 4T1-Luc2-
tdTomato (labeled) cells were delivered by intracardiac injection. Flow cytometry
was performed 24 hours post intracardiac injection to quantify the amount of labeled
tumor cells within tissues to assess the ability of the tissues to recruit metastatic cells.
6.6.5 Ex vivo bioluminescence imaging
Metastatic tumor burden of luciferase-expressing tumor cells (4T1-Luc2-tdTomato)
in explanted lungs and livers was measured by bioluminescence imaging with IVIS.
Tissues were incubated in 50 µM d-luciferin (Caliper) at room temperature for 10
minutes prior to imaging. Imaging was performed with large binning, and exposure
was automatically determined by the instrument to prevent signal saturation. Bi-
oluminescence signal intensity is reported as integrated light flux (photons/sec) as
calculated by the Living Image Software (Caliper Life Sciences).
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6.6.6 Flow cytometry
Flow cytometry was performed on primary cells obtained from explanted spleens,
lungs, primary tumors, and livers. Tissues were minced and enzyme digested with
Liberase TL or TM (Roche), then filtered through a 70 µm cell strainer (Corning)
to obtain a cell suspension. Whole blood was collected by cardiac puncture and
mixed with 10 v/v% 25mM EDTA (Life Technologies). Red blood cell lysis of whole
blood, spleens, and lungs was performed with ACK Lysing Buffer (Life Technolo-
gies). Cells were pelleted by centrifugation at 400 x g for 5 minutes and resuspended
in MACS buffer. Nonspecific staining was blocked with anti-CD16/32 (Biolegend)
and samples were stained for innate immune markers with anti-mouse CD45 AF700,
F4/80 PE-Cy7, Ly6G PacBlue, Ly6C FITC (Biologend), and CD11b BV510 (BD
Biosciences). Stained samples were analyzed using the MoFlo Astrios Flow Cytome-
ter or CytoFLEX (Beckman Coulter), and data were processed using FlowJo software
(BD).
6.6.7 Gr-1+ cell sorting
Gr-1+ cells were isolated by MACS from lungs, spleens, and scaffolds of tumor-
bearing mice at 3, 10, and 17 days post tumor inoculation. Tissues were explanted,
and a cell suspension was obtained for each tissue as described above. Red blood
cell lysis was performed on lung and spleen samples with ACK Lysing Buffer (Life
Technologies). Cells from multiple scaffolds in the same animal were pooled together.
Cells were incubated with anti-Gr-1 antibody-conjugated magnetic microbeads from
the mouse Myeloid-Derived Suppressor Cell Isolation Kit (Miltenyi), then passed
through LS MACS Columns (Miltenyi) as per manufacturers instructions. The sorted
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cells were washed and pelleted, then frozen and stored at -80C prior to gene expres-
sion analysis.
6.6.8 Gene expression analysis by RNA-seq
RNA was extracted from frozen Gr-1+ cells that were sorted from lungs, spleens,
and scaffolds as described above with the RNeasy Plus Mini spin column kit (Qiagen).
Purified RNA concentration was measured by UV spectroscopy using a Nanodrop
2000c (Thermo Scientific) to confirm all samples had concentrations 10 ng/L. RNA
quality control, QuantSeq 3’ mRNA-seq library prep and quality control, and se-
quencing were all performed by the Advanced Genomics Core at the University of
Michigan. Samples were sequenced using the Illumina NextSeq 550 sequencer. Raw
sequencing counts were normalized and differential gene expression was calculated in
R and using DESeq2 [95]. Normalization of raw counts was performed for principal
component analysis [119] and genes with differential expression (padj < 0.05 ) were
identified. To perform pathway analysis, mouse gene symbols for counts obtained
through RNA-seq were first converted to human gene symbols using the biomaRt
package in R. Gene Set Enrichment Analysis (GSEA) was performed on DESeq2-
normalized counts and the corresponding human gene symbols for a total of 5,944
MsigDB gene sets (Hallmark, Reactome, PID, and Gene Ontology (GO)). A positive
normalized enrichment score (NES) indicates enrichment compared to the control
cohort.
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6.6.9 Statistical analysis
One-way or two-way ANOVA and Tukeys multiple comparisons tests were per-
formed on groups with more than 2 conditions. Two-tailed unpaired t test was
used for single comparisons between two conditions. Median survival and survival
curves were analyzed with the log-rank (Mantel-Cox) test for statistical significance.
Following normalization of RNA-seq gene expression data with DESeq2, genes with
adjusted p-value < 0.05 were considered differentially expressed. Statistical analyses
were performed using Prism 8 (GraphPad Software). A p-value < 0.05 was consid-
ered to be statistically significant and all values are expressed in mean standard
deviation (SD). Error bars on plotted data represent standard error of the mean
(SEM).
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CHAPTER VII
Conclusions and Future Directions
7.1 Summary of Findings
The work presented here describes the development and application of two bio-
material strategies that can be used to monitor and treat metastatic cancer as well
as other immune-related disorders. Innate immune cells play a critical role in numer-
ous disease states ranging from cancer to autoimmune disease, and even spinal cord
injury. In spinal cord injury, neutrophils and monocytes are recruited to the injury
site and cause inflammation that results in scarring and prevents tissue regeneration.
The nanoparticles redirected and reprogrammed these innate cells, as evidenced by
a reduction in the number of innate cells and inflammatory factors at the injury
site, as well as an increase in pro-regenerative factors. Furthermore, nanoparticles
improved myelination and resulted in motor function recovery.
In metastatic cancer, tumor cells secrete factors that induce proliferation and
activation of suppressive innate immune cells, which inhibit T cell and NK cell killing
of tumor cells. PLG nanoparticles were also shown to target disease-induced myeloid
cells and decrease the abundancy of myeloid-derived suppressor cells at the metastatic
organ and in circulation. Particle internalization appears to reprogram the cells to
become more inflammatory, overcoming tumor-induced immunosuppression at the
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tumor and lung. Furthermore, combination therapy of nanoparticles with anti-PD-
1 increased IL-2 production in the lung, and increased cell killing at the tumor,
resulting in slower growth of the primary tumor and lower metastatic burden in the
lung.
This work also expands upon the applications of the PCL scaffold previously
developed in the Shea lab. These scaffolds have previously been shown to recruit
immune and tumor cells. The immune cells actively traffic to the scaffold due to the
presence of the primary tumor, and as such, can be used as an indicator of disease
progression. Gene expression analysis identified a panel of 10 genes that was able to
capture systemic and disease-specific immune changes, and expression of these genes
could be reduced to a scoring system that can be used to predict and monitor lung
metastasis following resection of the primary tumor.
The scaffold was also used to study the phenotypes of Gr-1+ cells within tissues
and across multiple time points in the context of disease progression and metasta-
sis. Anti-Gr-1 eliminated Gr-1+ cells in the lung, liver, and spleen, while a fraction
remained in the tumor, yet was shown to exacerbate tumor growth and metastasis
when administered early. The phenotype of Gr-1+ cells is shown to be dynamic with
disease state (pre-, early, or late metastasis) as well as depend on the tissue of origin
(scaffold, lung, or spleen), as indicated by their ability to suppress T cell prolifera-
tion and tumor cell recruitment, as well as by changes in their gene expression and
pathway regulation.
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7.2 Significance and Impact
This thesis highlights novel ways in which we can leverage biomaterial-immune
interactions to address both acute inflammation in spinal cord injury and immuno-
suppression in metastatic cancer. We demonstrated targeting of the disease-induced
innate immune cells in these models based on phagocytic phenotype alone rather
than with targeting ligands, and observed phenotypic reprogramming of the immune
cells that internalize them. Interestingly, the effect of PLG nanoparticles on immune
cells appears to depend on the disease state of the animal. While nanoparticles re-
duced inflammation in the context of spinal cord injury, they appeared to increase
inflammatory gene expression at the primary tumor and metastatic sites. These
nanoparticles can easily be manufactured and are stable for long periods of time.
This flexibility and potential tunability, combined with safety make nanoparticles a
promising therapy for a wide variety of immune-related disorders.
In metastatic cancer, PCL scaffolds facilitate the formation of a local microen-
vironment that reflects immune changes at metastatic sites, which have previously
studied only with biopsies of metastatic tissue. This work not only introduces a
potential diagnostic or sensor for metastasis, but also adds to the understanding of
immunosuppressive phenotypes of immune cells within metastatic sites. We observed
that depletion of Gr-1+ cells with anti-Gr-1 at early timepoints exacerbates disease
and increases metastasis, and observed severe off-target effects with other treatment
schedules. These negative outcomes may be under-reported as we were able to find
only one other study that reported similar findings when using anti-Gr-1. The neg-
ative outcomes seen with anti-Gr-1 at certain timepoints highlight the need for the
development of companion diagnostics and/or careful consideration of appropriate
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dosing schedules in addition to the types of therapies that can target MDSCs and
other innate immune cells.
7.3 Future Directions
7.3.1 Understanding the heterogeneity of Gr-1+ cells within metastatic
sites
MDSCs are known to be comprised of both granulocytic (G) and monocytic (M)
populations, and that the two are phenotypically distinct. The relatively low abun-
dance of M-MDSCs makes them difficult to sort by surface markers in order to
study their gene expression in bulk. A recent study examined Gr-1+ cells sorted
from the spleen using single-cell RNA sequencing (scRNAseq) and identified previ-
ously unknown cell surface markers specific for a population of MDSCs within the
spleen [165]. Applying scRNA to Gr-1+ cells at the scaffold compared to those at
the lung and spleen would help to elucidate whether the change in bulk gene expres-
sion with disease progression is due to changes in the relative abundance of Gr-1+
populations or due to the appearance of a distinct population of Gr-1+ cells at the
early metastatic timepoint. In addition, scRNAseq may be able to identify unique
druggable targets or surface receptors for pro-tumor Gr-1+ cells to avoid off-target
effects and negative outcomes observed with anti-Gr-1. In our studies, we assessed
functional phenotype of Gr-1+ cells based on their ability to suppress T cell prolif-
eration. Additional functional studies such as quantifying production of nitric oxide
or reactive oxygen species can be useful in further characterizing the dynamics of
Gr-1+ cells.
143
7.3.2 Optimizing nanoparticle properties for targeting specific cell types
As more is uncovered about the phenotype of the pro-tumor or pro-disease innate
immune cells, more specific targeting of these cell types will likely be required. The
work presented here took a first step at tuning PLG nanoparticles for preferential
internalization by Ly6Chi monocytes and MDSCs. As briefly described in Chapter
IV, particle uptake can be tuned by physicochemical properties such as surface charge
and particle size. Surface modification such as PEGylation of nanoparticles has
also been explored by our group and others. To approach this, we can create a
combinatorial library of rationally designed nanoparticles by using polymers with
different molecular weights and varying surfactants.
Though intravascular infusion of nanoparticles is already a currently used and
translatable method, we can also explore other routes of administration. Inhalable
nanoparticles, for example, may be more effective for targeting the lung. However,
where the cells are internalizing particles and where the cells accumulate if they leave
the lung or circulation is a remaining question. To investigate this, we can incubate
blood leukocytes with labeled nanoparticles and adoptively transfer them into mice
that did not receive particle treatment to asses if particle biodistribution is different
from that of mice injected with particles.
7.3.3 Monitoring of therapeutic response in other disease models
We demonstrated here that the scaffold facilitates the formation of an immune mi-
croenvironment that reflects disease-induced immune cell changes, but it is not known
to what extent these changes can be detected. Recent studies suggest that these
scaffolds are able to sense and predict the onset of relapse in a model of relapsing-
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remitting multiple sclerosis (Morris et al., unpublished), even when there were no
detectable changes in immune cell abundance or phenotype. These findings indicate
the potential utility of the scaffold in a range of immune disorders. One such use
may be to detect therapeutic efficacy for cancer vaccines. Robust T cell responses are
necessary to generate tumor cell-specific immunity that results in tumor regression
or prevention of metastasis. As such, it may be helpful to detect T cell changes or
changes in other immune cells that engage with T cells in order to monitor thera-
peutic efficacy.
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